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ABSTRACT 
 
ROLE OF ESTROGEN ON THE MAINTENANCE AND 
HOMING CAPACITY OF BONE MARROW DERIVED RAT 
MESENCHYMAL STEM CELLS 
 
Fatma AYALOĞLU BÜTÜN 
Ph.D. in Molecular Biology and Genetics  
Supervisor: Assist. Prof. Dr. K. Can Akçalı 
August 2011, 130 Pages 
Mesenchymal Stem Cells (MSCs) can self renew and differentiate into different cell 
types like, adipocytes, osteoblasts, chondrocytes, neurons, hepatocytes and 
endothelial cells. Their ability to differentiate into wide variety of cell types, non-
immunogenic characteristics, along with homing capacity to injured tissue and the 
absence of any ethical issue related to their uses, make MSCs important in 
regenerative medicine and tissue engineering. Their ability to migrate to the site of 
injury raises the opportunity of these stem cells to be considered also as in vivo 
delivery agents. However, one major obstacle in using MSCs in cell based therapies 
is their limited numbers. Estrogen is known to have role in growth, proliferation and 
apoptosis. Therefore our aim was to study the possible role and mechanism of 
estrogen in their maintenance and their homing capacity. We used MSCs derived 
from female and ovariectomized female rat bone marrow in our research. Our 
  
ii 
 
results revealed that estrogen treatment increased the number of colonies and the 
number of cells constituting a colony. Estrogen decreased the differentiation 
capacity of MSCs to the adipogenic lineages as shown by reduced of Oil Red O 
staining Estrogen also affected MSCs’ homing capacity. Estrogen treatment 
resulted in the migration of increased number of DiI labeled MSCs to the site of 
injury after partial hepatectomy (PH) compared to that of untreated MSCs. 
Furthermore, estrogen treatment decreased the rate of apoptosis. Our data showed 
that estrogen regulates apoptosis through Bcl-2 family of genes in MSCs. This 
regulation was at the protein level but not at the transcript level. Estrogen addition 
increased the expression of anti-apoptotic members of the Bcl-2 family of proteins, 
Bcl-2 and Bcl-xL. The decrease in the apoptosis was not observed when Bcl-xL and 
Bcl-2 genes were knocked down. The silencing histone code H3K27me3 was also 
decreased in estrogen treated MSCs, suggesting an epigenetic regulation of MSCs 
upon estrogen treatment. Altogether our results show that estrogen increased the 
number of functional MSCs, decreased spontaneous apoptosis in these cells, and 
improved the homing capacity of rat bone marrow derived MSCs. Therefore, 
estrogen treatment of MSCs may offer new opportunities for the therapeutic actions 
of these cells. 
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ÖZET 
ÖSTROJEN HORMONUNUN SIÇAN KEMİK İLİĞİNDEN 
ALINMIŞ MEZENKİMAL KÖK HÜCRELERİNİN 
MUHAFAZASINDA VE HASARLI DOKUYA 
ULAŞMASINDAKİ ROLÜ 
 
Fatma AYALOĞLU BÜTÜN 
Moleküler Biyoloji ve Genetik Doktorası  
Tez Yöneticisi: Doç. Dr. K. Can Akçalı 
Ağustos 2011, 130 Sayfa 
 
Mezenkimal Kök Hücreler (MKH) kendilerini yenileyebilen ve adiposit, osteosit, 
kondrosit, sinir hücresi, hepatosit ve endotel hücresi gibi farklı hücrelere 
farklılaşabilen hücrelerdir. MKHlerin yüksek farklılaşma kapasitesi, immün 
reaksiyon oluşturmama özelliği, hasarlı dokuya gitme özelliği ve kullanımı ile ilgili 
etik sorunların olmaması, bu hücrelerin rejeneratif tıp ve doku mühendisliğinde 
önemli bir yerde olmalarının sebebidir. MKHlerin hasarlı dokuya ulaşabilmeleri 
aynı zamanda bu hücrelerin in vivo taşıyıcı ajan olarak kullanılması olasılığını da 
ortaya çıkarmıştır. Fakat MKHleri terapide kullanmanın önündeki en büyük zorluk 
onların sayıca az olmalarıdır. Östrojen hormonu büyüme, proliferasyon ve 
apoptozda rol aldığı bilinmektedir. Bu yüzden amacımız, östrojenin MKHlerin 
hasarlı dokuya yönelme ve yerleşmesindeki ve bu hücrelerin devamlılığındakı 
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rolünü calışmaktı. Çalışmalarımızda dişi sıçanın kemik iliğinden alınan MKHler ve 
overleri çıkarılmış dişi sıçanın kemik iliğinden alınmış MKHler kullanıldı. Östrojen 
koloni sayısını ve kolonideki hücre sayısını arttırdı. Oil Red O boyaması ile 
görüldüğü gibi, östrojen aynı zamanda MKHlerin yağ hücresine farklılaşmasını 
azalttı. Östrojen verilen MKHler verilmeyen MKHlere gore kısmı hepatektomi 
yapılan sıçanların karaciğerlerine daha fazla sayıda gidip yerleştiler. Bunlara ek 
olarak östrojen MKHlerinin apoptozunu azalttı. Sonuçlarımız östrojenin apoptozu 
Bcl-2 gen ailesi üzerinden kontrol ettiğini gösterdi. Bu kontrol mRNA seviyesinde 
değil fakat protein seviyesindeydi. Östrojen eklenmesi Bcl-2 protein ailesinin anti-
apoptotik üyelerinin protein seviyesini arttırdı. Apoptozdaki bu azalma Bcl-xL ve 
Bcl-2 susturulduğu zaman görülmedi. Susturucu histon kodu olan H3K27me3 
östrojen ile azalmakta, ve bu MKH gen ifadelerinin epigenetik bir yolla kontrol 
edildiği fikrini otaya atmaktadır. Bütün bu sonuçlar östrojenin fonksiyonel 
MKHlerin ve hasarlı dokuya ulaşan MKH sayısını arttırdığını, spontan olan 
apoptozu önlediğini göstermektedir. Bu sebeple bu hücrelerin östrojene maruz 
bırakılması onların tedavide kullanılmasına yeni olanaklar sunabilir. 
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Chapter 1  
INTRODUCTION 
Stem cells have attracted a lot of interest in the last three decades. Not only 
researchers but also the community is interested in this field due to their potential 
usage in regenerative therapy.  Despite to the high attention and focus on these cells 
there is no definitive description of the stem cell concept.  However, the National 
Institude of Health (NIH) defines stem cells as “ Cells that can divide infinitely and 
give rise to differentiated cells in vivo and in vitro” (http://stemcells.nih.gov/). 
Therefore self-renewal, differentiation and in vivo reconstition are critical features 
of stem cells. 
Generally stem cells can be classified according to their source of origin and their 
potency. During early embryonic development, inner cell mass (ICM) give rise to 
embryonic stem cells (ESCs). Stem cells that are isolated at later developmental 
stages and postnatal period collectively are called adult stem cells (ASC). Another 
classification is related to their potency. Totipotent stem cells give rise to the cells 
from the extraembryonic tissues in addition to the cells from the three germ layers, 
(ectoderm, endoderm and mesoderm), whereas the pluripotent stem cells give rise 
to the cells from the three germ layers but not to the extra embryonic cells. 
Multipotent stem cells differentiate into the cell types from their original germ layer 
and another germ layer (http://stemcells.nih.gov/). ESCs and the induced 
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pluripotent stem cells (iPSC) are pluripotent whereas most of the adult stem cell are 
multipotent, and the zygote is the only cell that is totipotent. 
Use of stem cells in therapy has brought new hope in the field of regenerative 
medicine. The capacity of stem cells to differentiate into different types of cells 
after correct stimuli made them a very trustworthy agents in medicine for the 
treatment of several genetic, chronic and non-infectious diseases like osteogenesis 
imperfecta, parkinsons disease, chronic heart diseases, spinal cord injuries, liver 
cirrhosis, and diabetes (http://www.clinicaltrials.gov). Embryonic stem cells (ESC) 
are very promising agents since they can differentiate into the cells of all three germ 
layers. However their use is very limited due to the ethical problems since embryo 
is the source. To overcome this, researchers developed induced pluripotent stem 
(iPS) cells which are pluripotent like embryonic stem cells, but do not require the 
embryo therefore have no ethical problems. However, these cells are not completely 
characterized and it will take time before seing them in medicine. Mesenchymal 
stem cells (MSCs) on the other hand, are multipotent stem cells that can 
differentiate into many types of cells upon induction. Since they are adult stem cells 
there is not any ethical concern related to the usage of them. They are known for 
nearly 40 years and are almost fully characterized. That is why, great hope has been 
evolved for the usage of MSCs in therapies.  
To increase the quantity of MSCs for further use, estrogen is an important factor. 
Estrogen can induce apoptosis in some cells and prevent apoptosis in other cells. 
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Treating MSCs with estrogen can have great impact in using these cells in cell 
based therapies.  
Our aim in this study was to investigate the role of estrogen in MSC  maintenance 
and the molecular mechanism of its effect.  
In this thesis first, stem cells based on their potency will be explained. After 
defining the the pluripotent stem cells, ESCs and iPS cells, the multipotent stem 
cells will be described with an emphasis on MSCs. Estrogen and apoptosis will be 
explained afterwards. For the possible regulatory mechanism behind this event, 
epigenetic modification with an emphasis on histone post translational modification 
(PTM) will be defined.  
 PLURIPOTENT STEM CELLS 1.1
As mentioned before, pluripotent stem cells are the cells that have the capacity to 
differentiate into the cells of all three germ layers, not to the cells of the 
extraembryonic tissue (http://stemcells.nih.gov/). ESCs and iPSCs are the examples 
for pluripotent stem cells. 
 EMBRYONIC STEM CELL 1.1.1
Embryonic stem cells were first isolated by Evans and Kaufmann in 1981 from 
mice blastocysts [1] and by Thomson and coworkers in 1998 from human 
blastocysts [2]. ESCs express spesific pluripotency marker genes, which are called 
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the intrinsic pluripotency factors, Sox2, Nanog, and Oct4. These genes are  
responsible for holding them in an undifferentiated state [3-6]. They are able to 
form teratomas when injected into blastocysts of an immunosuppressed mouse and 
also contribute to the generation of chimeras [7, 8]. They form embryoid bodies in 
vitro which have cells of all the three germ layers in a disorganized manner [1]. 
ESCs have high telomerase activity which results in long telomeres and immortality 
[8]. These cells can be maintained indefinitly in undifferentiated state in vitro 
without loosing normal karyotype [8, 9]. X chromosome inactivation does not occur 
in undifferentiated ESCs [10]. ESCs cause immune rejection when injected into 
immunocompetent recipient [11]. Besides having common features of mouse ESCs 
(mESCs) and human ESCs (hESCs) there are also differences between them. 
Human ESCs are able to differentiate into trophoblast like cells while mESC can 
not [9]. hESCs require a feeder layer composed of mouse embryonic fibroblasts 
(MEF) for in vitro propagation [9]. However, mESCs do not require MEF if 
leukemia inhibitory factor (LIF) is added to the media [9, 12] 
The signaling molecules required for ESC maintenance also differ between mESCs 
and hESCs. LIF and BMP are the main two extrinsic signaling pathways that are 
responsible for mESC self renewal. Constitutive expression of c-myc is required for 
self renewal. LIF activates c-myc either directly or indirectly through two different 
mechanism, the JAK/ STAT3 pathway [13-15] and the phosphatidylinositol 3 
kinase (PI3K) dependent pathway [16]. The other pathway required for stem cell 
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maintanance involves the BMP signaling. Several laboratories have shown that 
BMP acts in a repressive manner by inhibiting the differentiation of mESC and 
maintaining their pluripotent state [17-19]. On the other hand, hESC self renewal is 
controlled via different factors like Fgf2, TGF-β, noggin, activin, and Wnt [20-24]. 
Greber and friends showed that hESC cultured with MEFs retained their self 
renewal activity when supported with Fgf2 [25]. Since there are some differences 
between mESCs and hESCs, the results from mESCs cannot be directly 
extrapolated to hESCs [9]. That is why hESC research has to be performed 
independent from different species. Major handicap for hESCs research is their 
source. During their isolation from blastocyst, the embryo is destroyed. Even 
though there are very strict regulations of using embryos from IVF clinics, this is a 
very important ethical concern around the world. This prompted the researchers to 
find alternative sources for pluripotent stem cells without ethical concerns. Inducing 
pluripotent stem cells from differentiated somatic cells through redifferentiation 
was a major breakthrough in stem cell research.  
 INDUCED PLURIPOTENT STEM CELL 1.1.2
Induced pluripotent stem cells (iPS) were first made by Yamanaka group from 
mouse fibroblast in 2006 [26]. They started with 24 pluripotency related genes and 
narrowed them down to 4 minimaly required genes, c-Myc, Sox-2, Klf-4 and Oct-4, 
for inducing pluripotency when transfected into mouse fibroblasts. These factors are 
now called the Yamanaka Factors. iPS cells have similarity with ESCs in their 
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ability to form teratomas. However, they could not contribute to the formation of 
chimeras or to germ lines as efficient as ESCs. Compared to ESCs iPS cells had 
been shown to have incomplete promoter demethylation, and to express low levels 
of some pluripotency related genes [26]. Thereafter, new iPS cell lines were 
generated by different research groups and the features of this new lines were more 
similar both functionally and molecularly to ESCs [27-29]. Different laboratories 
developed iPSC from human, rat and monkey by using factors other than the 
Yamanaka Factors [30-33]. Not only fibroblasts but also B cells [34], hepatocytes 
[35], keratinocytes [36], and amniotic cells [37] were used as a starting cell to make 
iPSC. A list of the cell source of iPS cells and the factors that are used to generate 
them is given in table 1.1. Another improvement in iPS cell research was to use 
safer methods for transfections. Yamanaka group used retroviruses as delivery 
agents. 
For this purpose different delivery methods were used; i) retroviral vectors that 
integrate into the genome, ii) inducible lentiviral vectors whose expression can be 
controlled [38, 39], iii) plasmids or nonintegrative adenovectors which do not 
integrate into the genome but have low transfection efficiency [40-42], iv) Cre/LoxP 
approach which enables to remove the vector afterwards by transient expression of 
Cre recombinase [43], v) PiggyBac transposons which can also be removed from 
the genome by expression of transposases [44, 45], vi) chemical defined approach 
that uses only chemical compounds for reprograming [46] , and vii) delivering the 
purified recombinant protein without any virus or plasmid which prevents any 
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integration into the host genome, but has a low transfection efficiency [47, 48]. In 
2010 a group of scientist developed an efficient and safe delivery method to 
generate iPS cells. They used modified RNA molecules encoding the four 
Yamanaka Factors and Lin28 and transfected them into fetal fibroblasts, postnatal 
fibroblasts, and cells derived from skin biopsy from a cystic fibrosis patient. These 
RNA derived iPS cells (RiPSC) were generated with high efficiency and directed 
the iPS biology to a new path [49]. 
Table 1.1: IPS cells derived from different species and cell types by different 
factors. O: Oct4, S: Sox2, K:Klf4, M: cMyc, L: Lin28, C: C/EBPα 
SPECIES 
CELL 
SOURCE FACTORS REFERENCES 
mouse fibroblast OKSM [26] 
human fibroblast OKS [30] 
human fibroblast OSLN [31] 
rat fibroblast OKSM [32] 
rhesus 
monkey 
ear skin 
fibroblast OKSM [33] 
mouse B cell OKSM+ C [34] 
human hepatocytes OKSM [35] 
human keratinocytes OKSM/OKS [36] 
human amniotic cells OKSM [37] 
mouse dermal papilla OKM/OK [50] 
mouse fibroblast OKS [30], [51] 
 
iPS cells are promising candidates to be used in therapy since they can be isolated 
from the patient himself and therefore immune rejection of the transplant is not an 
issue. In 2007 iPS cells generated from fibroblast of a sickle cell anemia murine 
model was used to cure the disease. Before the fibroblast were redifferentiated, the 
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genetic defect in the hemoglobin gene was treated in vitro. The engineered iPS cells 
were differentiated to hematopoietic progenitor cells and these cells were given to 
the donor mouse. It was observed that the mature erythrocytes had no defect in 
hemoglobin gene [52]. Another group used iPS cells to restore liver function in 
FAH deficient mice model, in which they had to have the drug, 2-(2-nitro-4-
fluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC), in order to prevent liver 
failure. After injection of the iPS cells to the blastocyst, the drug NTBC was 
withdrawn. It was observed that the iPS cells contributed to the formation of 
chimera and the mice had functional liver with FAH expressing hepatocytes [53]. 
Although iPS cells are promising candidates in cell therapy there is still a long way 
before this could happen. However, a more realistic approach of iPS cells in therapy 
is  the use of disease specific iPS cells to mimic the disease and provide a patient 
spesific cell line to study the pathology in the culture. Several disease spesific iPSC 
have been established. A group of scientist generated a large number patient 
spesific iPS cell lines from patients with Adenosine deaminase deficiency-related 
severe combined immunodeficiency, Gaucher disease type III, Duchenne and 
Becker muscular dystrophy, Parkinson disease , Huntington disease , juvenile-onset, 
type 1 diabetes mellitus [54], spinal muscular atrophy [55], familial dysautonomia 
[56], and fanconi anemia [57]. Some of the iPS cell lines generated from this 
patients showed the disease profile in the culture and provided new opportunities to 
study the molecular mechanism of he disease and to search for drugs [58]. 
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 MULTIPOTENT ADULT STEM CELLS  1.2
Adult stem cells (ASC) are stem cells that are found in the adult organ or tissue of 
an organism. Unlike the ESCs or the iPSCs, ASCs are not pluripotent. Many of the 
ASCs are multipotent and a few are unipotent. ASCs can be thought of a reservoir 
of cells, which normaly stay in an undifferentiated state in the niche which is the 
environment where the ASCs reside. Like all stem cells ASCs possess two universal 
features; the ability to self renew and to differentiate [59], which is called stemness 
[60]. The maintenance of ASC pool is not clear, but the most accepted view is that 
ASCs divide in an assymetric fashion, giving rise to two different daughter cells 
with different fates. The one that is still in the niche becomes the self renewing 
sister for protecting the reservoir, while the other sister cell leaves the niche and 
differentiates into the desired cell type [61, 62]. Different ASCs have been 
identified. The first identified and so far the best charecterized ASCs are 
hematopoietic stem cells (HSCs). HSCs were first mentioned in the 60s by Till and 
McCulloch [63], and Siminovitch et al. [64]. These HSCs were able to reconstitude 
all of the blood cells [65, 66]. Two subsets of the HSCs have been classified; the 
Long term and short term reconstitutive cells (LT-HSC and ST-HSC, respectively) 
[65, 67]. In mouse in addition to these two subsets, there are also two other 
progenitor derived from the HSCs, Common Lyphocytes Progenitors (CLPs) and 
the Common Myeloid Progenitors (CMPs) [68, 69]. Different surface markers are 
used to separate these subtypes from each other [69].  
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Table 1.2: The location of different kinds of ASCs in the body and their 
differentiated progeny. (adopted from [70]). 
CELL TYPE 
TISSUE SPECIFIC 
LOCATION 
CELLS OR TISSUE PRODUCED 
Hematopoietic 
stem cells 
bone marrow, peripheral 
blood 
bone marrow and blood 
lymphohematopoietic cells 
Mesenchymal 
stem cells 
bone marrow, peripheral 
blood 
bone, cartilage, tendon, adipose 
tissue, muscle, marrow stroma, 
neural cells 
Neural stem 
cells 
ependymal cells, 
subventricular zone of the 
central nervous system 
neurons, astrocytes, 
oligodendrocytes 
Hepatic stem 
cells 
in or near the terminal bile 
ductules 
oval cells that subsequently generate 
hepatocytes and ductular cells 
Pancreatic 
stem cells 
intraislet, nestin positive 
cells, oval cells, duct cells 
beta cells 
Skeletal-
muscle stem 
cell/satellite 
cells 
muscle fibers skeletal muscle fibers 
stem cells of 
the skin 
basal layer of the 
epidermis, bulge zone of 
the hair follicles 
epidermis, hair follicles 
Epithelial 
stem cells of 
the lung 
tracheal basal and mucus 
secreting cells, 
bronchiolar Clara cells, 
alveolar type II 
pneumocyte 
mucous and ciliated cells, type I and 
II pneumocystis 
Stem cells of 
the intestinal 
epithelium 
epithelial cells located 
around the base of each 
crypt 
paneths cells, brush border 
enterocytes, mucus secreting goblet 
cells, enteroendocrine cells of the 
villi 
 
Other than HSCs, intestinal stem cells, neuronal stem cells, hepatic stem cells, skin 
stem cell, mammary stem cells, pancreatic stem cells, and mesenchymal stem cells 
are other well characterized ASCs. These ASCs have the capacity to differentiate 
into different types of cells upon tissue damage or any other means of requirement 
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to maintain their homeostasis [70]. A list of the ASCs and their tissue spesific 
localization together with the spesific cell or tissue produced from are given in table 
1.2.  
 MESENCHYMAL STEM CELL 1.2.1
MSCs) were first isolated from rat bone marrow and described in 1966 by 
Friedenstein et al [71] and further characterized by Pittenger et al. [72]. MSC 
contribution in the bone marrow is only 0.001% to 0.01%. These small number of 
cells can be isolated and cultured in vitro and induced to differentiate into bone, fat, 
cartilage, muscle, cardiomyocytes, neurons, endothelial cells and blood vessel as 
reviewed by Barry and Murphy [73]. Cell cycle analysis revealed that most of the 
MSCs stay at G0/G1 phase and do not enter the cell cycle [74]. There is variation on 
the proliferative capacity of MSCs in culture between the research groups. This 
difference could be due to the isolation procedure, source of MSCs, culture 
conditions and donor age [75]. It has been also shown that depending on the culture 
condition, MSCs retain their telomerase activity and karyotype in vitro [72]. 
However culturing these cells for long time can result in spontenous apoptosis [74] 
and senescence [75]. MSCs are promising tool for regenerative medicine due to 
easy harvesting and culturing, high differentiation potential and their 
nonimmunogenic nature. However, their rareness is a major roadblock. Therefore 
new strategies should be developed to increase the number of MSCs for further use 
without increasing their in vitro culturing time. Another important feature of MSCs 
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which makes it easy to work, is their diverse source in the body. Several groups 
successfully isolated MSCs from adipose tissue, periosteum, synovium, skeletal 
muscle, umblical cord blood, amniotic fluid, placenta, preipheral blood, lung, dental 
pulp, tendon and salivary gland [73, 75-77].  
1.2.1.1 CHARACTERIZATION OF MSC 
For the characterization of MSCs several aspects have been used. These include 
their morphology, their surface markers and capacity to differentiate into specific 
cells.  
MSCs showed fibroblastic like appearance and formed colonies in petri dish. [78, 
79]. The colony numbers has ben shown to vary in different organisms and in 
different culture conditions [77]. Although the colonies are derived from one 
precursor cell, studies have shown that the colonies may also contains heterogenous 
cell mixtures. Several groups have defined the cells in a colony as small spindle 
shaped cells which proliferate at high rate, large cuboidal shape cells which 
proliferate at a slower rate and a much smaller cell type which has the highest self 
renewing rate [80-82]. This variety in colonies makes it necessary to look for other 
characteristics for MSCs. 
MSCs isolated from bone marrow are positive for the expression of CD44, CD105, 
CD106, CD90, CD166, CD29, CD73, CD117, CD146, CD157, STRO-1, Sca-1, 
integrins α1, α5 and β5, ICAM-1,ICAM-2, LFA-3 and L-selectin and negative for 
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CD11b, CD14, CD31, CD33, CD34, CD133 and CD45 [72, 74, 83-86]. However no 
unique marker has been identified yet to characterize MSC. Several studies have 
shown that a combination of some of the markers listed above are sufficient and 
necessary to determine MSCs [77]. The source of the MSC, the isolation procedure 
and the culture condition can effect the surface marker profile of the MSC [77]. 
Therefore the Mesenchymal and Tissue Stem Cell Committee of the International 
Society for Cellular Therapy proposed minimal criteria for MSC definition. 
According to this definition, MSCs must adhere to plastic surfaces, express CD105, 
CD73 and CD90 and not express CD45, CD34, CD14 or CD11b, CD79α or CD19 
and HLA-DR; and differentiate to osteoblasts, adipocytes and chondroblasts in vitro 
[87]. 
Besides differentiation into the mesenchymal lineage, MSCs have been also shown 
to differentiate to other cell types like cardiomyocytes, astrocytes, endothelial cells 
and epithelial cells such as retinal pigment cells, skin cells, sebaceous duct cells and 
epithelial cells in the kidney and to tenocytes [73, 88]. The differentiation procedure 
to osteoblasts, adipocytes and chondrocytes is well established  [72, 73, 76, 77, 89-
92]. Figure 1.1 summarizes the differentiation of MSCs to osteogenic, chondrogenic 
and adipogenic lineages, indicating the agents that are required to induce the 
differentiation and the detection methods to test the result.  
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Figure 1.1: The differentiation potential of MSCs into the mesenchymal 
lineage.  Adapted from [77]. Dex= dexamethasone, IBMX= isobuthyl methyl 
xanthine, Indo= indomethacine, Asc= ascorbic acid, β-gp= beta 
glycerophosphate. 
1.2.1.2 MESENCHYMAL STEM CELL HOMING 
Upon damage or aging of somatic cells, stem cells leave the niche and migrate to 
the site of action and differentiate into the specific cell type of demand [72, 93, 94]. 
The homing capacity of MSCs decreases with long term culture [73, 77]. The 
homing mechanism of MSCs is not known for sure however the chemokine 
receptors on the surface of the MSCs are thought to be responsible for this 
mechanism. Several groups, although with a high variety among them, have 
identified different chemokine receptors on MSCs [95]. The presence of different 
chemokine receptors on the MSCs suggests a role for trafficking the MSCs through 
different paths to reach various tissues in the organism. Besides the chemokine 
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receptors, the adhesion molecules also play a role in MSC homing. P-selectin was 
shown to be involved in the rolling of intravenously administered human MSCs in 
the blood vessels. In P-selectin deficient mice, the administered MSCs were not 
able to roll along the walls of the blood vessels [96]. Since the MSCs do not express 
the known ligands for P-selectin, it was suggested that MSCs have a novel P-
selectin ligand. The same study showed that VLA-4/VCAM-1 are required for 
hMSCs to adhere to endothelial cells [96]. Increased number of MSCs were in the 
peripheral blood after vascular injury in mice compared to noninjured ones [97]. 
Also the mobilization of MSCs to the blood after acute burns, skeletal muscle injury 
and in response to chronic hypoxia has been shown [95]. Besides mobilization to 
the peripheral blood, MSCs also migrate from blood to the damaged tissue, which 
was shown by different in vivo studies [98, 99]. Studying the molecular mechanism 
of the entire process of MSC homing, may provide new knowledge to develop more 
effective strategies in the field of regenerative medicine. Exploring the mechanism 
of stem cell homing could help in reducing the needs for high number of MSCs, by 
developing new methods for the enhanced recruitment of ex-vivo cultured MSCs to 
the injured tissue [100].  
It has been shown that there are two types of homing; long-distance traffic which is 
via the blood stream and short- distance homing which is a local movement [75]. 
The short distance homing of MSCs to an injured site was shown in different cases 
like cartilage, muscle and heart injury, bone repair, migration throughout forebrain 
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and cerebellum [75]. MSC when injected through the intravenous infusion was 
capable of migrating to a specific site of injury like in the case of bone fracture, 
cerebral ischemia and myocardial infarction [77].  
Besides all the research being done on MSC homing there are typical problems 
faced by the researchers. One problem regarding the MSC research in general is the 
lack of a universal definition, thus the heterogeneity of MSCs used in different 
studies. To overcome this, a particular MSC characterization should be performed. 
Since there aren’t any standart protocols for determining the homing efficiency and 
correlation, with functional effect, a direct comparison based on the outcome of the 
researches can not be done. A recommended action for this problem is that every 
paper should compare or contrast their results with previously published results. 
This comparison should include the number of cells that were administered, the 
infusion site, the time passed between MSC administration and assessment of 
homing, methods used to determine homing, homing efficieny and functional 
outcome of the experiment. Another problem that the researchers face with is the 
difficulty to determine the cell type that actualy has homed. The individual MSCs 
should be labelled in culture and tracked after administration to the organism [100]. 
To get a more accurate result in MSC homing research these problems should be 
solved and standart methods should be developed to compare different results. As 
the whole protocol of the experiments can effect the functional outcome every step 
should be explained clearly. MSCs are promising agents in stem cell therapy, 
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however their rareness and the high number of MSC needed for infusion makes it 
difficult to use them. After clearifiying the MSC homing mechanism, the MSCs 
could be used more efficiently in regenerative medicine. Direct targeting of the 
MSCs to the site of action could eliminate the demand for high number of cells to 
be administered.  
1.2.1.3 MESENCHYMAL STEM CELLS IN REGENERATIVE MEDICINE 
The discovery of stem cells opened a new era in the field of therapy. Currently there 
are over 3000 clinical trials involving stem cells and 174 of them are with MSCs 
(http://www.clinicaltrials.gov). The beneficial effects of MSCs in the treatment of 
different cases are via different properties of the MSCs. MSCs can support the 
survival of endogenous cells [101, 102], induce angiogenesis [103], inhibit immune 
response [104], reduce apoptosis [105] , home to the site of injury,  directly 
differentiate to the cell of the tissue, and release some chemicals which act on the 
near by cells to stimulate them [106].  
Two features of MSCs made them a popular candidate in stem cell therapy. One is 
the ability to differentiate into various types of cells as mentioned above and the 
other is their immunosuppressive nature. It has been shown that MSC prevent T-cell 
activation either by direct contact or via secreted molecules [95]. Other studies have 
also shown that MSCs can hinder dendritic cell and B-cell maturation [95].  
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The immunosuppressive nature of MSCs was used in a case study in which the 
patient developed Graft versus Host Disease (GvHD) after HSC transplantation.  
MSC treatment in this patient resulted in the healing of the gut epithelium tissue 
and the patient was in a good condition after 1 year of follow up [107]. MSCs have 
also been used in ischemic heart diseases, pancreatic regenaration, neurological 
disorders, hepatic cirrhosis, limb ischemia, skin regenaration, rheumatoid arthritis 
and bone related diseases [106]. The ability of MSC to differentiate into 
cardiomyocytes made them a candidate for the treatment of heart failures. After 
bone marrow transplantion bone marrow derived cardiomyocytes were shown to be 
engrafted into the heart of the patient [108]. In another study it was shown that bone 
marrow derived cells delivered to the infarcted heart and resulted in a dramatic 
increase in the heart function [109]. MSCs are also prominent candidates for the 
treatment of muscular dystrophy [110], and environmental induced lung disease 
[111], Since MSCs are able to promote remyelineation [112], and to differentiate 
into neurons after transplantation [113, 114], and partially recover their function 
[115] they can be used in neuronal injuries. Clinical trials for osteogenesis 
imperfecta have shown an improve in the bone formation after MSC 
transplantation. The bone mineral content and the growth velocity increased, 
whereas the bone fracture frequencies reduced [116]. Treatment of severe idiopathic 
aplastic anaemia with MSCs showed improvement of marrow stromal function 
[117].   
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Besides being a promising tool as regenerative agents, there are some handicaps in 
the therapeutic application of MSCs. Although clinical trials show promising 
results, long term effect of MSC transplantation is not known. Most of the 
knowledge of MSCs come from in vitro studies. However how these cells act in 
vivo is not very clear. What is the safe duration of transplanted MSCs, in other 
words for how long do they reside in the organism and function properly [106]? The 
amount of MSCs needed for regenerative medicine is high. How can we increase 
the  number of MSCs without increasing the culture time? Short preparation times 
are important for urgent cell based therapies. Lastly, sufficient MSCs should reach 
the site of action after infusion to the organism in short time periods. These 
problems must be solved before using MSCs in routine therapeutic applications. 
The proliferative and antiapoptotic effects of estrogen makes it a promising 
candidate in solving the last two problems.  
 ESTROGEN 1.3
Estrogen is one of the steroid hormone that is produced in the ovaries from 
cholesterol. 17β-estradiol, estrone and estriol are found in humans and 17β-estradiol 
is the most abundant one among them [118]. It does not only have an effect on the 
reproductive system but also on many other organs and systems like, brain, bone 
and organs of the cardiovascular system [119, 120] in female and male. Depending 
on the cell type, estrogen can have a proliferative, antiapoptotic or apoptotic effect 
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by changing the activity of cell cycle related or cell death related genes [121-125]. 
After menapouse, when estrogen levels decrease, increase in osteoporosis and 
coronary heart diseases occur [126, 127]. This suggests a role for estrogen in MSC 
biology. Determining the effects of estrogen on MSCs can provide insights for 
development of new strategies in MSC based therapies.  
Estrogen exert its effects via the estrogen receptors alpha or beta (ERα or ERβ). 
These receptors are members of the nuclear receptor superfamily which are ligand 
induceable transcription factors [128].  
 ESTROGEN RECEPTOR PATHWAY  1.3.1
Two types of pathways are known so far  that are involved in the action of estrogen. 
The genomic or classical pathway and the non genomic pathway. In the classical 
pathway, the hormone estrogen activates estrogen receptor (ER) in the cytosol and 
the receptor forms homodimer. Activated ER is translocated to the nucleus and 
binds to the estrogen response element (ERE) located mostly at the promoter region 
of the target gene. Subsequently, coactivators are also recruited to the receptor–
DNA complex, which results in the expression of the target gene [120, 129]. 
Estrogen induced genes do not always contain EREs yet they are activated by ERs.  
The non ERE dependent genomic pathway involves the action of other transcription 
factors which bind both to the ER-ligand complex and to the target gene promoter. 
In this way ligand activated ER activates the transcription factor and the target gene 
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is expressed. It has been shown in various studies that ER enhance the activity of 
several genes that do not have an ERE but contains AP-1 site, CRE-like element, 
electrophile response element, GC-rich promoter site. Several binding partners of 
ER on such non-ERE sites such as Jun/Fos, Jun/ATF, ATF, SP-1, NFκB, C/EBPβ 
are known but there are also unknown ones [118, 129].  
A third form of genomic pathway involves growth factors instead of estrogen and is 
called as ligand independent genomic pathway. In this model the nuclear ERs are 
activated via phosphorylation by protein kinases which then become active upon 
growth factor stimulation. The activated ERs bind to ERE sites to start the 
expression of the target genes.  
The second type of ER signaling is the nongenomic pathway. In this pathway 
estrogen activates the membrane bound ER and this starts a cascade of kinase 
signaling pathways such as MAPK, PI3/AKT, JAK/STAT pathway [130]. The 
nongenomic pathway does not involve transcription or translation but translational 
modification for the activity, thus it results in a very rapid cell type spesific 
response [118]. Figure 1.2 summarizes the ER signaling pathway. 
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Figure 1.2: The ER signaling. 1. ligand dependent genomic pathway, 2. non-
ERE dependent genomic pathway, 3. ligand independent genomic pathway 
and, 4. non genomic pathway  
 
 ESTROGEN AND MESENCHYMAL STEM CELLS 1.3.2
Gender specific responses to various stimuli by MSCs have been attributed to sex 
hormones. For example MSCs from female donor express less pro-inflammatory 
cytokines, TNF-α and IL-6, compared with MSCs from male donor in response to 
acute LPS and hypoxia [131]. Also the hypoxia induced apoptosis was different in 
male MSC compared to female ones. The MSCs from male donor underwent a 
significantly higher apoptosis compared to the female MSCs [132]. Another 
difference between female and male MSC was in the treatment of heart ischemia. 
After transplantation of MSCs from female donors, heart exhibited improved 
contractility compared to MSCs from male donors [133]. Estrogen also have an 
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effcet on the proliferation of MSC in a gender dependent fashion. MSCs from 
female donors shows an increase in proliferation upon estrogen treatment, while 
MSC from male donors do not [134]. Another relationship between estrogen and 
MSC is that estrogen increases the telomerase activity and hTERT expression via 
ERα [135]. Estrogen has also an effect on the differentiation and proliferation of 
MSCs. It stimulates the osteogenic differentiation [134] which can be assessed by 
the increase of calcium deposition and the expression of the osteogenic markers. 
Estrogen also increases the adipogenic differentiation evidenced by the increase in 
the lipid droplets [136]. However, the molecular mechanism of estrogen action on 
MSCs is not known. Understanding the molecular mechanism of their interaction is 
important in regulating MSCs and obtaining the maximum efficiency from this 
colloboration. Our group has previously shown that estrogen had no effect on genes 
related to cell cycle progression and senescence on rat bone marrow derived MSCs 
(Scientific and Technological Research Council of Turkey, TUBITAK, SBAG-
3200(105S393)). Since estrogen also has an effect on apoptosis, apoptotic pathways 
are important candidates in the regulation of MSCs. After explaining apoptosis, the 
relation between estrogen and apoptosis will be illustrated with examples. 
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 CELL DEATH AND APOPTOSIS 1.4
Cell death can occur through two distinct pathways called necrosis and apoptosis.  
Until recently necrosis was described as cell death which is not apoptosis or 
autophagy. However, latest research findings have provided more clear explanation 
for necrosis. Defined signaling pathways and catabolic mechanisms were found to 
have crucial role in necrotic cell death [137, 138]. Increased intracellular Ca2+, or 
Reactive oxygen species (ROS), decreased ATP generation [139], tumor necrosis 
factor- α (TNF-α) [140], poly-ADP-ribose polymerase-1 (PARP-1) [141] were 
shown to be important mediators of necrosis.  
Apoptosis was first described by Kerr and friends upon typical morphological 
changes that occur in the dying cell [142]. According to the Nomenclature 
Committee on Cell Death (NCCD) cell death can be defined as apoptosis when it 
possesses all or some of the following characteristics. i) rounding-up and shrinkage 
of the cell, ii) retraction of pseudopods, iii) condensation of the chromatin, iv) 
nuclear disruption, v) preservation of the organelles, vi) apoptotic body formation 
while maintaining the membrane integrity and vii) phagocytosis by neighboring 
cells. The NCCD proposes that, programmed cell death (PCD) should not be used 
to exclusively define apoptosis [143] since cell death that occurs during 
development is programmed but not apoptotic [144, 145]. One should also not think 
of apoptosis merely as caspase dependent process [146]. It can also occur in a 
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caspase independent manner, although in some cases the outcome has a slight 
variation in the cytological features as compared to known apoptotic structures 
[146]. 
The molecular events that occur during necrosis and apoptosis are different as is the 
morphology (Table 1.3). While cells and the cytoplasmic organelles swell during 
necrosis, apoptotic cells shrink and the organelles undergo a minor change. Necrotic 
cell membrane ruptures, but the apoptotic cell membranes integrity is preserved. 
DNA breakage is random and caspases are not involved in necrosis but, DNA 
fragmentation occurs and caspases are required in apoptosis. Also necrosis leads to 
an inflammatory response but apoptosis does not [143, 147].  
Table 1.3: Characteristics of apoptosis and necrosis 
  APOPTOSIS NECROSIS 
MORPHOLOGY cell shrinks  cell swells  
MEMBRANE 
INTEGRITY 
preserved lost 
DNA BREAKAGE fragmentation random 
CASPASES involved not required 
INFLAMMATORY 
RESPONSE  
no yes 
ORGANELLES 
minor 
modifications 
swelling 
 EXTRINSIC AND INTRINSIC PATHWAY  1.4.1
Well defined signaling pathways have roles in the apoptotic cell death. These 
pathways can be divided into two: the extrinsic (death receptor) and the intrinsic 
(mitochondrial) pathway [148]. Figure 1.3 represents the extrinsic and intrinsic 
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apoptotic pathways. After explaining the pathways, and the role of mitochondria in 
apoptosis, special focus will be given to the Bcl-2 family members and their 
function in apoptosis. The relation between estrogen and apoptosis will be 
explained with known examples. 
The extrinsic pathway is activated when death ligands, TNF-α, TRAIL and FasL 
bind to their cognate receptors in the plasma membrane.  This binding induces 
receptor oligomerization and recruitment of an adaptor protein.  These adaptor 
proteins are Fas associated death domain (FADD) and TNF associated death 
domain (TRADD). After the joining of pro-caspase-8 or pro-caspase-10 the 
complex death inducing signaling complex (DISC) is formed. The initiator caspase 
is activated via proteolytic cleavage. This activation triggers the effector caspases, 
caspase-3 or caspase-7 and apoptosis occurs [149, 150].  
The intrinsic pathway occurs mainly through the mitochondria. Various stimuli can 
trigger the mitochondrial pathway. Hypoxia, growth factor deprivation, reactive 
oxygen species, DNA damage, UV/ gamma irradiation are some of the apoptotic 
signals activating the intrinsic pathway. Mitochondria are crucial for cell survival 
due to their vital role in many metabolic activities [151]. Recent studies have 
established important roles for mitochondria during different stages of the cell death 
process. They are involved in energy generation for the cell death process, calcium 
homeostasis, ROS generation, pro-apoptotic proteins releasing, apoptosome 
formation and caspase activation [151].  
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Figure 1.3: The extrinsic and intrinsic apoptotic pathways. [149] 
 
Normally mitochondria have a transmembrane potential which creates an 
electrochemical gradient across the inner membrane that is essential for ATP 
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generation. The disruption of this transmembrane potential due to the 
permeabilization of the mitochondrial membranes results in cell death [151, 152]. 
Mitochondrial membrane permeabilization can occur through lipids [153-155], 
mitochondrial permeability transition pore (MPTP) [156, 157], or Bcl-2 family of 
proteins. The induction of the mitochondrial membrane permeabilization results in 
the release of apoptotic factors from the mitochondria to the cytosol or nucleus and 
initiates apoptosis.  
The pro-apoptotic members, BCL2-antagonist/killer (Bak) and Bcl2-associated X 
protein (Bax) of the Bcl-2 family of proteins permeabilize the outer membrane of 
the mitochondria, which results in the release of pro-apoptotic proteins such as 
cytochrome c (Cyt c), apoptosis inducing factor (AIF) and endonuclease G from the 
mitochondria to the cytosol. While AIF and endonuclease G goes to the nucleus and 
induce DNA fragmentation [158, 159] in a caspase independent form [159, 160], 
Cyt c stays in the cytoplasm.  In the cytosol, Cyt c together with apoptotic protease-
activating factor (Apaf-1), dATP and pro-caspase-9 forms the apoptosome complex. 
After proteolytic cleavage of pro-caspase-9 in the apoptosome, it is activated and 
can activate the effector caspase, caspase-3 [161].  
 BCL-2 FAMILY MEMBERS 1.4.2
According to their function, Bcl-2 family of proteins is divided into two types, anti-
apoptotic and pro-apoptotic members. The pro-apoptotic ones are further 
categorized as the multi-domain proteins and the BH3 only proteins due to their 
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structural and functional difference. More than 25 members of this family are 
known [162, 163]. (Figure 1.4) 
All of the members share one or more conserved Bcl-2 homology (BH) domains. 
The four BH domains which are specific to the family members are BH1, BH2, 
BH3, and BH4 [164]. These domains are required for the function of the proteins 
[165-168]. Many of the Bcl-2 family proteins also have a carboxy terminal 
hydrophobic domain. The localization of the members to the mitochondria is 
directed through this domain [162, 169, 170].  
 
Figure 1.4: The structure of the Bcl-2 family members. BH= Bcl-2 homology 
domain and TM= transmembrane domain.[170] 
  
Among anti-apoptotic members of the family, B cell lymphoma like X (Bcl-xL) and 
B-cell leukemia/lymphoma 2 (Bcl-2), have all the four BH domains and are 
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generally integrated mostly to the mitochondrial outer membrane but also can be 
found in the endoplasmic reticulum membrane or the cytosol [171, 172]. Bcl-2 
prevents cell death by inhibiting free radical production, suppressing caspase 
activation, regulating calcium sequestration, and by preventing the pro-apoptotic 
factors from inducing apoptosis [173]. Bcl-2 is widely expressed during 
embryogenesis but it decreases and becomes much more restricted postnatally in the 
nervous system [174]. Bcl-2 and Bcl-xL prevent apoptosis either by segmenting 
caspases or by preventing the release of mitochondrial apoptogenic factors such as 
cytochrome c and AIF into the cytoplasm [175]. 
The multi domain pro-apoptotic members have the BH1-3 in common and lack the 
BH4 domain. The localizations of the proteins are different in that in healthy cells, 
Bak is in the outer mitochondrial membrane whereas Bax is mostly in the cytosol 
and travels to the mitochondria upon apoptotic stimuli [176-179]. The presence of 
either Bax or Bak, which are thought to function mainly at the mitochondria, seem 
to be crucial for apoptosis in many cell types since most death stimuli converge on 
their activation [180, 181]. Bax heterodimerizes with Bcl-2 and homodimerizes with 
itself. When Bax is overexpressed, apoptotic death in response to a death signal 
accelerates, but when Bcl-2 is overexpressed, it heterodimerizes with Bax and 
apoptosis is repressed [182]. Therefore the ratio of Bax and Bcl-2 is important in 
regulating apoptosis. 
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The BH3 only proteins possess only the conserved BH3 domain. The BH3 only 
proteins are known to function in two distinct mechanisms.  Some, like Bid, can 
either directly activate the multidomain pro-apoptotic members while others, like 
Bad and NOXA, inactivate the anti-apoptotic members [183, 184].  
The interaction between the anti-apoptotic, pro-apoptotic and BH3 only proteins 
determines apoptosis [171]. Several distinct models have been proposed to explain 
the relationship between the anti-apoptotic, the pro-apoptotic and the BH3 only 
proteins during regulating apoptosis (Figure 1.5). In the first model the pro-
apoptotic members are sequestered and hold in an inactive state, by the anti-
apoptotic ones when there is no need for apoptosis. Upon apoptotic stimulus the 
BH3 only proteins bind to the anti-apoptotic members and set free the pro-apoptotic 
ones. This release results in activation of the pro-apoptotic members and 
subsequently apoptosis. In the second proposed model again the anti-apoptotic ones 
prevent the pro-apoptotic ones from inducing apoptosis, however this time the pro-
apoptotic members are activated by the BH3 only members via direct interaction 
between these two members. In the third model the anti-apoptotic members hinder 
the BH3 only members to activate the pro-apoptotic ones. Upon apoptotic stimuli 
the BH3 only proteins overcome the hurdle and activate the pro-apoptotic members 
[170]. 
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Figure 1.5: Regulation of Bcl-2 proteins. A)BH3-only proteins sequester anti-
apoptotic proteins and allow the pro-apoptotic ones to initiate apoptosis. B) 
BH3-only proteins directly activate pro-apoptotic members. C)the anti-
apoptotic proteins sequester the BH3-only proteins and thereby preventing 
apoptosis. [170] 
1.4.2.1 SIGNALING PATHWAY  
After activating the intrinsic pathway through various stimuli like growth factor 
deprivation or DNA damage, the signaling pathway starts. The first reaction 
involves the activation of the multi-domain pro-apoptotic proteins. This activation 
is mainly at post translational level where the inactive protein becomes activated 
through conformational changes. Upon apoptotic stimuli, the C-terminal and N-
terminal domains of Bax undergo a conformational modification, which results in 
the translocation of the protein from the cytosol to the mitochondrial outer 
membrane where it forms oligomers [176, 185, 186]. Since Bak is already in the 
mitochondrial outer membrane, there is no need for its translocation. However, 
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studies have shown that also at the N-terminus of Bak a conformational alteration 
occurs after an apoptotic stimulus [187] suggesting that there are other 
consequences of the modification than translocating to the mitochondria. Pro-
apoptotic proteins, Bak and Bax form channels on the outer mitochondrial 
membrane by homo- or hetero-oligomerization [151]. These channels cause the 
release of the pro-apoptotic activators from the mitochondria to the cytosol. There 
are also other models to explain the role of Bak and Bax oligomers on inducing 
apoptosis. One of these models is that, Bak and Bax cause a change in the lipid 
bilayer of the outer mitochondrial membrane. This change facilitates the release of 
the apoptotic factors like Cyt c to translocate to the cytosol [188, 189]. Other 
mechanism by which Cyt c is released includes the interaction of Bax with the 
mitochondrial protein voltage dependent anion channel (VDAC) [190] but the 
detailed function of VDAC in this process is not known [152].  Once in the cytosol, 
Cyt C, binds to APAF-1.  As discussed above Cyt C, APAF-1 and dATP forms a 
complex called the apoptosome. In this complex APAF-1 undergoes a 
conformational change and as a result of this, its caspase recruitment domain 
(CARD) becomes exposed. The pro-caspase 9 is recruited to the apoptosome and 
proteolytic cleavage occurs to activate the caspase. The active caspase activates the 
effector caspases, caspase 3 or 7, which leads to apoptosis [161, 191]. Other 
mitochondrial proteins which are involved in this caspase dependent cell death 
pathway, is Smac/DIABLO and HtrA2/Omi. Both proteins bind and sequester the 
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inhibitor of apoptosis proteins (IAP), whereby they prevent them from inhibiting 
the caspases [192-195].  
  ESTROGEN, APOPTOSIS AND THE BCL-2 FAMILY OF 1.4.3
GENES 
The effect of estrogen on apoptosis depends on the cell type, the duration and 
amount of estrogen and the downstream target signaling pathway. It has been 
shown that estrogen prevents apoptosis in mouse neurons by upregulating the anti-
apoptotic genes bcl-2, bcl-xL, bcl-W, blf-1 and by downregulating TRADD [196]. It 
has also been shown that estrogen had an antiapoptotic effect on rat osteocytes 
[197], human umbilical vein endothelial cells [198], rat hippocampal neurons by 
increasing the expression of Bcl-xL [199], mice neurons by inhibiting Fas- 
mediated-apoptosis after ischemia [200], some breast cancer cell lines by increasing 
the expression of Bcl-2 [123]. On the other hand, it promoted apoptosis in 
osteoclasts [201, 202], thymocytes [203], neurons via ERβ [204]. It has been shown 
that estrogen could have opposing effect on the apoptosis of neurons. It may 
function as a neuroprotective agent or an inducer of apoptosis, depending on the 
estrogen receptor-subtype present in the cell. Thus, ERα has a neuroprotective 
effect, while ERβ mediates the induction of apoptosis in neuronal cells [204]. 
Although the mechanism of the apoptotic or antiapoptotic function of estrogen is 
not always through the same pathway, the Bcl-2 family of genes are one of the 
major candidates in this process. Several studies have shown a direct or an indirect 
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relation between estrogen and the expression status of the members of the Bcl-2 
family of genes. It is thought that estrogen increases the expression of bcl-xL 
through a putative ERE site on Bcl-X gene [199]. Several ERE sites are found on the 
bcl-2 gene [205]. Estrogen also prevents the upregulation of Bax in ovariectomized 
rats neurons [206]. All these data show that estrogen influences the expression of 
the Bcl-2 family of genes either via the ERE dependent classical pathway or 
through the non-genomic pathway. 
 EPIGENETICS 1.5
Different definitions for the term “epigenetics” have been made since mid 1900s. 
The first scientists who used the epigenetic concept were mainly developmental 
biologists who were aware of the fact that although the genetic sequences were 
same, the phenotype might not be same in every cell. Conrad Waddington is the 
scientist who came up with the word epigenetics and defined as “the interaction 
between genes and their products which brings the phenotype into being”, more 
than 60 years ago [207]. Today it is accepted that epigenetics involves two main 
concepts; first, without changing the DNA sequence, modifications occuring in the 
chromosome or in the proteins changes the outcome, and second, these 
modifications are mitotically inherited [208, 209]. The mechanism beyond this is 
now a huge area to study. Several distinct pathways have been identified that lead to 
epigenetic changes. The molecular mediators of these pathways can be divided into 
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three; the epigenators which are the environmental signals and give the signal for 
that particular pathway to start, the epigenic initiators like DNA binding factors 
which locate the precise place on the chromatin to be modified upon the epigenator 
signals, and lastly, the epigenetic maintainers like the histone/DNA modifiers, 
histone variants which keep the modification in every generation [210].  
 TYPES OF EPIGENETIC MODIFICATIONS  1.5.1
Two of the best known epigenetic modifications are DNA methylation and histone 
protein post translational modifications (PTM). The concept of DNA methylation 
can be traced back to 1970s. The importance of this phenomena was understood 
when researchers found out that mostly the promoters of inactive genes were 
methylated whereas the the active gene promoters were not or ligthly methylated 
[211, 212]. The specific Cytosine that is methylated in the DNA sequence is a 
Cytosine nucleotide preceeding a Guanidine nucleotide. This dinucleotide sequence 
in the DNA is called CpG island and is required for the DNA methyltransferase 
enzyme family to add a methyl group to the cytosine. Members of this family can 
start a de novo methylation in the early developmental stage or/and fully methylate 
the hemimethylated CpG in a daughter cell. This feature of the DNA 
methyltransferase enzymes and the semiconservative replication nature of the DNA 
makes this modification sustained in the next generations. DNA methylatransferase 
searches for the hemimethylated CpG island in the new cell and methylates the C in 
the newly synthesized strand [209, 213].  
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Another epigenetic modification that gained high attention is histone modification. 
The eucaryotic genomic DNA is wrapped around nucleosome which consists of the 
nucleosome core particle and an octamer formed by the four core histone proteins, 
H2A, H2B, H3, and H4, and 146 bp of DNA [214], [215]. For other DNA binding 
proteins, like transcription or replication factors to reach the DNA sequence of 
interest, these histone proteins have to be modified to allow access at the right time 
to the right position of the DNA [216]. These modifications are either histone PTM 
namely methylation, acetylation, ubiquitylation, sumoylation and phosphorylation 
or the alteration of the chromatin packaging directly by moving of the histones 
namely remodeling. Histone PTMs are seen on the canonical histones H2A, H2B, 
H3 and H4 and on the variant histones H3.1, H3.3 and HTZ.1. Most of the 
modifications are on the amino- and carboxy-terminal domain whereas few 
modifications are localized to the histone globular domains (Figure 1.6) [217].  
Histone modifications render the DNA in an active or inactive state. However there 
is not always a direct correlation between the histone mark and the on or off state. It 
is found that several histone modifications functioning in activating a gene may also 
have repressing effects or visa versa [218]. The type of modification does not 
always indicate the function of it. For example, although acetylation is mainly 
activating, the effect of methylation is context dependent meaning that the other 
PTMs are also important. For example 3 methylation of nineth lysine residue on 
histone 3 (H3K9me3) is known as a repressive mark however when it is found on 
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chromosomes with H3K4me3 mark than they function in activating a gene. Besides, 
also the residue to which the methy moiety is attached to is important in defining 
the expression state of a gene. For example euchromatins have mostly acetylation in 
their histone tails and H3K4, H3K36 and H3K79 methylation, whereas the 
heterochromatins are defined by H3K9, H3K27 and H4K20 methylation [218]. 
Several histone marks and their regulatory role are listed in table 1.4. 
 
 
Figure 1.6: Covalent modifications of the core histone proteins. Ph; 
phosphorylation, ac; acetylation, ub1; ubiquitylation, me; methylation. N; 
amino terminal domain, C; carboxy terminal domain [217].  
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Table 1.4: The regulatory roles of several histone marks. (Adopted from [218]) 
PTM RESIDUE 
TRANSCRIPTIONAL 
STATUS 
Acetylated lysine (K,ac) H3 (9, 14, 18, 56), Activation 
 H4 (5, 8, 13, 16), Activation 
 H2A, H2B Activation 
Methylated arginine 
(R,me) H3 (17, 23), Activation 
 H4 (3) Activation 
Methylated lysine (K,me) H3 (4, 36, 79) Activation 
 H3 (9, 27), Repression 
 H4 (20) Repression 
 
The activating effect of acetylation comes from the rendering the chromatin in a 
more open state which facilitates the binding of coactivators. Indeed some 
coactivators like, CBP-p300, SRN-1 have an intrinsic histone acetylase activity 
[217]. 
Histone methylation occurs via histone methylatransferases. In contrast to histone 
acetylases these enzymes are more spesific to their substrates. Methylation can 
occur on arginine (R) and lysine (K) residues [217]. For a long time, it was thought 
that histone methylation was an irreversible modification, since only histone 
methylases were known but no demethylases. Only recently lysine demethylases 
have been found [219]. These enzymes remove the methyl moiety from the N 
terminal tail of the histones through complex biochemical reactions [219]. Lysine 
Specific Demethylase 1 (LSD1) is the first demethylase that was discovered. It 
demethylates mono-dimethylated histone 3 at lysine 4 (H3K4) through amine 
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oxidation reaction [220]. After LSD1 other demethylases have been identified. The 
Jumonji-C (JmjC) domain proteins catalyze the removal of methyl moieties from 
various methylated histone tails [219]. The list of demethylases with their substrates 
is given in table 1.5. 
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Table 1.5: Demethylases and their substrates. (Adopted from [217]). 
ENZYME SPECIFICITY 
LSD1 
H3K4me2, me1, 
H3K9me2 
D.melanogaster Lid H3K4me3 
UTX, JMJD3 H3K27me3, me2 
JHDM1 H3K36me2, me1 
JHDM2 H3K9me2, me1 
JHDM3 (JMJD2) 
H3K9 and K36 me2, 
me1 
JARID1A (RBP2), JARID1B (PLU-1), 
JARID1C (SMCX) 
HEK4me3, me2 
 
 HISTONE MODIFICATIONS, STEM CELL, APOPTOSIS, 1.5.2
AND ESTROGEN 
The pluripotency and differentiation of stem cells are controlled by various 
epigenetic modifications. In the undifferentiated state, the chromatin of the ESCs 
are mostly in euchromatin state and upon differentiation they gain heterochromatic 
structure [221]. The epigenetic modification on the stem cell chromosomes are 
stable enough to be inherited in one lineage, and also reversible to be changed 
during differentiation. The first feature is important for the self renewal and the 
second feature is important for the potency of the stem cells [222]. The histone 
proteins that bind to the chromatin of undifferentiated ESCs are more loosely 
attached compared to histone proteins binding to differentiated cells [223]. The 
promoters of lineage spesific genes are mostly occupied by repressive H3K27me3, 
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and activating H3K4me, histone mark, which is called bivalent chromatin marks. 
These genes are silenced, however can be activated upon correct stimuli [224]. If 
the gene is spesifically expressed by the committed lineage, then the histone mark 
on the promoter of that gene will be an activating mark, (H3K4me) otherwise it will 
be a repressive mark, (H3K27me3) [225]. This phenomena could also explain how 
the normaly inactive genes during the undifferentiated state are turned on quickly 
upon differentiation [226].  
The relationship between apoptosis and some types of histone PTMs have been 
identified. Phosphorylation, dephosphorylation, acetylation, methylation and 
deubiqutylation of some histone variants are related to apoptosis [227]. Some of 
these modifications are phosphorylation of H1, H2A, acetylation of H4, methylation 
of H3K27, phosphorylation of H2BS14 [227]. 
The effect of estrogen on histone PTMs have been shown mostly in breast cancers, 
but other researches have also linked estrogen to histone PTM. In Mcf-7 cell line 
the demethylation of H3K9me3 and the methylation of H3K4 occurs as a result of 
ERα signaling pathway. The enzyme complex that is responsible for that is 
JMJD2B/MLL2. JMJD2B is a target of ERα signaling pathway and also required 
for the expression of estrogen responsive genes [228].  
Another histone modification enzyme that is involved in ERα pathway is Sirt1 
which is an histone deacetylase. In the absence of this enzyme the ligand activated 
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ERα pathway is impaired [229]. In an early study it was shown that estrogen 
increased the global acetylation in rat uterus [230]. It was also responsible for an 
increase in acetylation of spesific histones in endometrial  stromal cells [231].  
Two different studies showed the linkage between enhancer of zeste homolog 2 
(EZH2), the methyltransferase for H3K27me3 mark and estrogen. First Hwang and 
friends showed that when overexpressed, EZH2 repressed the expression of 
estrogen regulated genes in the presence of a protein called the repressor of estrogen 
receptor activity (REA) [232]. Later Bredfeldt and friends showed that 
phosphorylation of EZH2 was followed by the decrease in H3K27me3 upon 
estrogen and xenoestrogen addition both in Mcf-7 cells and uterine tissue. The 
ceasing of the activity of EZH2 resulted in increased expression of estrogen 
regulated genes that were substrates for EZH2 [233]. In both of the studies there 
were a direct connection between estrogen and H3K27me3 mark.
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Chapter 2  
AIM OF THE STUDY 
MSCs have high therapeutic value due to their immuno suppressive characteristics, 
capacity to differentiate into various cell types, ability to home to the site of injury, 
ease of handling and no ethical concerns. However, a major handicap in using 
MSCs in medicine is their limited numbers. Therefore the number of MSCs should 
be increased effectively. Estrogen is a promising candidate in the regulation of 
MSC maintenance due to its role in proliferation and apoptosis. It is known that 
apoptosis is an important regulatory mechanism in all organisms and is a conserved 
system which emphasizes its importance throughout evolution. The Bcl-2 family of 
proteins have critical members that are controlled by estrogen in other systems. 
They are regulated either directly or indirectly via estrogen. Therefore the members 
of the Bcl-2 family of proteins are strong candidates in the regulation of MSC. In 
this thesis we aimed to tudy the effect of estrogen on MSC maintenance and the 
molecular mechanism of this effect. 
.  
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Chapter 3  
MATERIALS AND METHOD 
 ANIMALS 3.1
Normal female and ovariectomized Spraque Dawley rats were used in the 
experiments. They were kept in the animal facility laboratory of the Molecular 
Biology and Genetics Department at Bilkent University with unlimited access of 
food and water and under a controlled environment with 12 hour light/dark cycles 
and at 22
0
C. The experimental procedures have been approved by Bilkent 
University Local Ethical Committee (BILHADYEK). 
 OVARIECTOMIZATION 3.1.1
The ovariectomization procedure was performed under full anesthesia with 
Ketamine (Park Davis, Michigan, USA) at a concentration of 30mg/kg. Two 
incisions were made on both sides of the vertebrate, ovaries at the tip of each uteri 
horn were tied with silk and then removed. The animals were sutured and kept 
under supervision until they fully recovered from the anesthesia. Ovariectomized 
animals were used approximately after 2 months after the operation to ensure the 
total deprivation of estrogen from their bodies.  
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 PARTIAL HEPATECTOMY (PH) 3.1.2
Liver resections consisting of 70% of the liver mass were surgically performed after 
injecting Ketamine (Park Davis) subcutaneously at a dose of 30mg/kg. Sham (SH) 
group of animals had undergone the same preoperative anesthesia procedure and all 
the surgical operations same as PH, but the liver lobes were not resected. 
Operations were performed between 8:00 AM and 12:00 PM to minimize diurnal 
effects. After completion of the procedure, the animals were placed under a lamp to 
prevent the hypotermy and then put into cages (one animal per cage) with 
continuous supply of food and water.  
 HARVESTING AND CULTURING OF THE BONE 3.2
MARROW DERIVED MESENCHYMAL STEM 
CELLS 
The bone marrow cells were isolated from the tibia and femur of the rats. Animals 
were sacrificed with cervical dislocation. Tibia and femur were removed and 
cleaned from the adherent tissue. Both ends of the bones were cut open. The bone 
marrow was flushed with DMEM (HyClone, Logan, USA) containing 10% Fetal 
Bovine Serum (HyClone) and 1% penicillin/streptomycin antibiotic solution 
(HyClone), by using a 5 ml syringe. The suspension was centrifuged at 1500 rpm 
for 5 minutes and the supernatant was removed. To wash the cells the pellet was 
resuspended in 10 mL of 1XPBS and centrifuged again at 1500 rpm for 5 minutes. 
Supernatant was removed and the washing step with the same conditions was 
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performed two more times. The bone marrow cells were resuspendet in MesenCult 
media (Stem Cell technologies, Vancouver, Canada ) with supplement (Stem Cell 
Technologies, Vancouver, Canada), and 1% penicillin/streptomycin antibiotic 
solution (HyClone). The cells were counted with hemacytometer and equal number 
of cells were plated onto the culture flasks. The calculation was done according to 
the formula below 
Total number of cells= number of cells in mm
3
 X 10
4 
X dilution factor 
 The media was changed at the first day and then every 4-5 days until 14 days of 
culture. 10
-7
 M estrogen (17 ß-estradiol, Sigma, Germany) was added to the culture 
plates from the first day of culture and until the last day to obtain the estrogen 
treated counterparts. The tamoxifen treated samples were prepared by adding 10
-6
M 
tamoxifen (Sigma) to the culture plates from the first day of culture until the last 
day. For every experiment at least three sets of animals was used. summary of the 
animal models is shown in figure 3.1. 
 ADIPOGENIC AND OSTEOGENIC 3.3
DIFFERENTIATION 
MSCs were trypsinized and plated onto appropriate culture dishes or flasks at day 
14 of their culture and incubated with Mesencult media until they reached 85-95% 
confluence. After that, the media was replaced with adipogenic induction media 
(AIM) containing 1µM dexamethasone (Sigma), 100µM indomethacine (Sigma), 
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0.5mM IBMX (Sigma), 10µg/mL insulin (Sigma, Germany), 10% FBS (HyClone), 
1% penicillin/streptomycin (HyClone) in DMEM-LG (HyClone) or with osteogenic 
induction media (OIM) containing 0.1µM dexamethasone, 0.2mM ascorbic acid ɣ-
irradiated (Sigma), 10mM glycerol phosphate disodium salt hydrate (Sigma), 10% 
FBS and 1% penicillin/streptomycin in DMEM-LG. The media was changed three 
times a week. AIM and OIM were prepared freshly before every medium change.  
 
 
Figure 3.1: Animal models and MSCs groups used in the thesis.  
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 OIL RED O STAINING  3.4
The medium was aspirated and cells were washed with 1XPBS. Afterwards they 
were incubated in 10% formaldehyde for 10 minutes at room temperature (RT). 
Then they were washed first with 1XPBS and then with water. Cells were incubated 
with Oil red O (Sigma) solution for 50 minutes at RT. Subsequently Oil red O 
solution was removed and the cells were washed with tap water. Photos were taken 
under light microscope.  
 ALIZARIN RED S STAINING 3.5
The medium was removed and cells were washed with 1XPBS. Next they were 
fixed with 70% ethanol at RT for 1 hour. Next the cells were washed with ddH2O 
and stained with 40mM Alizarin Red S (Sigma) (pH:4.1) for 30 minutes at RT. 
Afterwards the cells were washed with tap water. Images were taken under light 
microscope. 
 DiI LABELING 3.6
A stock solution of 2 mg/mL CM-DiI (C7001 Molecular Probes) was prepared in 
dimethyl sulfoxide (DMSO) and stored at -20°C. The stock solution was diluted in 
1X PBS to achieve a final concentration of 5 μg/mL. The MSCs to be labeled were 
washed with 1X PBS and afterwards the 5 μg/mL DiI working solution was added 
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directly into flasks. The flasks were incubated for 5 minutes at 37°C and for 15 
minutes at 4°C. After washing twice with 1X PBS, MesenCult (StamCell 
Technologies) was added to the flasks. 
In the fifth day of CM-DiI labeling, the cells were taken from flasks by trypsinizing. 
The cell concentration was adjusted to 1X10
5
cells/ml in 1X PBS for all injections 
and chilled on ice. 7.5X10
5
 labeled cells were injected to the, 3 day PH and SH rats 
under anesthesia through the tail vein. After 3 days the animals were sacrificed and 
their livers were taken and frozen in liquid nitrogen. 5µm liver sections were taken 
and visualized under fluorescence microscope after mounting with DAPI (Santa 
Cruz, CA, USA Biotechnology). 
 COLONY FORMING UNIT (CFU) ASSAY 3.7
MSCs were washed with 1X PBS and let to air dry. Subsequently the cells were left 
in ice cold methanol for 5 minutes for fixation and let to air dry again. Afterwards 
giemsa (Carlo Erba, Italy) was added to the samples for 5 minutes. The reaction 
was stopped by the addition of tap water. The purple colonies were counted under 
light microscope. To count the cells in a colony MSCs were fixed with ice cold 
methanol for 10 minutes and than mounted with UltraCruz (Santa Cruz) mounting 
medium with DAPI. The cells in the colonies were counted under fluorescence 
microscope. 359nm wavelength was used to detect the DAPI staining. 
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 TUNEL ASSAY 3.8
TUNEL assay is based on the detection of fragmented internucleosomal DNA. The 
fragmented DNA causes free 3’-hydroxytermini where the enzyme terminal 
deoxynucleotidyl transferase (TdT) adds labeled dUTP, hence the name, terminal 
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL). TUNEL assay was 
performed on the MSCs adhered to the cover slip with In Situ Cell Death Detection 
Kit, Fluorescein (Roche Diagnostics, Mannheim, Germany) according to the 
manufacturer’s manual. The cells were washed with 1XPBS and fixed with 4% 
freshly prepared paraformaldehyde in 1XPBS. The incubation was done in dark for 
1 hour at RT (RT). After washing the cells with 1XPBS, they were incubated for 2 
minutes at +4
0
C with cold permeabilization solution (0.1% Triton X-100, 0.1% 
sodium citrate) which was also freshly prepared. Next the cells were washed again 
with 1XPBS and incubated with TUNEL reaction mixture for 1 hour at 37
0
C in an 
humidified environment. At the end the samples were washed with 1XPBS and 
mounted with the UltraCruz (Santa Cruz) mounting medium with DAPI. Samples 
were analysed under fluorescent microscope. The excitation wavelength of FITC 
was 490nm and the excitation wavelength for DAPI filter was 359nm.  
 TOTAL RNA ISOLATION FROM CULTURED MSC 3.9
The cells were washed twice with 1XPBS and trypsinized (HyClone). The cell 
suspension was transferred into a falcon tube and centrifuged at 1500rpm for 5 
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minutes. The total RNA from the cell pellet was isolated by using the NucleoSpin
R
 
RNA II Kit (Macherey-Nagel, Germany) according to the manufacturer’s protocol. 
The cell pellet was lysed with 350µl RA1 containing 3.5µl β-Mercaptoethanol and 
350µl 70% DEPC-treated ethanol was added to the lysate. The lysate was 
transferred into the column supplied by the manufacturer and centrifuged at 13000 
rpm for 1 minute. The flow through was discarded and 350µl MDB solution was 
added on the column containing the lysate and centrifuged again at 13000 rpm for 1 
minute. 95µl of the DNase reaction mixture was added slowly onto the samples in 
the column and incubated at RT for 20 minutes. Next the column was removed and 
placed in another collection tube and washed with 200µl RA2 and centrifuged at 
13000 rpm for 1 minute. After that the flow through was discarded and the sample 
was washed with 600µl RA3 and centrifuged at 13000 for 1 minute. After removing 
the flow through the sample was washed for the last time with 250µl RA3 and 
centrifuged at 13000 rpm for 2 minutes. The RNA was eluted with RNase free 
water and the concentration was determined with NanoDrop ND1000 
spectrophotometer (Nanodrop technology, USA). 
 cDNA SYNTHESIS 3.10
2µg of RNA was used for each cDNA synthesis reaction. The synthesis was 
performed with the DyNAmo cDNA Synthesis Kit (Finnzymes, Finland) according 
to the manufacturer's protocol. 2µg RNA was mixed with DEPC treated ddH2O to a 
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total volume of 12µl and 2µl of Oligo (dT) primer was added to the mixture. The 
samples were incubated at 65
0
C for 5 minutes and then chilled on ice for 3 minutes. 
20µl of 2X RT buffer including dNTP mix and MgCl2, and 4µl of M-MuLV RT 
RNase H
+
 enzyme was added to the samples and then they were incubated at 25
0
C 
for 10 minutes, 45
0
C for 45 minutes and 85
0
C for 5 minutes. The cDNAs were kept 
at -20
0
C. 
 PRIMER DESIGN 3.11
Primers were designed by using Primer exe and Primer3 programs. The amplicon 
size of the PCR products of each primer and the specificity of each primer were 
controlled with publically available NCBI and ENSEMBLE databases.  
 SEMI QUANTITATIVE PCR 3.12
PCR for the anti-apoptotic genes, bcl2, bcl-xL, the pro-apoptotic genes bak, bax, the 
positive and negative markers of MSCs, CD90, CD71, CD29, CD45, CD34, the 
estrogen responsive gene, mmp12, and for the housekeeping genes gapdh, and β-
Actin was performed by using DyNAzyme II (Finnzymes). The primers and RT-
PCR conditions are indicated in table 3.1 and table 3.2 respectively.  
The RT-PCR mixture contained 1X Taq Buffer (Finnzymes), 1U Taq DNA 
polymerase (Finnzymes), 1.5 mM MgCl2 (Finnzymes), 1 µL 10 pM  forward and 1 
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µL 10 pM reverse primers, 0.2 µM dNTP (Finnzymes),and  1 µL cDNA in a total of 
volume 25 µL that was completed with ddH2O. 
 AGAROSE GEL ELECTROPHORESIS 3.13
1X TAE was used to prepare 1.5 % agarose gel. 1mg/mL ethidium bromide was 
added to the gel prior to polymerization of the gel. Agarose gel loading dye was 
added to the samples at a final concentration of 1X and the samples were loaded 
onto the gel. The gel was run at 80 Volt for 25-40 min and visualized with 
transluminator (Vilber Lourmat, France). ChemiCap (Vilber Lourmat) software was 
used to take the photos and Bio1D (Vilber Lourmat) software was used to calculate 
the band intensities. Gene ruler DNA ladder mix (Fermentas, Canada) and 50bp 
DNA Ladder (New England, Biolabs, MA, USA) was used as markers. 
 TOTAL PROTEIN ISOLATION AND 3.14
QUANTIFICATION 
MSCs were scraped with a scraper and centrifuged at 1500 rpm for 5 minutes. The 
pellet was dissolved in lysis buffer and put on ice for 30 minutes with finger tipping 
every 5 minutes. Afterwards the samples were centrifuged at 13000 rpm for 20 
minutes at 4
0
C. The supernatant was taken and kept at -80
0
C. The protein 
concentration was detected with the Bradford assay [234]. 
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Table 3.1:  Primer used in the study 
gapdh Forward 
Reverse 
5’-CCTCCTCATTGACCTCAACTAC -3’ 
5’-CATGGTGGTGAAGACGCCAG-3’ 
210 bp 
bak Forward 
Reverse 
5’-CCGGAATTCCAGGACACAGAGGA-3’ 
5’-CCAAGCTTGCCCAACAGAACCAC-3’ 
536 bp 
bax Forward 
Reverse 
5’-AATCATGGACGGGTCC-3’ 
5’- GCCCATCTTCTTCCAG-3’ 
578 bp 
bcl-2 Forward 
Reverse 
5’-CCTGGCATCTTCTCCTTC-3’ 
5’-TGCTGACCTCACTTGTGG-3’ 
584 bp 
bcl-xL Forward 
Reverse 
5’-TCAATGGCAACCCTTCCTGG-3’ 
5’-ATCCGACTCACCAATACCTG-3’ 
346 bp 
beta actin Forward 
Reverse 
5'-CTGGCCTCACTGTCCACCTT- 3' 
5'-GGGCCGGACTCATCGTACT- 3' 
65 bp 
CD 90 Forward 
Reverse 
5’- CCAGTCATCAGCATCACTCT- 3’ 
5’- AGCTTGTCTCTGATCACATT- 3’ 
374 bp 
CD 34 Forward 
Reverse 
5’- TGTCTGCTCCTTGAATCT -3’ 
5’- CCTGTGGGACTCCAACT- 3’ 
281 bp 
CD 71 Forward 
Reverse 
5’- ATGGTTCGTACAGCAGCAGA- 3’ 
5’- CGAGCAGAATACAGCCATTG- 3’ 
182 bp 
CD 29 Forward 
Reverse 
5’-ACTTCAGACTTCCGCATTGG -3’ 
5’- GCTGCTGACCAACAAGTTCA- 3’ 
190 bp 
CD 45 Forward 
Reverse 
5’- ATGTTATTGGGAGGGTGCAA-3’ 
5’- AAAATGTAACGCGCTTCAGG-3’ 
175 bp 
mmp 12 Forward 
Reverse 
5’- GGCAACTGGACACCTCAACT -3’ 
5’- GTCCAGGTTTCTGCCTCATC -3’ 
382 bp 
 
lpl Forward 
Reverse 
5’-ACTGCCACTTCAACCACAGC -3’ 
5’-AATACTTCGACCAGGCGACC-3’ 
467 bp 
pparγ Forward 
Reverse 
5’-GGACCTCTCTGTGATGGATGA-3’ 
5’-GGACGCAGGCTCTACTTTGA-3’ 
198 bp 
runX Forward 
Reverse 
5’-CTACGAAATGCCTCTGCTGT-3’ 
5’-TGTCTGTGCCTTCTTGGTTC-3’ 
194 bp 
oc Forward 
Reverse 
5’-ATGAGGACCCTCTCTCTGCTC-3’ 
5’-GTGGTGCCATAGATGCGCTTG-3’ 
293 bp 
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Table 3.2: RT-PCR conditions for each primer 
Genes 
Initial 
denaturation 
Denaturation Annealing Extension Cycle 
Final 
extension 
gapdh 95°C, 5 min 94°C 45 sec 55°C 40 sec 72°C 40 sec 23 72°C, 5 min 
bak 95°C, 5 min 94°C 30 sec 55°C 30 sec 72°C 30 sec 27 72°C, 5 min 
bax 95°C, 5 min 94°C 30 sec 60°C 30 sec 72°C 30 sec 28 72°C, 5 min 
bcl-2 95°C, 5 min 94°C 40 sec 63°C 35 sec 72°C 40 sec 36 72°C, 5 min 
bcl-xL 95°C, 5 min 94°C 30 sec 52°C 30 sec 72°C 30 sec 31 72°C, 5 min 
beta actin 95°C, 5 min 94°C 40 sec 60°C 35 sec 72°C 40 sec 25 72°C, 5 min 
CD 90 95°C, 5 min 94°C 30 sec 55°C 30 sec 72°C 30 sec 30 72°C, 5 min 
CD 34 95°C, 5 min 94°C 30 sec 55°C 30 sec 72°C 30 sec 30 72°C, 5 min 
CD 71 95°C, 5 min 94°C 40 sec 66°C 60 sec 72°C 40 sec 35 72°C, 5 min 
CD 29 95°C, 5 min 94°C 30 sec 60°C 30 sec 72°C 30 sec 29 72°C, 5 min 
CD 45 95°C, 5 min 94°C 30 sec 60°C 30 sec 72°C 30 sec 23 72°C, 5 min 
mmp 12 95°C, 10 min 94°C 40 sec 48°C 60 sec 72°C 40 sec 28 72°C, 5 min 
lpl 95°C, 10 min 94°C 30 sec 61°C 45 sec 72°C 30 sec 30 72°C, 5 min 
pparγ 95°C, 10 min 94°C 30 sec 61°C 45 sec 72°C 30 sec 30 72°C, 5 min 
oc 95°C, 10 min 94°C 30 sec 61°C 45 sec 72°C 30 sec 30 72°C, 5 min 
runX 95°C, 10 min 94°C 30 sec 61°C 45 sec 72°C 30 sec 30 72°C, 5 min 
 HISTONE PROTEIN EXTRACTION FROM CELL 3.15
CULTURE (ACID EXTRACTION) 
Cells were scraped and centrifuged at 1200 rpm for 10 minutes and the supernatant 
was removed. The pellet was re-suspended in 1X PBS and centrifuged as before. 
The cell pellet was dissolved in 400 µL TEB buffer (1XPBS/0.5%Triton X-
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100/0.02%NaN3/1X protease inhibitor) by pipetting up and down and incubated on 
ice for 10 minutes. After that the samples were centrifuged at 2000 rpm for 10 
minutes at +4
0
C. The supernatant was removed and half of the TEB buffer was 
added to the samples. The samples were centrifuged again at 2000 rpm for 10 
minutes at +4
0
C. The pellet was re-suspended in 150 µL 0.2N HCl and incubated at 
+4
0
C with constant rotating for over night (o.n.) Afterwards the samples were 
centrifuged at 2000 rpm for 10 minutes at +4
0
C. The supernatant was collected and 
the protein concentration was determined with the Bradford assay. 
 WESTERN BLOT 3.16
 SDS- POLYACRYLAMIDE GEL ELECTROPHORESIS 3.16.1
The protein samples, were separated by SDS-PAGE gel with 10% resolution gel, 
and 5% stacking gel while the histone proteins were separated with 17% resolution 
gel. 30µg protein sample for the former group and 5-10µg samples for the histone 
proteins were mixed in, 1% cracking buffer with 10% β-mercapthoethanol and 
boiled at 90
0
C for 10 minutes. The samples and the prestained protein marker 
(Fermentas) were loaded on the gel and run at 70V until leaving the stacking gel. 
Then the voltage was increased first to 90V and after 30 minutes to 110V while the 
samples were in the resolution gel. The running was terminated when the samples 
had run enough by comparing the separation of the bands of the marker. 
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 TRANSFER OF PROTEINS TO THE MEMBRANE 3.16.2
3.16.2.1 SEMI DRY TRANSFER 
Proteins in the range of 20-75 kDa were transferred by semi dry transfer method. 
The PVDF transfer membrane (0,45µm, Thermo Scientific, MA, USA) was put first 
in methanol for 20 seconds for its activation and then in ddH2O for 2 minutes to 
remove the excess methanol and lastly in semidry transfer buffer. The gel was taken 
and washed with ddH2O and the resolution part was cut and left in the semidry 
transfer buffer. 4 whatman papers were cut according to the size of the gel and left 
also in the semidry transfer buffer. They were placed onto the semidry transfer 
apparatus (Bio-Rad, CA, USA) in a specific order. At the bottom two whatman 
papers were placed, on top of them the membrane, and gel and lastly two more 
Whatman papers. Transfer was performed on the semi-dry transfer apparatus with a 
current of 3,5 mA/cm
2
 membrane for 25 minutes. The gel was stained with 
comassie brilliant blue and destained with destaining solution for o.n. to detect the 
transfer of the proteins from the gel to the membrane. 
3.16.2.2 WET TRANSFER 
The histone proteins which are smaller than 20kDa were transferred with the wet 
transfer method. The PVDF transfer membrane (0,45µm, Thermo Scientific) was 
put first in methanol for 20 seconds for its activation and then in ddH2O for 2 
minutes. The gel was taken and washed with ddH2O. Then the gel, membrane, 4 
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whatman papers and 2 sponges were soaked into the wet transfer buffer for small 
proteins. The proteins from the gel were transferred to the membrane with the 
BioRad gel tank (Bio-Rad). Transfer was done at 40V and lasted for 2.5 hours at 
+4
0
C. Afterwards the gel was stained with comassie dye for 15 minutes and 
destained with destaining solution for o.n.  
 IMMUNOLOGICAL DETECTION OF THE PROTEINS ON 3.16.3
THE MEMBRANE 
Membrane was washed for 5 minutes with 1X 0.3% tween 20-TBS (0.3%TBS-T). 
Afterwards it was incubated with the blocking solution as indicated in table 3.3 for 
different antibodies for 2 hours. The primary antibodies were diluted in block 
solution at various concentrations as indicated in table 3.3. The membrane was left 
in the primary antibodies for o.n. at 4
0
C with constant shaking. Next, the membrane 
was washed 3 times for 10 minutes with 1X 0.3%TBS-T and incubated with the 
secondary antibody of Anti-Rabbit-HRP (Cell signaling, MA, USA) at a 
concentration of 1:2000 for 1 hour at RT on an orbital shaker (RotaMix, 
Thermolyne, IA, USA). Subsequently the membrane was washed for 4 times for 10 
minutes with 1X 0.3% TBS-T. Detection was done with Super Signal West Femto 
Maximum Sensitivity Substrate (Thermo Scientific). The reagent was added to the 
membrane and incubated for 4 minutes the excess reagent was drained off and then 
radiography was detected. 
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Table 3.3: Antibodies used in western blotting 
antibody Block solution dilution 
Bcl-2 (Santa Cruz, CA, 
USA) 
4% milk powder in  0.3% TBS-T 1:500 
Bcl-xL (Santa Cruz, CA, 
USA) 
4% milk powder in  0.3% TBS-T 1:500 
Bak (Santa Cruz, CA, 
USA) 
4% milk powder in  0.3% TBS-T 1:500 
Bax (Santa Cruz, CA, 
USA) 
4% milk powder in  0.3% TBS-T 1:500 
ERα (Santa Cruz, CA, 
USA) 
4% milk powder in  0.3% TBS-T 1:200 
ERβ (Santa Cruz, CA, 
USA) 
4% milk powder in  0.3% TBS-T 1:200 
Actin (Santa Cruz, CA, 
USA) 
4% milk powder in  0.3% TBS-T 1:1000 
Anti-Histone H3 
(Upstate) 
5% BSA in 0.1% TBS-T 1:1000 
Anti-Histone H4 
(Upstate) 
5% BSA in 0.1% TBS-T 1:1000 
Anti-trimethyl-Histone 
H3 (Lys27) 
(Upstate) 
5% BSA in 0.1% TBS-T 1:750 
 IMMUNOFLUORESCENCE STAINING FOR NON-3.17
HISTONE PROTEINS 
For immunofluorescence staining the cells were grown on cover slips (Deckglaser 
100 No.1 12mm) in the cell culture plates. At the 14
th
 day of culture cells were 
washed twice with 1X PBS and fixed with Methanol for 7 minutes. Then they were 
washed again twice with 1X PBS and left in 3% H2O2 for 15 minutes. Next the cells 
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were washed again twice with 1XPBS, and left in blocking solution for 30 minutes 
at RT. Without any further washing, the blocking solution was removed and the 
cells were incubated with the primary antibodies, diluted in the block solution, for 
o.n at +4 
0
C with the concentrations stated in table 3.4. The next day, the cells were 
taken and washed twice with 1X PBS and incubated with FITC labeled secondary 
antibodies diluted in the block solution, for 1 hour at RT at the concentrations 
written in table 3.4. Lastly the cells were washed again with 1XPBS and mounted 
with UltraCruz (Santa Cruz) mounting medium with DAPI. The samples were 
investigated under fluorescent microscope with the wavelength 490nm and 359nm 
for FITC and DAPI respectively. 
 IMMUNOCYTOCHEMISTRY FOR HISTONE 3.18
PROTEINS 
Samples were fixed with freshly prepared 4% paraformaldehyde for 30 minutes and 
washed once with ddH2O and twice with 1XPBS. The permeabilization was done 
with 1XPBS/0.5% saponin/0.3% tritonX-100 three times for 5 minutes each. After 
the permeabilization the samples were blocked with 1XPBS containing 10% FBS 
and 0.3% tritonX-100 for one hour at 37
0
C. Before the addition of the primary 
antibody the samples were washed with 1XPBS. The primary antibodies were 
diluted in 1XPBS containing 2% FBS and 0.3% tritonX-100 as stated in table 3.4 
and left for o.n. incubation at +4
0
C. The next day the samples were washed first 
with 1XPBS and than three times with 1XPBS containing 2% FBS and 0.3% 
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tritonX-100 for 5 minutes each. Then the cells were incubated with universal 
biotinylated link (DakoCytomation, Denmark) for 10 minutes at RT and washed 
with 1XPBS afterwards. Next the samples were incubated with streptavidinHRP 
(DakoCytomation) for 10 minutes at RT and washed afterwards first with 1XPBS 
and subsequently with 1XPBS containing 2% FBS and 0.3% tritonX-100. For the 
brown color development DAB Chromogen (DakoCytomation) was used. This 
solution was applied to the samples and waited for 2-4 minutes for color 
development. The reaction was stopped with ddH2O. The samples were 
counterstained with eosin for 1 minute and mounted with mounting medium 
(DakoCytomation). 
Table 3.4: Antibodies used in immunostaining 
antibody dilution 
Bcl-2 (Santa Cruz, CA, USA) 1:500 
Bcl-xL (Santa Cruz, CA, USA) 1:500 
Bak (Santa Cruz, CA, USA) 1:500 
Bax (Santa Cruz, CA, USA) 1:500 
Anti-trimethyl-Histone H3(Lys9) (Upstate) 1:1000 
Anti-trimethyl-Histone H4(Lys20) (Upstate) 1:500 
Anti-trimethyl-Histone H3(Lys4) (Upstate) 1:1000 
Anti-trimethyl-Histone H3(Lys27) (Upstate) 1:1000 
Anti-trimethyl-Histone H3(Lys36) (Upstate) 1:500 
Anti-dimethyl-Histone H3(Arg2) (Upstate) 1:500 
Anti-dimethyl-Histone H4(Arg3) (Upstate) 1:250 
Anti-monomethyl-Histone H3(Lys27) (Upstate) 1:1500 
FITC-anti rabbit (Sigma, Germany) 1:200 
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 shRNA TRANSFECTION 3.19
 shRNA PLASMID PREPARATION 3.19.1
 
Figure 3.2: vector pLKO.1 map. 
 
The shRNAs were in pLKO.1 vector and purchased from Openbiosystems (AL, 
USA). The vector map is shown in figure 3.2. Agar plates containing ampicillin 
were prepared. E.coli in glycerol stock with shRNA (shRNA Bcl-2; 
Openbiosystems RMM3981-9573452 and RMM3981-9573456 shRNA Bcl-xL; 
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Openbiosystems RMM3981-9573460) were inoculated onto the agar plates and 
incubated at 37
0
C for o.n. One E.coli colony was picked and transferred into 5ml 
ampicillin containing LB and incubated at 37
0
C for 8 hours by constantly shaking at 
227 rpm. 100µL from the culture was taken and transferred to 100ml ampicillin 
containing LB and incubated at 37
0
C for 16 hours at 227 rpm. Next day plasmid 
isolation was done with Plasmid Midi Kit (QIAGEN, CA, USA) according to 
manufacturers guideline. Prior to the isolation, QIAGEN-tip 100 was equilibrated 
by applying 4ml QBT buffer. The column was allowed to empty by gravity. The 
bacterial cells were harvested by centrifugation at 6000 x g for 20 minutes at +4
0
C. 
The pellet was resuspended in 4ml RNase A containing P1 buffer. Then 4ml of P2 
buffer was added to the mixture and mixed thoroughly by vigorously inverting the 
tube several times and incubated at RT for 5 minutes. Next 4ml of chilled P3 buffer 
was added to the mixture and mixed immediately and vigorously. Then it was 
incubated on ice for 15 minutes. The samples were centrifuged at 20000 x g for 30 
minutes at +4
0
C. The supernatant containing the plasmid was removed promptly 
and centrifuged again at 20000 x g for 15 minutes at +4
0
C. Then the supernatant 
was removed immediately and applied to QIAGEN-tip 100 and allowed to enter the 
resin by gravity flow. The QIAGEN-tip was washed twice with 10ml QC buffer and 
the DNA was eluted with 5ml QF buffer. To precipitate the DNA 3.5ml RT 
isopropanol was added to the eluted DNA, mixed and centrifuged immediately at 
15000 x g for 30 minutes at +4
0
C. The supernatant was removed carefully. The 
DNA pellet was washed with 2ml RT 70% ethanol and centrifuged at 15000 x g for 
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10 minutes. Then the supernatant was removed and the pellet was air dried. The 
DNA was resuspended in 200-400µl TE buffer, pH 8.0.  
 TRANSFECTION 3.19.2
MSCs were trypsinized and plated in antibiotic free Mesencult and supplement in 6 
well plates for RNA isolation and in 24 well plates for TUNEL assay at day 13 of 
their culture. They were incubated for o.n at 37
0
C with 5% CO2. The next day 1µg 
shRNA (two shRNAs for bcl-2; Openbiosystems RMM3981-9573452 and 
RMM3981-9573456, 1 shRNA for bcl-xL; Openbiosystems RMM3981-9573460 ) 
was added to 100µL serum free antibiotic free DMEM-LG (HyClone). Two 
shRNAs, 1µg of each, were used for knock down of bcl-2 and 1 shRNA, 1µg, was 
used for knock down of bcl-xL. In another tube 4µL and 3µL transfection reagent 
(thermo scientific, dharmafect 1) was diluted with 196µL and 197µL serum free 
antibiotic free DMEM-LG for bcl-2 and bcl-xL respectively. After 5 minutes 
incubation the contents of shRNA and Transfection reagent containing tubes were 
mixed and incubated at RT for 20 minutes. 1200 µL antibiotic free complete 
DMEM-LG was added to the mixture. The cells were washed with 1X PBS and 
1500µL transfection mixture was added to 6 well, 375µL to 24 well cultures. 
DMEM-LG and Transfection reagent only was given to the cells as two types of 
control. Next day the medium was changed with complete mesencult. 4 days after 
transfection RNA isolation and TUNEL assay was done.  
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 STATISTICAL ANALYSIS 3.20
The statistical difference between two groups was analyzed by the two-tailed, 
Student’s t test using Microsoft Office Excel. Significant difference between two 
groups was declared if p<0.05. 
 SOLUTIONS AND BUFFERS 3.21
Solutions and buffers used in this study are given in Appendix A.
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Chapter 4  
RESULTS 
In this thesis MSCs were isolated from two different animal groups; normal female 
and ovariectomized female (ovx). Furthermore to test its effect 10
-7
M estrogen was 
added to the isolated MSCs. Therefore our experimental groups were as fallows; 
MSCs from normal female rats (F), estrogen treated MSCs from normal female rat 
(FE), estrogen and tamoxifen treated MSCs from normal female rat (FET), 
tamoxifen treated MSCs from normal female rat (FT), MSCs from ovx female rat 
(O), and estrogen treated MSCs from ovx female rat (OE). estrogen and tamoxifen 
treated MSCs from ovx female rat (OET) and tamoxifen treated MSCs from ovx 
female rat (OT) The experiments were done after culturing MSCs for 14 days in 
tissue culture with Mesencult media. Cells were used at P0 passage. 
 CD MARKER EXPRESSION 4.1
To characterize MSCs several markers were used. MSCs isolated from normal 
female rats and from ovx female rats as well as the estrogen treated samples were 
positive for MSC markers, CD29, CD90 and CD71 and negative for hematopoietic 
markers, CD34 and CD45 (Figure 4.1). Estrogen treatment did not cause a change 
of the CD marker expression, indicating that estrogen treatment did not interfere 
  
68 
 
with the MSC characteristics (Figure 4.1). Beta actin was used as loading control. 
RT-PCR made with RNA template instead of cDNA template was done in order to 
examine genomic DNA contamination which would interfere with the results. 
Negative result here showed that there is no genomic DNA contamination. 
 
Figure 4.1: Characterization of bone marrow derived MSCs.  The expression 
of the MSC markers CD29, CD90 and CD71 and the hematopoietic markers 
CD34 and CD45 by RT-PCR. Beta actin was used as loading control. RNA 
samples were used to search for genomic DNA contamination. neg= sample 
without cDNA. 
 ER PROTEIN EXPRESSION AND ESTROGEN 4.2
RESPONSIVENESS OF MSCs 
Estrogen exerts its effect mainly via the estrogen receptors. Since we focused on the 
role of estrogen on MSCs, the presence of ERα and/or ERβ is important in the 
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signaling of estrogen. To investigate the presence of ERs in MSCs, ER protein 
expression was examined by western blotting. As shown in figure 4.2 MSCs 
isolated from normal female and ovx female animals expressed ERα and ERβ in the 
presence and absence of estrogen.  
To test whether estrogen addition was functional we checked the estrogen 
responsiveness of the MSCs. In order to test this, mRNA expression of the estrogen 
responsive gene mmp12 was analyzed. The mRNA level of mmp12 increased after 
treatment the MSCs with estrogen in both normal female and ovx groups as seen by 
RT- PCR (Figure 4.3). To test whether mmp12 expression was mediated via ER we 
treated the MSCs with 10
-6
M tamoxifen, which is an ER antagonist. Tamoxifen 
treatment decreased the mmp12 expression in MSCs isolated from normal female 
and from ovx female rat as seen in figure 4.3. 
 
Figure 4.2: Protein expression of ER α and β in MSCs determined by western 
blot. Actin was used as loading control. 
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Figure 4.3: mRNA expression of estrogen responsive gene mmp12 determined 
by RT-PCR. Beta actin was used as loading control.  
 CFU-F ASSAY 4.3
We also investigated the effect of estrogen on their colony forming feature. MSCs 
isolated from normal female and ovx female showed spindle like morphology and 
formed colonies when plated onto plastic surfaces in the presence and absence of 
estrogen (Figure 4.4A-D). The colonies were counted under light microscope with 
10X objective. After staining the colonies with DAPI the cells in the colonies were 
counted under fluorescence microscope. Estrogen treatment increased the number 
of colonies both for MSCs isolated from normal female and from ovx female 
(Figure 4.4E). Moreover, the number of cells in the colonies also increased when 
MSCs were treated with estrogen (Figure 4.4F)  
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Figure 4.4: CFU activities of MSCs.  Light microscope images of colonies 
formed by MSCs isolated from A-B) normal female, and C-D) ovx female rats. 
and cultured in the A-C) absence and B-D) presence of estrogen. E) Number of 
colonies formed by MSCs. n=3 F) Number of cells in a colony. n=7 * indicates 
p<0.05. mean ±standart deviations. 
 DIFFERENTIATION OF MSCs 4.4
To test the effect of estrogen on the differentiation capacity of the MSC samples, 
adipogenic and osteogenic differentiation was induced with defined stimuli. All of 
the samples were able to differentiate into adipogenic and osteogenic lineages. 
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Differentiation capacity was screened by Oil Red O staining and Alizarin Red S 
staining for adipogenic and osteogenic lineage respectively. We observed that the 
differentiation potency of MSCs into adipogenic lineage but not to osteogenic 
lineage could be affected by estrogen. After adipogenic induction the samples 
showed high lipid vacuoles as shown by the Oil Red O staining. Estrogen treatment 
reduced the lipid vacuole formation in MSCs isolated from normal female rats 
(Figure 4.5A). Alizarin detects the calcium deposits and is used for detection of 
mineralization and thereby assessing osteogenic differentiation. When MSCs were 
cultured with OIM, we detected positive alizarin staining (Figure 4.5B). The 
negative controls were cultured in the absence of the differentiation inductive 
agents. Negative samples stained neither with Oil Red O nor with Alizarin Red S.  
To further evaluate the effect of estrogen on the adipogenic and osteogenic 
differentiation of MSCs, adipogenic and osteogenic specific marker gene 
expressions were analyzed. Lipoprotein lipase (lpl), and peroxisome proliferator 
activated receptor gamma (pparγ) were chosen as adipogenic markers and runt-
related transcription factor 2 (runx2) and osteocalcin (oc) were chosen as osteogenic 
markers. Estrogen addition did not prevent the differentiation capacity of the MSCs 
however lpl and pparγ expression dropped drastically after estrogen treatment in 
MSCs isolated from normal female rats (Figure 4.5C), which is in correlation with 
the Oil Red O staining. The osteogenic marker oc slightly increased after estrogen 
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treatment in female and ovariectomized MSCs. Runx2 expression did not change in 
estrogen treated MSCs. 
 HOMING OF MSCs 4.5
The migration of MSCs to the site of injury is called homing. To investigate the 
homing capacity of MSCs, liver damage was generated by performing partial 
hepatectomy (PH). Sham operated rats (SH) were used as control group. 
 LABELING OF MSCs WITH DiI AND DETERMINING THE 4.5.1
OPTIMUM TIMING FOR THE ADMINISTRATION INTO 
THE RATS 
The MSCs were labeled with DiI for 5 days in culture. After 5 days they showed a 
high DiI staining under the fluorescence microscope (Figure 4.6A and C). In our 
experimental design, PH was performed and the rats were let to recover from the 
surgery for 1 day (1 PH), 3 days (3 PH) and 5 days (5 PH). To find the optimum 
timing for the administration of MSCs to the rats after PH we injected the DiI 
labeled MSCs into 1 PH, 3 PH and 5PH rats through the tail vein. Our results 
showed that no DiI labeled MSCs migrated to the liver of 1 PH animals and 
estrogen addition did not change this result (Figure 4.7). We observed the highest 
amount of DiI labeled MSCs in the liver of 3 PH rats. In the absence of estrogen no 
DiI labeled MSCs were observed in the livers of 5 PH group. On the other hand, 
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few labeled MSCs were detected in the same group when these cells were treated 
with estrogen (Figure 4.7).  
 
 
Figure 4.5: Differentiation capacity of MSCs isolated from normal female and 
ovx female in the absence and presence of estrogen.  MSCs were stained with 
A) Oil Red O to detect the adipogenic differentiation and with B) Alizarin Red 
S to detect the osteogenic differentiation. C) mRNA expression of adipogenic 
(lpl, and pparγ) and osteogenic (oc and runx2) marker genes after the 
differentiation of MSCs. neg=without cDNA. Beta actin is used as loading 
control. (magnification 20X) 
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Figure 4.6: Image of in vitro DiI labeled MSCs. A,B) MSCs cultured in the 
absence of estrogen and C,D) MSCs cultured in the presence of estrogen. A,C) 
fluorescence image of DiI labeled MSCs and B,D) the same cells under light 
microscope 
 EFFECT OF ESTOGEN ON MSC HOMING 4.5.2
Labeled MSCs were injected to the 3 day PH rats and SH rats through the tail vein 
of the rat to test the effect of estrogen on the homing capacity of MSCs. The rats 
were sacrificed 3 days after the injection and the liver sections were analyzed. DiI 
labeled MSCs were observed under the fluorescence microscope. In addition to the 
transplanted MSCs, the native MSCs also migrated to the liver as observed by the 
expression of the MSC marker, CD90 staining (Figure 4.8E).  
Our results have shown that estrogen treatment increased the homing capacity of 
MSCs to the injured liver (Figure 4.9E vs 4.9F). MSCs from ovx female rat did not 
home to the injured liver of normal female or ovx female rats and estrogen 
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treatment did not improve this result (Figure 4.9A-D). We did not observe any DiI 
labeled MSCs isolated from female rat that migrated to the liver in SH animals 
(Figure 4.9G and H). 
 
 
Figure 4.7: Effect of recovery time after PH on the homing capacity of DiI 
labeled MSCs in the liver.  Liver sections from A) 1 days post PH, B) 3 day 
post PH and C) 5 day post PH rats after MSC injection. 
 
A) 
B) 
C) 
Host rat 
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Figure 4.8: Localization of MSCs to the liver after PH. A, C) DAPI staining of 
the liver section. B,D) The migration of the labeled MSCs was detected by DiI 
staining, and E) the presence of native MSCs and the administered MSCs was 
detected with CD90 staining. Green staining indicates the CD90 staining. 
Yellow staining indicates the merging of DiI staining with the CD90 staining. 
C,D and E are the larger images of A and B. 
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Figure 4.9: Effect of estrogen on the homing capacity of MSCs Liver sections from, 
A, B) ovx female rats with PH, C-F) normal female rats with PH and G,H) normal 
female rats with SH. DiI labeled MSCs A-D) from ovx female, and E-H) from normal 
female in the A,C,E,G) absence and B,D,F,H) presence of estrogen were injected to 
either female rats with PH, ovx rats with PH or female rat with SH as indicated. 
(Magnification is 40X). 
Host rat 
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 MSC MAINTENANCE 4.6
 APOPTOSIS 4.6.1
To find the mechanism by which estrogen increases the amount of MSCs, apoptotic 
pathway was searched. It is known that estrogen plays role in apoptosis in different 
systems. To measure the apoptotic rate of MSCs, TUNEL assay was done. In this 
assay apoptotic cells are detected according to the fact that apoptotic cells have 
fragmented internucleosomal DNA. FITC labeled dUTP was observed under 
fluorescence microscope with 490nm excitation wavelength. To count all of the 
cells the samples were also stained with DAPI and observed under fluorescence 
microscope with 359nm excitation wavelength. Figure 4.10A shows representative 
images of TUNEL staining (Figure 4.10A). Number of TUNEL positive cells were 
counted and divided to the number of total cells and TUNEL positive percentage 
was calculated. In our system apoptosis was not induced. We searched for the 
spontaneous physiological apoptosis rate. Therefore our TUNEL positivity 
percentage is very low. Estrogen treatment significantly decreased the TUNEL 
positive percentage both in MSCs isolated from female and MSCs isolated from 
ovariectomized rat (Figure 4.10B). This suggests a role for estrogen in preventing 
spontaneous apoptosis in MSCs.  
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Figure 4.10: Effect of estrogen on MSC apoptosis shown by in situ analysis of 
DNA fragmentation (TUNEL). A) Representative IF images of TUNEL 
staining of MSCs isolated from normal female and ovx female and cultured in 
the absence and presence of estrogen Arrow indicates the TUNEL positive 
cells. B) Percentage of TUNEL positive cells. * indicates p<0.05. n=3. Mean ± 
standart deviations. (Magnification 20X) 
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4.6.1.1 mRNA EXPRESSION of BCL-2 FAMILY OF GENES 
To explore the mechanism by which estrogen might prevent apoptosis, Bcl-2 family 
of members were searched. These are involved in the intrinsic apoptotic pathway 
and some members of the family have been shown to be affected by estrogen. The 
pro-apoptotic members Bak and Bax and the antiapoptotic members Bcl-2 and Bcl-
xL were analyzed in this study.  
To see whether the MSCs isolated from normal female and ovx female rats express 
the Bcl-2 family members at mRNA level in the absence and presence of estrogen, 
RT-PCR was performed. All of the groups tested express bak, bax, bcl-xL and bcl-2 
at the mRNA level (Figure 4.11A) However we could not detect a significant 
change at the mRNA expression level upon estrogen treatment in these genes 
(Figure 4.11B). 
4.6.1.2 PROTEIN EXPRESSION of BCL-2 FAMILY  
IF staining and western blot were performed in order to explore the protein 
expression status of the Bcl-2 family members. The IF staining revealed that MSCs 
isolated from normal female and ovx female rat and cultured in the absence and 
presence of estrogen expressed Bak, Bax, Bcl-2 and Bcl-xL (Figure 4.12). 
To evaluate the changes in their expression western blot analysis was done Total 
proteins were loaded on SDS-PAGE and analyzed for the expression levels of Bak, 
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Bax, Bcl-2 and Bcl-xL. Our results showed that the anti-apoptotic members were 
 
 
Figure 4.11: Effect of estrogen on the expression profile of the bcl-2 family of 
genes in MSCs  A) mRNA expression of the Bcl-2 family members, bak, bax, 
bcl-xL and bcl-2 by RT-PCR. B) Semi quantitative data of RT-PCR shown with 
box-whisker plot. Beta actin was used as a loading control. n=3 
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affected by estrogen. We observed an increase at the protein levels of Bcl-2 and 
Bcl-xL upon estrogen treatment in MSCs isolated from normal female rats. (Figure 
4.13A) The pro-apoptotic members of the Bcl-2 family were also affected by 
estrogen, however this change was not as significant as the change in the anti-
apoptotic ones (Figure 4.13B)  
 
Figure 4.12: Immunofluorescein staining of the Bcl-2 family of proteins on 
MSCs isolated from normal female and ovx female rat and cultured in the 
absence and presence of estrogen. (Magnification 20X). 
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Figure 4.13: Protein expression of the Bcl-2 family of genes in MSCs 
determined by western blotting. Three sample blots of the A) antiapoptotic 
Bcl-xL and Bcl-2, and B) proapoptotic Bak an Bax. Actin was used as a loading 
control. 
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 KNOCK DOWN OF THE ANTIAPOPTOTIC MEMBERS OF 4.6.2
BCL-2 FAMILY 
To further confirm the role of the anti-apoptotic members of the Bcl-2 family in 
estrogen regulated apoptosis of MSCs we used knock down strategy. Since the 
protein levels of Bcl-2 and Bcl-xL were increased upon estrogen treatment in MSCs 
isolated from normal female rat, we knocked down the expression of these members 
in MSCs isolated from normal female rat by using shRNA plasmids. The 
transfection was done on the 14
th
 day of cell culture, and the cells were incubated 
for further 4 days to achieve an optimum silencing. After 4 days total RNA was 
isolated and the efficiency of knock down was confirmed by RT- PCR (Figure 
4.14A and B). After achieving the knock down, TUNEL assay was performed on 
the cells and TUNEL positive samples were counted as explained before. At least 
two different observers counted the cells to get accurate results. In the absence of 
Bcl-xL or Bcl-2, estrogen addition caused an increase at the percentage of TUNEL 
positive cells (Figure 4.14C and D) suggesting a role for the anti-apoptotic members 
in the estrogen regulation of apoptosis in MSCs. 
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Figure 4.14: Effect of silencing bcl-xL and bcl-2 on the apoptotic rates of MSCs 
The mRNA expression of A) bcl-xL and B) bcl-2 in MSCs transfected with 
shRNA of bcl-xL and bcl-2 Gapdh was used as loading control. Percentage of 
TUNEL positive cells after MSCs were transfected with C) bcl-xL shRNA  and 
D) bcl-2 shRNA. Mean ± standart deviation TR=Transfection reagent. n=3. 
 EFFECT OF ESTROGEN ON HISTONE 4.7
MODIFICATIONS OF MSCs 
Estrogen treatment caused a change in the maintenance of the MSCs. Since 
estrogen works mainly via the estrogen receptors and regulate thereby the 
expression of target genes, it was important to search for the possible mechanism. 
One way is that estrogen could change the modifications on the histone proteins and 
thereby enable or prevent the expression of genes. Histone protein modifications 
were compared in estrogen treated and untreated MSC groups. The 
immunocytochemistry staining revealed that all the samples were positive for 
H3K9me3, H3K4me3, H4R3me2, H3R2me2, H3K27me1, H4K20me3, H3K36me3 
and H3K27me3 (Figure 4.15). Interestingly, we observed a decrease in the staining 
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density of H3K27me3 in estrogen treated MSCs. Therefore, we performed western 
blot to evaluate the change of this modification upon estrogen treatment.. 
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Figure 4.15: The expression of histone proteins by immunocytochemistry.  A) 
H3K9me3, B) H3K4me3, C) H4R3me2, D) H3R2me2, E) H3K27me1, F) 
H4K20me3, G) H3K36me3 and H) H3K27me3 staining is shown I) Negative 
sample without any primary antibody. (Magnification 40X). 
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Acid extracted histone proteins from estrogen treated MSCs and untreated MSCs 
were loaded on SDS-PAGE and blotted with anti-3mH3K27 antibody. Our results 
showed that in estrogen treated MSCs 3mH3K27 expression was decreased (Figure 
4.16).  
 
 
Figure 4.16: Western blotting of modified histone. Histone 3 was used as 
loading control. 
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Chapter 5  
DISCUSSION 
The importance of stem cells is rising from day to day. Over 60000 articles have 
been published is this field in the last 5 years (www.pubmed.com). Also stem cell 
societies from different parts of the world are gaining more and more members. The 
number and the participants of the conferences in this field have been increasing. 
All of this implicates that stem cells are gaining great attention over the years. 
These special cells are the hope for the treatment of several diseases since they have 
the ability to differentiate into different kinds of cells of the body. ESCs are 
pluripotent cells which can differentiate into the cells of the three germ layers. That 
is why a great deal of work is related to the ESCs. However, besides their amazing 
differentiation potential there is a huge handicap for these cells, is their source. 
ESCs are isolated from the blastocysts of embryos whereby the embryo is 
destroyed. This brings about ethical problems, which makes it difficult if not 
impossible to work with the ESCs or use these cells in a therapy. The use of ASCs 
has no ethical issue and is also being used in disease treatment. MSCs are ASCs 
that can be isolated from various parts of the body like bone marrow or adipose 
tissue and can be differentiate to the cells of the mesenchymal lineage like 
osteoblasts, chondrocytes, and adipocytes and also of other lineages like neurons, 
skin cells and tenocytes. Although MSCs have no ethical or immunogenic problems 
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there is one draw back of these cells; their rareness. To use these cells in any kind 
of therapy the number of them has to be increased. Estrogen is known to play role 
in increasing proliferation and decreasing apoptosis. Estrogen can modulate 
apoptosis through the Bcl-2 family of proteins in different systems. It can either 
directly or indirectly affects the expression of these proteins. Therefor we aimed in 
this study to search for the effects of estrogen on MSC apoptosis and tried to find 
molecules involved in this regulation. 
To test the effects of estrogen on MSCs we added 10
-7
M estrogen to the culture 
dishes after the day we harvested MSCs from rat femur and tibia. As a control we 
used MSCs without adding estrogen. We used MSCs from either untreated or 
ovariectomized female rats in our experiments. To start with our experiments we 
first characterized our samples. All four MSC samples were positive for MSC 
markers CD29, CD90 and CD71 and negative for hematopoietic markers CD34 and 
CD45 (Figure 4.1). This showed that estrogen did not change the marker expression 
of our samples which was an indication of not changing the MSC property. 
Therefore we concluded that it is safe to use estrogen in our studies.  
Since we want to see the effects of estrogen we searched for the ER α and β 
expression. Western blot experiment revealed that MSCs isolated from normal 
female and ovx female and cultured in the absence and presence of estrogen express 
both of the receptors (Figure 4.2). In addition to that we tested the estrogen 
responsiveness of the MSC samples. Semi quantitative PCR was done to evaluate 
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the expression of the estrogen responsive gene mmp12 (Figure 4.3). Both in MSCs 
isolated from normal female rat and from ovx female rat, estrogen treatment 
increased the expression of mmp12. We evaluated also whether this increase is 
mediated through the ERs. Therefore we treated the MSCs in addition to estrogen 
also with tamoxifen, since tamoxifen is an ER antagonist. The mmp12 expression 
decreased upon tamoxifen treatment suggesting that estrogen is acting through the 
ERs in mediating mmp12 expression. As a conclusion we can say that MSCs are 
estrogen responsive and can react to the action of estrogen and this is mediated via 
the ERs found in the MSCs. 
Another feature of MSCs is formation of colonies. To test whether estrogen had an 
impact on these characteristics we performed CFU assay. We could observe 
colonies in all MSC groups tested (Figure 4.4A-D) with an increase in the colony 
numbers in the presence of estrogen (Figure 4.4E). In addition to that we could 
observe a significant (p<0.05) increase in the number of cells that was present in 
one colony in estrogen treated samples compared to the untreated ones (Figure 
4.4F). As a conclusion we can say that estrogen treatment did not hinder the MSC 
marker expression or colony formation, but had a positive effect on the number of 
colonies formed and on the number of cells in a colony. This effect could be 
attributed to estrogen’s proliferative activity. Our results were also parallel to a 
previous study where it was shown that estrogen increased the number of MSCs 
obtained from ovariectomized rats [235].  
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Next we tested the differentiation potential of our MSCs. Upon induction with 
defined agents we could differentiate our samples into adipogenic and osteogenic 
lineages as shown by oil red o and alizarin staining, respectively (Figure 4.5A-B). 
Also the adipogenic markers lpl and pparγ and osteogenic markers oc and runx2 
expression confirmed the differentiation of our MSCs (Figure 4.5C). It has been 
shown that estrogen has important role in adipocyte metabolism [236] and that the 
adipogenic differentiation capacity of MSCs was increased in post menopausal 
women [237] which could be attributed to the loss of estrogen. We found that 
estrogen did not prevent the differentiation capacity of any of the samples, however 
a decrease in the lipid droplets formed and a decrease in the lpl and pparγ 
expression was observed when estrogen was added to the differentiation medium of 
MSCs isolated from normal female. Previously it was reported that MSCs from 
osteoporotic post menopausal women had an increase in their adipogenic 
differentiation potential which was shown by increased pparγ expression. This 
could be the result of altered bioavailability of estrogen in these women [238]. 
Another study showed that the serum from post menopausal in comparison to serum 
from pre menopausal women, were able to induce adipogenic differentiation in hOP 
7 cells which can differentiate into adipocytes and osteocytes like the MSCs [239]. 
Our result suggested an inhibitory role for estrogen on MSC adipocyte 
differentiation. Defining the mechanism of this could give new insights to the 
treatment of obesity and obesity related diseases. It is clearly important to know the 
relation between estrogen and MSC differentiation, which could explain the 
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increase of fat tissue in post menopausal women. Another important factor is that 
we did not see the same scenario in MSCs from ovariectomized rats. This shows 
that estrogen treatment alone is not responsible for the decrease in adipogenic 
differentiation capacity of MSCs. Other factors or pathways are involved in this 
process, which are absent or not responsive after ovariectomization. The molecular 
mechanism behind this event is not known and should be searched for further 
clarification.  
Another characteristic of MSCs is their homing capacity to injured tissue. For that 
purpose we performed partial hepatectomy in rats to mimic liver injury. The in vitro 
cultured MSCs were labeled with the fluorescein dye DiI (Figure 4.6), to track them 
after they were injected to the rats through their tail vein. We administered the 
MSCs to the rats 1 day post PH, 3 days post PH and 5 days post PH. We observed 
the highest number of DiI labeled MSCs in the livers of 3 days post PH rats (Figure 
4.7). when we injected the MSCs 1 day after the PH we did not see any DiI labeled 
MSCs in the liver sections. This could be due to loss of signaling molecules to 
attract the MSCs to the site of injury at that time. We did not observe any MSCs in 
the liver sections of 5 days post PH rats. A reason for this could be that the native 
MSCs has reached the injured liver earlier and eliminated the need for the 
administered MSCs. Determining the optimum timing for the transplantation of the 
MSCs would increase the benefit of using MSCs in therapies.  
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We could observe under fluorescein microscope, that both the estrogen treated and 
the untreated MSCs isolated from normal female migrated to the injured liver of 
female rats (Figure 4.9E-F) but not to the SH rats’ liver (Figure 4.9G-H). However 
there was a difference in their amount that was present in the liver. The fluorescein 
microscope images revealed a higher number of estrogen treated MSCs that 
migrated to the site of injury in contrast to the untreated MSCs. This increase 
cannot be attributed to the number of MSCs that were initially injected to the rats, 
because the initial numbers were same in every case. Other mechanisms should be 
involved in the higher homing capacity of estrogen treated MSCs to the injured 
liver. The proliferative action of estrogen could have increased the MSCs after 
injection so that more MSCs were available for migrating. Another possibility could 
be that estrogen treated MSCs responded faster and more effectively to factors 
secreted from the injured liver and so reached the site of action earlier. Another 
important finding here is the absence of DiI labeled ovariectomized MSCs at the 
site of injury after injection (Figure 4.9A-D). This could be a result of being 
deprived of estrogen for a long time. Loss of estrogen could have disrupt the 
homing capacity of MSCs, which would attribute an important role to estrogen in 
MSCs homing. It is clearly an important issue to reveal the mechanism behind this 
in order to use the homing capacity of MSCs to the injured tissues in a more 
efficient way. This would improve the usage of MSCs in therapies by decreasing 
the treatment time and the need for high numbers of MSCs.  
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The proliferative effect of estrogen has been shown on rat bone marrow-derived 
MSCs before [134]. However, the effect of estrogen on the maintenance of MSCs 
isolated from normal animals have not been reported. To test the effect of estrogen 
on MSCs maintenance we searched for apoptosis. It is known that estrogen have a 
dual effect on apoptosis, it can inhibit or promote apoptosis in different cells. In our 
system we did not induce any kind of apoptosis, but searched for the physiological 
apoptosis of the MSCs. We compared the apoptotic cells by TUNEL assay. The 
overall apoptotic rate was less than 10%, which is normal since we did not induce 
apoptosis in any way. The TUNEL positive cells were significantly (p<0.05) 
decreased in the estrogen treated MSCs. This decrease was observed in both normal 
female group and ovariectomized female group (Figure 4.10B). From this we 
conclude that estrogen has an inhibitory role on MSCs spontaneous apoptosis.  
The Bcl-2 family of proteins plays a pivotal role in apoptosis. It is also being 
reported that some of the members are regulated via estrogen like Bcl-2, and Bcl-xL 
[123, 199, 205]. In our system we wanted to examine whether estrogen exerts its 
anti-apoptotic effect via regulation of the Bcl-2 family members. Bcl-2,, bcl-xL, bak 
and bax mRNA expression was checked with semi quantitative PCR. At the mRNA 
level we did not detect any significant difference between the estrogen treated and 
untreated MSC samples in neither of the groups (Figure 4.11). The Bcl-2 family 
members are mostly regulated at the protein levels. Therefore we further analyzed 
the protein levels of these members. IF staining showed that all of the samples 
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express Bak, Bax, Bcl-2 and Bcl-xL (Figure 4.12). To test if there is any difference 
in the expression of these proteins upon estrogen treatment we performed western 
blotting. Western blot analysis revealed that there was an increase in the Bcl-2 and 
Bcl-xL protein levels upon estrogen treatment in MSCs isolated from normal female 
group (Figure 4.13). This increase in the anti-apoptotic members could explain the 
decrease in the TUNEL positivity after estrogen treatment. We also observed slight 
changes in the expression levels of the the pro-apoptotic members upon estrogen 
treatment. However this change was not as meaningful as the change in the anti-
apoptotic ones yet we can not eliminate the role of the pro-apoptotic members in the 
estrogen regulation of apoptosis. Although the mRNA and protein levels of these 
proteins did not change, post translational modifications like phosphorylation or 
compartmentalization could be involved in the regulation of these members and 
further studies had to be made for the confirmation of this. To test the effect of the 
anti-apoptotic members on the estrogen regulated apoptosis of MSCs we performed 
silencing of the anti-apoptotic members in MSCs and treated our samples with 
estrogen for further four days. We observed a statistical increase in the apoptotic 
rates of the estrogen treated MSCs in the presence of Bcl-xL shRNA and Bcl-2 
shRNA in comparison to the estrogen treated MSCs in the absence of Bcl-xL 
shRNA and Bcl-2 shRNA (Figure 4.14C and D). All together these show that 
estrogen decreases apoptosis in MSCs via the anti-apoptotic members of the Bcl-2 
family.  The interaction between estrogen and Bcl-xL and Bcl-2 is not known. 
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Estrogen could directly interact with the members or indirectly affect their function. 
One possible mechanism could be through epigenetic modifications.  
Histone protein modifications determine the on-off state of a gene. They include 
acetylation, methylation, phosphorylation, sumoylation and ubiqutylation. Several 
studies have revealed a correlation between estrogen and these modifications. The 
relation between stem cells and histone modification is that in an undifferentiated 
state the stem cells mainly possess poised chromatins with silencing and activating 
chromatin marks together on the chromatin. This means that upon differentiation to 
a specific lineage the promoter of a gene, specific to that lineage will become open 
in other words the activating mark will dominate over the repressive mark and the 
gene will be expressed. If the gene is not expressed in that lineage than the silencing 
mark will be dominate over the activating mark and the gene won’t be expressed 
[224, 225]. To test whether this could be the case in our system we looked for a 
global expression of several histone methylation marks. Histone methylation can be 
activating or silencing depending on the specific location of that modification on 
the histone tail. Immunostaining revealed the presence of several histone 
methylations on the MSCs (Figure 4.15). H3K27me3 is an important histone 
modification in stem cells. It is found on bivalent promoters and has a critical role 
in determining the transcriptional status of the genes. Previously relation between 
H3K27me3 and estrogen has been shown [232, 233]. The immunostaining showed a 
decrease in the intensity of the H3K27me3 mark upon estrogen treatment (Figure 
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4.15). To further confirm this we performed western blot analysis and detect a 
decrease in the global H3K27me3 in the estrogen treated MSCs compared to the 
untreated samples (Figure 4.16). Since the H3K27me3 modification is a silencing 
mark we concluded that estrogen treatment activated some genes that were not 
active before. This could also be the case for Bcl-xL and Bcl-2. However since we 
did not see any significant difference at the mRNA level of them it is more probable 
that the anti-apoptotic members are a downstream target of a signaling cascade that 
is activated by a decrease in the H3K27me3 mark. Chromatin immunoprecipitation 
should be done on bcl-xL and bcl-2 to demonstrate the presence or absence of this 
mark on these genes and if and how it changes upon estrogen treatment. Knocking 
down the demethylase JMJD3, and observing the change in the protein expression 
after estrogen treatment would reveal the importance of this histone mark in the 
regulation of Bcl-xL and Bcl-2. These histone PTM could also explain the reduced 
adipogenic differentiation capacity in estrogen treated samples. Estrogen may have 
an effect on the poised chromatins in the undifferentiated MSCs. It could favor the 
loss of H3K27me3 in factors that are preventing adipogenic differentiation.  
As a conclusion in this study we showed that estrogen does not interfere with the 
stem cell properties of the rat bone marrow derived MSCs. It increases the number 
of colonies and decreases the adipogenic differentiation potential of MSCs. 
Estrogen has a positive effect of MSC homing to injured liver. It decreases the 
spontaneous apoptosis of MSCs Estrogen exerts its anti-apoptotic effects mainly via 
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the anti-apoptotic members of the Bcl-2 family. The molecular mechanism behind 
this is not known but histone PTMs can be the important players in this regulation. 
Knowing the mechanism behind the maintenance of the MSCs is important in 
obtaining more MSCs for further clinical investigations. 
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Chapter 6  
FUTURE PERSPECTIVES 
In this thesis the effect of estrogen on MSC maintenance was explored. We found 
that estrogen prevents the simultaneous apoptosis of MSCs through the anti-
apoptotic members of the Bcl-2 family. However the molecular mechanism behind 
this event is not known and should be further analyzed. The expression of bcl-xL 
and bcl-2 did not changed at the mRNA level but increased at the protein level upon 
estrogen treatment, and the reason of this should be searched. Post translational 
regulation like phosphorylation of the candidate proteins should be studied. We 
found that global H3K27me3 modification decreases after estrogen treatment in 
MSCs. Chromatin immunoprecipitation experiments should be performed in order 
to get a deep look into the histone mark of the Bcl-2 family members and other 
genes that are known to regulate them.  H3K27me3 mark is a repressive mark and 
the decrease of it upon estrogen treatment could activate some important genes, 
whose products are increasing the activity of Bcl-xL and Bcl-2. The enzyme 
responsible for this histone mark is Ezh2. This enzyme also regulates the 
transcription of estrogen responsive genes [232]. Also the demethylase JMJD3, 
which substrate is H3K27me3 seems to be important in Bcl-xL and Bcl-2 
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regulation. Detailed relation between estrogen, Ezh2, JMJD3 and Bcl-xL, Bcl-2 
regulation should be investigated. 
Estrogen also had an impact on the differentiation potential of MSCs. It decreased 
the number of lipid vacuoles after adipogenic differentiation as detected by Oil Red 
O staining. The molecular mechanism is not known and should be analyzed. 
Epigenetic modifications related to estrogen addition could be the reason of this 
decrease in differentiation potential, since differentiation is mainly related to the 
rapid transcriptional regulation, in other words the on or off status of transcription 
factors and other genes. Detailed inspection of the epigenetic changes of the 
transcription factors related to the different mesenchymal lineages should be made. 
The effect of histone methyltransferase Ezh2 and the demethylase JMJD3 on the 
target genes should be studied. The relation between obesity and MSCs should be 
inspected. Also the relation between post-menopausal weight gain and MSC 
differentiation should be searched. Finding the regulatory pathway, could provide 
new insights into the in vitro differentiation of MSCs, which would improve the 
usage of MSCs for therapeutic purposes. 
In this thesis we observed also that much more estrogen treated MSCs migrated to 
the injured liver compared to the untreated ones. Why this happened is not known 
and detailed analysis of this phenomenon is important in directing the MSCs 
through a path in vivo. Analyzing the chemoattractant factors secreted from the 
injured liver could give an insight to the mechanism. The role of estrogen in this 
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event is not known. Relation between estrogen and the injured liver, the secreted 
factors and/or the nearby environment should be studied. Other injury models 
should be checked also to determine whether the effect of estrogen on MSC homing 
is specific to liver injuries or a general matter. Controlling the path of MSCs would 
not only make them an ideal candidate for cell based therapies but also make them 
an ideal vehicle for targeted drug delivery in vivo.  
  
104 
 
References 
1. Evans, M. J., and Kaufman, M. H. (1981) Establishment in culture of 
pluripotential cells from mouse embryos, Nature 292, 154-156. 
2. Thomson, J. A., Itskovitz-Eldor, J., Shapiro, S. S., Waknitz, M. A., 
Swiergiel, J. J., Marshall, V. S., and Jones, J. M. (1998) Embryonic stem 
cell lines derived from human blastocysts, Science 282, 1145-1147. 
3. Avilion, A. A., Nicolis, S. K., Pevny, L. H., Perez, L., Vivian, N., and 
Lovell-Badge, R. (2003) Multipotent cell lineages in early mouse 
development depend on SOX2 function, Genes Dev 17, 126-140. 
4. Mitsui, K., Tokuzawa, Y., Itoh, H., Segawa, K., Murakami, M., Takahashi, 
K., Maruyama, M., Maeda, M., and Yamanaka, S. (2003) The homeoprotein 
Nanog is required for maintenance of pluripotency in mouse epiblast and ES 
cells, Cell 113, 631-642. 
5. Nichols, J., Zevnik, B., Anastassiadis, K., Niwa, H., Klewe-Nebenius, D., 
Chambers, I., Scholer, H., and Smith, A. (1998) Formation of pluripotent 
stem cells in the mammalian embryo depends on the POU transcription 
factor Oct4, Cell 95, 379-391. 
6. Bhattacharya, B., Miura, T., Brandenberger, R., Mejido, J., Luo, Y., Yang, 
A. X., Joshi, B. H., Ginis, I., Thies, R. S., Amit, M., Lyons, I., Condie, B. 
G., Itskovitz-Eldor, J., Rao, M. S., and Puri, R. K. (2004) Gene expression 
in human embryonic stem cell lines: unique molecular signature, Blood 103, 
2956-2964. 
7. Hanna, J. H., Saha, K., and Jaenisch, R. (2010) Pluripotency and cellular 
reprogramming: facts, hypotheses, unresolved issues, Cell 143, 508-525. 
8. Pera, M. F., Reubinoff, B., and Trounson, A. (2000) Human embryonic stem 
cells, J Cell Sci 113 ( Pt 1), 5-10. 
9. Ginis, I., Luo, Y., Miura, T., Thies, S., Brandenberger, R., Gerecht-Nir, S., 
Amit, M., Hoke, A., Carpenter, M. K., Itskovitz-Eldor, J., and Rao, M. S. 
(2004) Differences between human and mouse embryonic stem cells, Dev 
Biol 269, 360-380. 
10. Xu, C., Inokuma, M. S., Denham, J., Golds, K., Kundu, P., Gold, J. D., and 
Carpenter, M. K. (2001) Feeder-free growth of undifferentiated human 
embryonic stem cells, Nat Biotechnol 19, 971-974. 
11. Bifari, F., Pacelli, L., and Krampera, M. (2010) Immunological properties of 
embryonic and adult stem cells, World J Stem Cells 2, 50-60. 
12. Keller, G. (2005) Embryonic stem cell differentiation: emergence of a new 
era in biology and medicine, Genes Dev 19, 1129-1155. 
13. Matsuda, T., Nakamura, T., Nakao, K., Arai, T., Katsuki, M., Heike, T., and 
Yokota, T. (1999) STAT3 activation is sufficient to maintain an 
  
105 
 
undifferentiated state of mouse embryonic stem cells, EMBO J 18, 4261-
4269. 
14. Niwa, H., Burdon, T., Chambers, I., and Smith, A. (1998) Self-renewal of 
pluripotent embryonic stem cells is mediated via activation of STAT3, 
Genes Dev 12, 2048-2060. 
15. Raz, R., Lee, C. K., Cannizzaro, L. A., d'Eustachio, P., and Levy, D. E. 
(1999) Essential role of STAT3 for embryonic stem cell pluripotency, Proc 
Natl Acad Sci U S A 96, 2846-2851. 
16. Ohtsuka, S., and Dalton, S. (2008) Molecular and biological properties of 
pluripotent embryonic stem cells, Gene Ther 15, 74-81. 
17. Qi, X., Li, T. G., Hao, J., Hu, J., Wang, J., Simmons, H., Miura, S., Mishina, 
Y., and Zhao, G. Q. (2004) BMP4 supports self-renewal of embryonic stem 
cells by inhibiting mitogen-activated protein kinase pathways, Proc Natl 
Acad Sci U S A 101, 6027-6032. 
18. Ying, Q. L., Nichols, J., Chambers, I., and Smith, A. (2003) BMP induction 
of Id proteins suppresses differentiation and sustains embryonic stem cell 
self-renewal in collaboration with STAT3, Cell 115, 281-292. 
19. Kunath, T., Saba-El-Leil, M. K., Almousailleakh, M., Wray, J., Meloche, S., 
and Smith, A. (2007) FGF stimulation of the Erk1/2 signalling cascade 
triggers transition of pluripotent embryonic stem cells from self-renewal to 
lineage commitment, Development 134, 2895-2902. 
20. Levenstein, M. E., Ludwig, T. E., Xu, R. H., Llanas, R. A., VanDenHeuvel-
Kramer, K., Manning, D., and Thomson, J. A. (2006) Basic fibroblast 
growth factor support of human embryonic stem cell self-renewal, Stem 
Cells 24, 568-574. 
21. Wang, G., Zhang, H., Zhao, Y., Li, J., Cai, J., Wang, P., Meng, S., Feng, J., 
Miao, C., Ding, M., Li, D., and Deng, H. (2005) Noggin and bFGF 
cooperate to maintain the pluripotency of human embryonic stem cells in the 
absence of feeder layers, Biochem Biophys Res Commun 330, 934-942. 
22. Vallier, L., Alexander, M., and Pedersen, R. A. (2005) Activin/Nodal and 
FGF pathways cooperate to maintain pluripotency of human embryonic 
stem cells, J Cell Sci 118, 4495-4509. 
23. Sato, N., Meijer, L., Skaltsounis, L., Greengard, P., and Brivanlou, A. H. 
(2004) Maintenance of pluripotency in human and mouse embryonic stem 
cells through activation of Wnt signaling by a pharmacological GSK-3-
specific inhibitor, Nat Med 10, 55-63. 
24. Beattie, G. M., Lopez, A. D., Bucay, N., Hinton, A., Firpo, M. T., King, C. 
C., and Hayek, A. (2005) Activin A maintains pluripotency of human 
embryonic stem cells in the absence of feeder layers, Stem Cells 23, 489-
495. 
25. Greber, B., Lehrach, H., and Adjaye, J. (2007) Fibroblast growth factor 2 
modulates transforming growth factor beta signaling in mouse embryonic 
  
106 
 
fibroblasts and human ESCs (hESCs) to support hESC self-renewal, Stem 
Cells 25, 455-464. 
26. Takahashi, K., and Yamanaka, S. (2006) Induction of pluripotent stem cells 
from mouse embryonic and adult fibroblast cultures by defined factors, Cell 
126, 663-676. 
27. Maherali, N., Sridharan, R., Xie, W., Utikal, J., Eminli, S., Arnold, K., 
Stadtfeld, M., Yachechko, R., Tchieu, J., Jaenisch, R., Plath, K., and 
Hochedlinger, K. (2007) Directly reprogrammed fibroblasts show global 
epigenetic remodeling and widespread tissue contribution, Cell Stem Cell 1, 
55-70. 
28. Okita, K., Ichisaka, T., and Yamanaka, S. (2007) Generation of germline-
competent induced pluripotent stem cells, Nature 448, 313-317. 
29. Wernig, M., Meissner, A., Foreman, R., Brambrink, T., Ku, M., 
Hochedlinger, K., Bernstein, B. E., and Jaenisch, R. (2007) In vitro 
reprogramming of fibroblasts into a pluripotent ES-cell-like state, Nature 
448, 318-324. 
30. Nakagawa, M., Koyanagi, M., Tanabe, K., Takahashi, K., Ichisaka, T., Aoi, 
T., Okita, K., Mochiduki, Y., Takizawa, N., and Yamanaka, S. (2008) 
Generation of induced pluripotent stem cells without Myc from mouse and 
human fibroblasts, Nat Biotechnol 26, 101-106. 
31. Yu, J., Vodyanik, M. A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J. 
L., Tian, S., Nie, J., Jonsdottir, G. A., Ruotti, V., Stewart, R., Slukvin, II, 
and Thomson, J. A. (2007) Induced pluripotent stem cell lines derived from 
human somatic cells, Science 318, 1917-1920. 
32. Liao, J., Cui, C., Chen, S., Ren, J., Chen, J., Gao, Y., Li, H., Jia, N., Cheng, 
L., Xiao, H., and Xiao, L. (2009) Generation of induced pluripotent stem 
cell lines from adult rat cells, Cell Stem Cell 4, 11-15. 
33. Liu, H., Zhu, F., Yong, J., Zhang, P., Hou, P., Li, H., Jiang, W., Cai, J., Liu, 
M., Cui, K., Qu, X., Xiang, T., Lu, D., Chi, X., Gao, G., Ji, W., Ding, M., 
and Deng, H. (2008) Generation of induced pluripotent stem cells from adult 
rhesus monkey fibroblasts, Cell Stem Cell 3, 587-590. 
34. Hanna, J., Markoulaki, S., Schorderet, P., Carey, B. W., Beard, C., Wernig, 
M., Creyghton, M. P., Steine, E. J., Cassady, J. P., Foreman, R., Lengner, C. 
J., Dausman, J. A., and Jaenisch, R. (2008) Direct reprogramming of 
terminally differentiated mature B lymphocytes to pluripotency, Cell 133, 
250-264. 
35. Liu, H., Ye, Z., Kim, Y., Sharkis, S., and Jang, Y. Y. (2010) Generation of 
endoderm-derived human induced pluripotent stem cells from primary 
hepatocytes, Hepatology 51, 1810-1819. 
36. Aasen, T., Raya, A., Barrero, M. J., Garreta, E., Consiglio, A., Gonzalez, F., 
Vassena, R., Bilic, J., Pekarik, V., Tiscornia, G., Edel, M., Boue, S., and 
Izpisua Belmonte, J. C. (2008) Efficient and rapid generation of induced 
  
107 
 
pluripotent stem cells from human keratinocytes, Nat Biotechnol 26, 1276-
1284. 
37. Li, C., Zhou, J., Shi, G., Ma, Y., Yang, Y., Gu, J., Yu, H., Jin, S., Wei, Z., 
Chen, F., and Jin, Y. (2009) Pluripotency can be rapidly and efficiently 
induced in human amniotic fluid-derived cells, Hum Mol Genet 18, 4340-
4349. 
38. Brambrink, T., Foreman, R., Welstead, G. G., Lengner, C. J., Wernig, M., 
Suh, H., and Jaenisch, R. (2008) Sequential expression of pluripotency 
markers during direct reprogramming of mouse somatic cells, Cell Stem Cell 
2, 151-159. 
39. Stadtfeld, M., Maherali, N., Breault, D. T., and Hochedlinger, K. (2008) 
Defining molecular cornerstones during fibroblast to iPS cell 
reprogramming in mouse, Cell Stem Cell 2, 230-240. 
40. Zhou, W., and Freed, C. R. (2009) Adenoviral gene delivery can reprogram 
human fibroblasts to induced pluripotent stem cells, Stem Cells 27, 2667-
2674. 
41. Okita, K., Nakagawa, M., Hyenjong, H., Ichisaka, T., and Yamanaka, S. 
(2008) Generation of mouse induced pluripotent stem cells without viral 
vectors, Science 322, 949-953. 
42. Stadtfeld, M., Nagaya, M., Utikal, J., Weir, G., and Hochedlinger, K. (2008) 
Induced pluripotent stem cells generated without viral integration, Science 
322, 945-949. 
43. Sommer, C. A., Sommer, A. G., Longmire, T. A., Christodoulou, C., 
Thomas, D. D., Gostissa, M., Alt, F. W., Murphy, G. J., Kotton, D. N., and 
Mostoslavsky, G. (2010) Excision of reprogramming transgenes improves 
the differentiation potential of iPS cells generated with a single excisable 
vector, Stem Cells 28, 64-74. 
44. Woltjen, K., Michael, I. P., Mohseni, P., Desai, R., Mileikovsky, M., 
Hamalainen, R., Cowling, R., Wang, W., Liu, P., Gertsenstein, M., Kaji, K., 
Sung, H. K., and Nagy, A. (2009) piggyBac transposition reprograms 
fibroblasts to induced pluripotent stem cells, Nature 458, 766-770. 
45. Yusa, K., Rad, R., Takeda, J., and Bradley, A. (2009) Generation of 
transgene-free induced pluripotent mouse stem cells by the piggyBac 
transposon, Nat Methods 6, 363-369. 
46. Shi, Y., Desponts, C., Do, J. T., Hahm, H. S., Scholer, H. R., and Ding, S. 
(2008) Induction of pluripotent stem cells from mouse embryonic fibroblasts 
by Oct4 and Klf4 with small-molecule compounds, Cell Stem Cell 3, 568-
574. 
47. Zhou, H., Wu, S., Joo, J. Y., Zhu, S., Han, D. W., Lin, T., Trauger, S., Bien, 
G., Yao, S., Zhu, Y., Siuzdak, G., Scholer, H. R., Duan, L., and Ding, S. 
(2009) Generation of induced pluripotent stem cells using recombinant 
proteins, Cell Stem Cell 4, 381-384. 
  
108 
 
48. Kim, D., Kim, C. H., Moon, J. I., Chung, Y. G., Chang, M. Y., Han, B. S., 
Ko, S., Yang, E., Cha, K. Y., Lanza, R., and Kim, K. S. (2009) Generation 
of human induced pluripotent stem cells by direct delivery of 
reprogramming proteins, Cell Stem Cell 4, 472-476. 
49. Warren, L., Manos, P. D., Ahfeldt, T., Loh, Y. H., Li, H., Lau, F., Ebina, 
W., Mandal, P. K., Smith, Z. D., Meissner, A., Daley, G. Q., Brack, A. S., 
Collins, J. J., Cowan, C., Schlaeger, T. M., and Rossi, D. J. (2010) Highly 
efficient reprogramming to pluripotency and directed differentiation of 
human cells with synthetic modified mRNA, Cell Stem Cell 7, 618-630. 
50. Tsai, S. Y., Clavel, C., Kim, S., Ang, Y. S., Grisanti, L., Lee, D. F., Kelley, 
K., and Rendl, M. (2010) Oct4 and klf4 reprogram dermal papilla cells into 
induced pluripotent stem cells, Stem Cells 28, 221-228. 
51. Wernig, M., Meissner, A., Cassady, J. P., and Jaenisch, R. (2008) c-Myc is 
dispensable for direct reprogramming of mouse fibroblasts, Cell Stem Cell 
2, 10-12. 
52. Hanna, J., Wernig, M., Markoulaki, S., Sun, C. W., Meissner, A., Cassady, 
J. P., Beard, C., Brambrink, T., Wu, L. C., Townes, T. M., and Jaenisch, R. 
(2007) Treatment of sickle cell anemia mouse model with iPS cells 
generated from autologous skin, Science 318, 1920-1923. 
53. Espejel, S., Roll, G. R., McLaughlin, K. J., Lee, A. Y., Zhang, J. Y., Laird, 
D. J., Okita, K., Yamanaka, S., and Willenbring, H. (2010) Induced 
pluripotent stem cell-derived hepatocytes have the functional and 
proliferative capabilities needed for liver regeneration in mice, J Clin Invest 
120, 3120-3126. 
54. Park, I. H., Arora, N., Huo, H., Maherali, N., Ahfeldt, T., Shimamura, A., 
Lensch, M. W., Cowan, C., Hochedlinger, K., and Daley, G. Q. (2008) 
Disease-specific induced pluripotent stem cells, Cell 134, 877-886. 
55. Ebert, A. D., Yu, J., Rose, F. F., Jr., Mattis, V. B., Lorson, C. L., Thomson, 
J. A., and Svendsen, C. N. (2009) Induced pluripotent stem cells from a 
spinal muscular atrophy patient, Nature 457, 277-280. 
56. Lee, G., Papapetrou, E. P., Kim, H., Chambers, S. M., Tomishima, M. J., 
Fasano, C. A., Ganat, Y. M., Menon, J., Shimizu, F., Viale, A., Tabar, V., 
Sadelain, M., and Studer, L. (2009) Modelling pathogenesis and treatment 
of familial dysautonomia using patient-specific iPSCs, Nature 461, 402-406. 
57. Raya, A., Rodriguez-Piza, I., Guenechea, G., Vassena, R., Navarro, S., 
Barrero, M. J., Consiglio, A., Castella, M., Rio, P., Sleep, E., Gonzalez, F., 
Tiscornia, G., Garreta, E., Aasen, T., Veiga, A., Verma, I. M., Surralles, J., 
Bueren, J., and Izpisua Belmonte, J. C. (2009) Disease-corrected 
haematopoietic progenitors from Fanconi anaemia induced pluripotent stem 
cells, Nature 460, 53-59. 
58. Stadtfeld, M., and Hochedlinger, K. (2010) Induced pluripotency: history, 
mechanisms, and applications, Genes Dev 24, 2239-2263. 
  
109 
 
59. Potten, C. S., and Loeffler, M. (1990) Stem cells: attributes, cycles, spirals, 
pitfalls and uncertainties. Lessons for and from the crypt, Development 110, 
1001-1020. 
60. Mikkers, H., and Frisen, J. (2005) Deconstructing stemness, EMBO J 24, 
2715-2719. 
61. Morrison, S. J., and Kimble, J. (2006) Asymmetric and symmetric stem-cell 
divisions in development and cancer, Nature 441, 1068-1074. 
62. Neumuller, R. A., and Knoblich, J. A. (2009) Dividing cellular asymmetry: 
asymmetric cell division and its implications for stem cells and cancer, 
Genes Dev 23, 2675-2699. 
63. Till, J. E., and Mc, C. E. (1961) A direct measurement of the radiation 
sensitivity of normal mouse bone marrow cells, Radiat Res 14, 213-222. 
64. Siminovitch, L., McCulloch, E. A., and Till, J. E. (1963) The Distribution of 
Colony-Forming Cells among Spleen Colonies, J Cell Physiol 62, 327-336. 
65. Morrison, S. J., and Weissman, I. L. (1994) The long-term repopulating 
subset of hematopoietic stem cells is deterministic and isolatable by 
phenotype, Immunity 1, 661-673. 
66. Weissman, I. L. (2000) Stem cells: units of development, units of 
regeneration, and units in evolution, Cell 100, 157-168. 
67. Jones, R. J., Celano, P., Sharkis, S. J., and Sensenbrenner, L. L. (1989) Two 
phases of engraftment established by serial bone marrow transplantation in 
mice, Blood 73, 397-401. 
68. Kondo, M., Weissman, I. L., and Akashi, K. (1997) Identification of 
clonogenic common lymphoid progenitors in mouse bone marrow, Cell 91, 
661-672. 
69. Akashi, K., Kondo, M., Cheshier, S., Shizuru, J., Gandy, K., Domen, J., 
Mebius, R., Traver, D., and Weissman, I. L. (1999) Lymphoid development 
from stem cells and the common lymphocyte progenitors, Cold Spring Harb 
Symp Quant Biol 64, 1-12. 
70. Korbling, M., and Estrov, Z. (2003) Adult stem cells for tissue repair - a 
new therapeutic concept?, N Engl J Med 349, 570-582. 
71. Friedenstein, A. J., Piatetzky, S., II, and Petrakova, K. V. (1966) 
Osteogenesis in transplants of bone marrow cells, J Embryol Exp Morphol 
16, 381-390. 
72. Pittenger, M. F., Mackay, A. M., Beck, S. C., Jaiswal, R. K., Douglas, R., 
Mosca, J. D., Moorman, M. A., Simonetti, D. W., Craig, S., and Marshak, 
D. R. (1999) Multilineage potential of adult human mesenchymal stem cells, 
Science 284, 143-147. 
73. Barry, F. P., and Murphy, J. M. (2004) Mesenchymal stem cells: clinical 
applications and biological characterization, Int J Biochem Cell Biol 36, 
568-584. 
  
110 
 
74. Conget, P. A., and Minguell, J. J. (1999) Phenotypical and functional 
properties of human bone marrow mesenchymal progenitor cells, J Cell 
Physiol 181, 67-73. 
75. Minguell, J. J., Erices, A., and Conget, P. (2001) Mesenchymal stem cells, 
Exp Biol Med (Maywood) 226, 507-520. 
76. Lindner, U., Kramer, J., Rohwedel, J., and Schlenke, P. (2010) 
Mesenchymal Stem or Stromal Cells: Toward a Better Understanding of 
Their Biology?, Transfus Med Hemother 37, 75-83. 
77. Bobis, S., Jarocha, D., and Majka, M. (2006) Mesenchymal stem cells: 
characteristics and clinical applications, Folia Histochem Cytobiol 44, 215-
230. 
78. Friedenstein, A. J. (1976) Precursor cells of mechanocytes, Int Rev Cytol 47, 
327-359. 
79. Perkins, S., and Fleischman, R. A. (1990) Stromal cell progeny of murine 
bone marrow fibroblast colony-forming units are clonal endothelial-like 
cells that express collagen IV and laminin, Blood 75, 620-625. 
80. Bruder, S. P., Jaiswal, N., and Haynesworth, S. E. (1997) Growth kinetics, 
self-renewal, and the osteogenic potential of purified human mesenchymal 
stem cells during extensive subcultivation and following cryopreservation, J 
Cell Biochem 64, 278-294. 
81. Colter, D. C., Sekiya, I., and Prockop, D. J. (2001) Identification of a 
subpopulation of rapidly self-renewing and multipotential adult stem cells in 
colonies of human marrow stromal cells, Proc Natl Acad Sci U S A 98, 
7841-7845. 
82. Reyes, M., Lund, T., Lenvik, T., Aguiar, D., Koodie, L., and Verfaillie, C. 
M. (2001) Purification and ex vivo expansion of postnatal human marrow 
mesodermal progenitor cells, Blood 98, 2615-2625. 
83. Baddoo, M., Hill, K., Wilkinson, R., Gaupp, D., Hughes, C., Kopen, G. C., 
and Phinney, D. G. (2003) Characterization of mesenchymal stem cells 
isolated from murine bone marrow by negative selection, J Cell Biochem 89, 
1235-1249. 
84. Boiret, N., Rapatel, C., Veyrat-Masson, R., Guillouard, L., Guerin, J. J., 
Pigeon, P., Descamps, S., Boisgard, S., and Berger, M. G. (2005) 
Characterization of nonexpanded mesenchymal progenitor cells from 
normal adult human bone marrow, Exp Hematol 33, 219-225. 
85. Gronthos, S., Zannettino, A. C., Hay, S. J., Shi, S., Graves, S. E., Kortesidis, 
A., and Simmons, P. J. (2003) Molecular and cellular characterisation of 
highly purified stromal stem cells derived from human bone marrow, J Cell 
Sci 116, 1827-1835. 
86. Majumdar, M. K., Keane-Moore, M., Buyaner, D., Hardy, W. B., Moorman, 
M. A., McIntosh, K. R., and Mosca, J. D. (2003) Characterization and 
functionality of cell surface molecules on human mesenchymal stem cells, J 
Biomed Sci 10, 228-241. 
  
111 
 
87. Dominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini, F., 
Krause, D., Deans, R., Keating, A., Prockop, D., and Horwitz, E. (2006) 
Minimal criteria for defining multipotent mesenchymal stromal cells. The 
International Society for Cellular Therapy position statement, Cytotherapy 
8, 315-317. 
88. Phinney, D. G., and Prockop, D. J. (2007) Concise review: mesenchymal 
stem/multipotent stromal cells: the state of transdifferentiation and modes of 
tissue repair--current views, Stem Cells 25, 2896-2902. 
89. Heino, T. J., and Hentunen, T. A. (2008) Differentiation of osteoblasts and 
osteocytes from mesenchymal stem cells, Curr Stem Cell Res Ther 3, 131-
145. 
90. Jaiswal, N., Haynesworth, S. E., Caplan, A. I., and Bruder, S. P. (1997) 
Osteogenic differentiation of purified, culture-expanded human 
mesenchymal stem cells in vitro, J Cell Biochem 64, 295-312. 
91. Mackay, A. M., Beck, S. C., Murphy, J. M., Barry, F. P., Chichester, C. O., 
and Pittenger, M. F. (1998) Chondrogenic differentiation of cultured human 
mesenchymal stem cells from marrow, Tissue Eng 4, 415-428. 
92. Pelttari, K., Steck, E., and Richter, W. (2008) The use of mesenchymal stem 
cells for chondrogenesis, Injury 39 Suppl 1, S58-65. 
93. Fernandez, M., Simon, V., Herrera, G., Cao, C., Del Favero, H., and 
Minguell, J. J. (1997) Detection of stromal cells in peripheral blood 
progenitor cell collections from breast cancer patients, Bone Marrow 
Transplant 20, 265-271. 
94. Watt, F. M., and Hogan, B. L. (2000) Out of Eden: stem cells and their 
niches, Science 287, 1427-1430. 
95. Chamberlain, G., Fox, J., Ashton, B., and Middleton, J. (2007) Concise 
review: mesenchymal stem cells: their phenotype, differentiation capacity, 
immunological features, and potential for homing, Stem Cells 25, 2739-
2749. 
96. Ruster, B., Gottig, S., Ludwig, R. J., Bistrian, R., Muller, S., Seifried, E., 
Gille, J., and Henschler, R. (2006) Mesenchymal stem cells display 
coordinated rolling and adhesion behavior on endothelial cells, Blood 108, 
3938-3944. 
97. Wang, C. H., Cherng, W. J., Yang, N. I., Kuo, L. T., Hsu, C. M., Yeh, H. I., 
Lan, Y. J., Yeh, C. H., and Stanford, W. L. (2008) Late-outgrowth 
endothelial cells attenuate intimal hyperplasia contributed by mesenchymal 
stem cells after vascular injury, Arterioscler Thromb Vasc Biol 28, 54-60. 
98. Jiang, W. H., Ma, A. Q., Zhang, Y. M., Han, K., Liu, Y., Zhang, Z. T., 
Wang, T. Z., Huang, X., and Zheng, X. P. (2005) Migration of intravenously 
grafted mesenchymal stem cells to injured heart in rats, Sheng Li Xue Bao 
57, 566-572. 
99. Devine, S. M., Bartholomew, A. M., Mahmud, N., Nelson, M., Patil, S., 
Hardy, W., Sturgeon, C., Hewett, T., Chung, T., Stock, W., Sher, D., 
  
112 
 
Weissman, S., Ferrer, K., Mosca, J., Deans, R., Moseley, A., and Hoffman, 
R. (2001) Mesenchymal stem cells are capable of homing to the bone 
marrow of non-human primates following systemic infusion, Exp Hematol 
29, 244-255. 
100. Karp, J. M., and Leng Teo, G. S. (2009) Mesenchymal stem cell homing: 
the devil is in the details, Cell Stem Cell 4, 206-216. 
101. Lee, R. H., Seo, M. J., Reger, R. L., Spees, J. L., Pulin, A. A., Olson, S. D., 
and Prockop, D. J. (2006) Multipotent stromal cells from human marrow 
home to and promote repair of pancreatic islets and renal glomeruli in 
diabetic NOD/scid mice, Proc Natl Acad Sci U S A 103, 17438-17443. 
102. Mahmood, A., Lu, D., and Chopp, M. (2004) Marrow stromal cell 
transplantation after traumatic brain injury promotes cellular proliferation 
within the brain, Neurosurgery 55, 1185-1193. 
103. Tang, J., Xie, Q., Pan, G., Wang, J., and Wang, M. (2006) Mesenchymal 
stem cells participate in angiogenesis and improve heart function in rat 
model of myocardial ischemia with reperfusion, Eur J Cardiothorac Surg 
30, 353-361. 
104. Zappia, E., Casazza, S., Pedemonte, E., Benvenuto, F., Bonanni, I., Gerdoni, 
E., Giunti, D., Ceravolo, A., Cazzanti, F., Frassoni, F., Mancardi, G., and 
Uccelli, A. (2005) Mesenchymal stem cells ameliorate experimental 
autoimmune encephalomyelitis inducing T-cell anergy, Blood 106, 1755-
1761. 
105. Hung, S. C., Pochampally, R. R., Chen, S. C., Hsu, S. C., and Prockop, D. J. 
(2007) Angiogenic effects of human multipotent stromal cell conditioned 
medium activate the PI3K-Akt pathway in hypoxic endothelial cells to 
inhibit apoptosis, increase survival, and stimulate angiogenesis, Stem Cells 
25, 2363-2370. 
106. Si, Y. L., Zhao, Y. L., Hao, H. J., Fu, X. B., and Han, W. D. (2011) MSCs: 
Biological characteristics, clinical applications and their outstanding 
concerns, Ageing Res Rev 10, 93-103. 
107. Le Blanc, K., Rasmusson, I., Sundberg, B., Gotherstrom, C., Hassan, M., 
Uzunel, M., and Ringden, O. (2004) Treatment of severe acute graft-versus-
host disease with third party haploidentical mesenchymal stem cells, Lancet 
363, 1439-1441. 
108. Deb, A., Wang, S., Skelding, K. A., Miller, D., Simper, D., and Caplice, N. 
M. (2003) Bone marrow-derived cardiomyocytes are present in adult human 
heart: A study of gender-mismatched bone marrow transplantation patients, 
Circulation 107, 1247-1249. 
109. Stamm, C., Westphal, B., Kleine, H. D., Petzsch, M., Kittner, C., Klinge, H., 
Schumichen, C., Nienaber, C. A., Freund, M., and Steinhoff, G. (2003) 
Autologous bone-marrow stem-cell transplantation for myocardial 
regeneration, Lancet 361, 45-46. 
  
113 
 
110. Gussoni, E., Soneoka, Y., Strickland, C. D., Buzney, E. A., Khan, M. K., 
Flint, A. F., Kunkel, L. M., and Mulligan, R. C. (1999) Dystrophin 
expression in the mdx mouse restored by stem cell transplantation, Nature 
401, 390-394. 
111. Ortiz, L. A., Gambelli, F., McBride, C., Gaupp, D., Baddoo, M., Kaminski, 
N., and Phinney, D. G. (2003) Mesenchymal stem cell engraftment in lung 
is enhanced in response to bleomycin exposure and ameliorates its fibrotic 
effects, Proc Natl Acad Sci U S A 100, 8407-8411. 
112. Akiyama, Y., Radtke, C., and Kocsis, J. D. (2002) Remyelination of the rat 
spinal cord by transplantation of identified bone marrow stromal cells, J 
Neurosci 22, 6623-6630. 
113. Mezey, E., Key, S., Vogelsang, G., Szalayova, I., Lange, G. D., and Crain, 
B. (2003) Transplanted bone marrow generates new neurons in human 
brains, Proc Natl Acad Sci U S A 100, 1364-1369. 
114. Sanchez-Ramos, J. R. (2002) Neural cells derived from adult bone marrow 
and umbilical cord blood, J Neurosci Res 69, 880-893. 
115. Chopp, M., Zhang, X. H., Li, Y., Wang, L., Chen, J., Lu, D., Lu, M., and 
Rosenblum, M. (2000) Spinal cord injury in rat: treatment with bone 
marrow stromal cell transplantation, Neuroreport 11, 3001-3005. 
116. Horwitz, E. M., Prockop, D. J., Fitzpatrick, L. A., Koo, W. W., Gordon, P. 
L., Neel, M., Sussman, M., Orchard, P., Marx, J. C., Pyeritz, R. E., and 
Brenner, M. K. (1999) Transplantability and therapeutic effects of bone 
marrow-derived mesenchymal cells in children with osteogenesis 
imperfecta, Nat Med 5, 309-313. 
117. Fouillard, L., Bensidhoum, M., Bories, D., Bonte, H., Lopez, M., Moseley, 
A. M., Smith, A., Lesage, S., Beaujean, F., Thierry, D., Gourmelon, P., 
Najman, A., and Gorin, N. C. (2003) Engraftment of allogeneic 
mesenchymal stem cells in the bone marrow of a patient with severe 
idiopathic aplastic anemia improves stroma, Leukemia 17, 474-476. 
118. Bjornstrom, L., and Sjoberg, M. (2005) Mechanisms of estrogen receptor 
signaling: convergence of genomic and nongenomic actions on target genes, 
Mol Endocrinol 19, 833-842. 
119. Moriarty, K., Kim, K. H., and Bender, J. R. (2006) Minireview: estrogen 
receptor-mediated rapid signaling, Endocrinology 147, 5557-5563. 
120. Katzenellenbogen, B. S. (1996) Estrogen receptors: bioactivities and 
interactions with cell signaling pathways, Biol Reprod 54, 287-293. 
121. Altucci, L., Addeo, R., Cicatiello, L., Dauvois, S., Parker, M. G., Truss, M., 
Beato, M., Sica, V., Bresciani, F., and Weisz, A. (1996) 17beta-Estradiol 
induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation 
and p105Rb phosphorylation during mitogenic stimulation of G(1)-arrested 
human breast cancer cells, Oncogene 12, 2315-2324. 
  
114 
 
122. Foster, J. S., and Wimalasena, J. (1996) Estrogen regulates activity of 
cyclin-dependent kinases and retinoblastoma protein phosphorylation in 
breast cancer cells, Mol Endocrinol 10, 488-498. 
123. Gompel, A., Somai, S., Chaouat, M., Kazem, A., Kloosterboer, H. J., 
Beusman, I., Forgez, P., Mimoun, M., and Rostene, W. (2000) Hormonal 
regulation of apoptosis in breast cells and tissues, Steroids 65, 593-598. 
124. Lewis-Wambi, J. S., and Jordan, V. C. (2009) Estrogen regulation of 
apoptosis: how can one hormone stimulate and inhibit?, Breast Cancer Res 
11, 206. 
125. Zaldivar, V., Magri, M. L., Zarate, S., Jaita, G., Eijo, G., Radl, D., Ferraris, 
J., Pisera, D., and Seilicovich, A. (2009) Estradiol increases the Bax/Bcl-2 
ratio and induces apoptosis in the anterior pituitary gland, 
Neuroendocrinology 90, 292-300. 
126. Clarke, B. L., and Khosla, S. (2010) Female reproductive system and bone, 
Arch Biochem Biophys 503, 118-128. 
127. Skafar, D. F., Xu, R., Morales, J., Ram, J., and Sowers, J. R. (1997) Clinical 
review 91: Female sex hormones and cardiovascular disease in women, J 
Clin Endocrinol Metab 82, 3913-3918. 
128. Pettersson, K., and Gustafsson, J. A. (2001) Role of estrogen receptor beta 
in estrogen action, Annu Rev Physiol 63, 165-192. 
129. Kushner, P. J., Agard, D. A., Greene, G. L., Scanlan, T. S., Shiau, A. K., 
Uht, R. M., and Webb, P. (2000) Estrogen receptor pathways to AP-1, J 
Steroid Biochem Mol Biol 74, 311-317. 
130. Acconcia, F., and Kumar, R. (2006) Signaling regulation of genomic and 
nongenomic functions of estrogen receptors, Cancer Lett 238, 1-14. 
131. Crisostomo, P. R., Wang, M., Herring, C. M., Morrell, E. D., Seshadri, P., 
Meldrum, K. K., and Meldrum, D. R. (2006) Sex dimorphisms in activated 
mesenchymal stem cell function, Shock 26, 571-574. 
132. Crisostomo, P. R., Wang, M., Herring, C. M., Markel, T. A., Meldrum, K. 
K., Lillemoe, K. D., and Meldrum, D. R. (2007) Gender differences in 
injury induced mesenchymal stem cell apoptosis and VEGF, TNF, IL-6 
expression: role of the 55 kDa TNF receptor (TNFR1), J Mol Cell Cardiol 
42, 142-149. 
133. Crisostomo, P. R., Markel, T. A., Wang, M., Lahm, T., Lillemoe, K. D., and 
Meldrum, D. R. (2007) In the adult mesenchymal stem cell population, 
source gender is a biologically relevant aspect of protective power, Surgery 
142, 215-221. 
134. Hong, L., Sultana, H., Paulius, K., and Zhang, G. (2009) Steroid regulation 
of proliferation and osteogenic differentiation of bone marrow stromal cells: 
a gender difference, J Steroid Biochem Mol Biol 114, 180-185. 
135. Cha, Y., Kwon, S. J., Seol, W., and Park, K. S. (2008) Estrogen receptor-
alpha mediates the effects of estradiol on telomerase activity in human 
mesenchymal stem cells, Mol Cells 26, 454-458. 
  
115 
 
136. Hong, L., Colpan, A., and Peptan, I. A. (2006) Modulations of 17-beta 
estradiol on osteogenic and adipogenic differentiations of human 
mesenchymal stem cells, Tissue Eng 12, 2747-2753. 
137. Festjens, N., Vanden Berghe, T., and Vandenabeele, P. (2006) Necrosis, a 
well-orchestrated form of cell demise: signalling cascades, important 
mediators and concomitant immune response, Biochim Biophys Acta 1757, 
1371-1387. 
138. Golstein, P., and Kroemer, G. (2007) Cell death by necrosis: towards a 
molecular definition, Trends Biochem Sci 32, 37-43. 
139. Kroemer, G., Galluzzi, L., and Brenner, C. (2007) Mitochondrial membrane 
permeabilization in cell death, Physiol Rev 87, 99-163. 
140. Lin, Y., Choksi, S., Shen, H. M., Yang, Q. F., Hur, G. M., Kim, Y. S., Tran, 
J. H., Nedospasov, S. A., and Liu, Z. G. (2004) Tumor necrosis factor-
induced nonapoptotic cell death requires receptor-interacting protein-
mediated cellular reactive oxygen species accumulation, J Biol Chem 279, 
10822-10828. 
141. Ha, H. C., and Snyder, S. H. (1999) Poly(ADP-ribose) polymerase is a 
mediator of necrotic cell death by ATP depletion, Proc Natl Acad Sci U S A 
96, 13978-13982. 
142. Kerr, J. F., Wyllie, A. H., and Currie, A. R. (1972) Apoptosis: a basic 
biological phenomenon with wide-ranging implications in tissue kinetics, Br 
J Cancer 26, 239-257. 
143. Kroemer, G., Galluzzi, L., Vandenabeele, P., Abrams, J., Alnemri, E. S., 
Baehrecke, E. H., Blagosklonny, M. V., El-Deiry, W. S., Golstein, P., 
Green, D. R., Hengartner, M., Knight, R. A., Kumar, S., Lipton, S. A., 
Malorni, W., Nunez, G., Peter, M. E., Tschopp, J., Yuan, J., Piacentini, M., 
Zhivotovsky, B., and Melino, G. (2009) Classification of cell death: 
recommendations of the Nomenclature Committee on Cell Death 2009, Cell 
Death Differ 16, 3-11. 
144. Baehrecke, E. H. (2002) How death shapes life during development, Nat 
Rev Mol Cell Biol 3, 779-787. 
145. Roach, H. I., and Clarke, N. M. (2000) Physiological cell death of 
chondrocytes in vivo is not confined to apoptosis. New observations on the 
mammalian growth plate, J Bone Joint Surg Br 82, 601-613. 
146. Assuncao Guimaraes, C., and Linden, R. (2004) Programmed cell deaths. 
Apoptosis and alternative deathstyles, Eur J Biochem 271, 1638-1650. 
147. Cho, Y. S., Park, S. Y., Shin, H. S., and Chan, F. K. (2010) Physiological 
consequences of programmed necrosis, an alternative form of cell demise, 
Mol Cells 29, 327-332. 
148. Danial, N. N., and Korsmeyer, S. J. (2004) Cell death: critical control 
points, Cell 116, 205-219. 
  
116 
 
149. Petit, F., Arnoult, D., Viollet, L., and Estaquier, J. (2003) Intrinsic and 
extrinsic pathways signaling during HIV-1 mediated cell death, Biochimie 
85, 795-811. 
150. Schmitz, I., Kirchhoff, S., and Krammer, P. H. (2000) Regulation of death 
receptor-mediated apoptosis pathways, Int J Biochem Cell Biol 32, 1123-
1136. 
151. Borutaite, V. (2010) Mitochondria as decision-makers in cell death, Environ 
Mol Mutagen 51, 406-416. 
152. Antonsson, B. (2004) Mitochondria and the Bcl-2 family proteins in 
apoptosis signaling pathways, Mol Cell Biochem 256-257, 141-155. 
153. Belosludtsev, K., Saris, N. E., Andersson, L. C., Belosludtseva, N., 
Agafonov, A., Sharma, A., Moshkov, D. A., and Mironova, G. D. (2006) On 
the mechanism of palmitic acid-induced apoptosis: the role of a pore 
induced by palmitic acid and Ca2+ in mitochondria, J Bioenerg Biomembr 
38, 113-120. 
154. Lucken-Ardjomande, S., and Martinou, J. C. (2005) Newcomers in the 
process of mitochondrial permeabilization, J Cell Sci 118, 473-483. 
155. Siskind, L. J. (2005) Mitochondrial ceramide and the induction of apoptosis, 
J Bioenerg Biomembr 37, 143-153. 
156. Bernardi, P., and Petronilli, V. (1996) The permeability transition pore as a 
mitochondrial calcium release channel: a critical appraisal, J Bioenerg 
Biomembr 28, 131-138. 
157. Crompton, M. (1999) The mitochondrial permeability transition pore and its 
role in cell death, Biochem J 341 ( Pt 2), 233-249. 
158. Li, L. Y., Luo, X., and Wang, X. (2001) Endonuclease G is an apoptotic 
DNase when released from mitochondria, Nature 412, 95-99. 
159. Susin, S. A., Lorenzo, H. K., Zamzami, N., Marzo, I., Snow, B. E., Brothers, 
G. M., Mangion, J., Jacotot, E., Costantini, P., Loeffler, M., Larochette, N., 
Goodlett, D. R., Aebersold, R., Siderovski, D. P., Penninger, J. M., and 
Kroemer, G. (1999) Molecular characterization of mitochondrial apoptosis-
inducing factor, Nature 397, 441-446. 
160. van Loo, G., Schotte, P., van Gurp, M., Demol, H., Hoorelbeke, B., Gevaert, 
K., Rodriguez, I., Ruiz-Carrillo, A., Vandekerckhove, J., Declercq, W., 
Beyaert, R., and Vandenabeele, P. (2001) Endonuclease G: a mitochondrial 
protein released in apoptosis and involved in caspase-independent DNA 
degradation, Cell Death Differ 8, 1136-1142. 
161. Zou, H., Li, Y., Liu, X., and Wang, X. (1999) An APAF-1.cytochrome c 
multimeric complex is a functional apoptosome that activates procaspase-9, 
J Biol Chem 274, 11549-11556. 
162. Adams, J. M., and Cory, S. (1998) The Bcl-2 protein family: arbiters of cell 
survival, Science 281, 1322-1326. 
163. Reed, J. C. (2000) Mechanisms of apoptosis, Am J Pathol 157, 1415-1430. 
  
117 
 
164. Chan, S. L., and Yu, V. C. (2004) Proteins of the bcl-2 family in apoptosis 
signalling: from mechanistic insights to therapeutic opportunities, Clin Exp 
Pharmacol Physiol 31, 119-128. 
165. Chittenden, T., Flemington, C., Houghton, A. B., Ebb, R. G., Gallo, G. J., 
Elangovan, B., Chinnadurai, G., and Lutz, R. J. (1995) A conserved domain 
in Bak, distinct from BH1 and BH2, mediates cell death and protein binding 
functions, EMBO J 14, 5589-5596. 
166. Hirotani, M., Zhang, Y., Fujita, N., Naito, M., and Tsuruo, T. (1999) NH2-
terminal BH4 domain of Bcl-2 is functional for heterodimerization with Bax 
and inhibition of apoptosis, J Biol Chem 274, 20415-20420. 
167. Hunter, J. J., and Parslow, T. G. (1996) A peptide sequence from Bax that 
converts Bcl-2 into an activator of apoptosis, J Biol Chem 271, 8521-8524. 
168. Yin, X. M., Oltvai, Z. N., and Korsmeyer, S. J. (1994) BH1 and BH2 
domains of Bcl-2 are required for inhibition of apoptosis and 
heterodimerization with Bax, Nature 369, 321-323. 
169. Green, D. R., and Reed, J. C. (1998) Mitochondria and apoptosis, Science 
281, 1309-1312. 
170. Gustafsson, A. B., and Gottlieb, R. A. (2007) Bcl-2 family members and 
apoptosis, taken to heart, Am J Physiol Cell Physiol 292, C45-51. 
171. Chipuk, J. E., Moldoveanu, T., Llambi, F., Parsons, M. J., and Green, D. R. 
(2010) The BCL-2 family reunion, Mol Cell 37, 299-310. 
172. Krajewski, S., Tanaka, S., Takayama, S., Schibler, M. J., Fenton, W., and 
Reed, J. C. (1993) Investigation of the subcellular distribution of the bcl-2 
oncoprotein: residence in the nuclear envelope, endoplasmic reticulum, and 
outer mitochondrial membranes, Cancer Res 53, 4701-4714. 
173. Merry, D. E., and Korsmeyer, S. J. (1997) Bcl-2 gene family in the nervous 
system, Annu Rev Neurosci 20, 245-267. 
174. Susin, S. A., Zamzami, N., Castedo, M., Hirsch, T., Marchetti, P., Macho, 
A., Daugas, E., Geuskens, M., and Kroemer, G. (1996) Bcl-2 inhibits the 
mitochondrial release of an apoptogenic protease, J Exp Med 184, 1331-
1341. 
175. Janiak, F., Leber, B., and Andrews, D. W. (1994) Assembly of Bcl-2 into 
microsomal and outer mitochondrial membranes, J Biol Chem 269, 9842-
9849. 
176. Antonsson, B., Montessuit, S., Sanchez, B., and Martinou, J. C. (2001) Bax 
is present as a high molecular weight oligomer/complex in the 
mitochondrial membrane of apoptotic cells, J Biol Chem 276, 11615-11623. 
177. Eskes, R., Desagher, S., Antonsson, B., and Martinou, J. C. (2000) Bid 
induces the oligomerization and insertion of Bax into the outer 
mitochondrial membrane, Mol Cell Biol 20, 929-935. 
178. Gilmore, A. P., Metcalfe, A. D., Romer, L. H., and Streuli, C. H. (2000) 
Integrin-mediated survival signals regulate the apoptotic function of Bax 
  
118 
 
through its conformation and subcellular localization, J Cell Biol 149, 431-
446. 
179. Wolter, K. G., Hsu, Y. T., Smith, C. L., Nechushtan, A., Xi, X. G., and 
Youle, R. J. (1997) Movement of Bax from the cytosol to mitochondria 
during apoptosis, J Cell Biol 139, 1281-1292. 
180. Vander Heiden, M. G., and Thompson, C. B. (1999) Bcl-2 proteins: 
regulators of apoptosis or of mitochondrial homeostasis?, Nat Cell Biol 1, 
E209-216. 
181. Gross, A., McDonnell, J. M., and Korsmeyer, S. J. (1999) BCL-2 family 
members and the mitochondria in apoptosis, Genes Dev 13, 1899-1911. 
182. Kluck, R. M., Bossy-Wetzel, E., Green, D. R., and Newmeyer, D. D. (1997) 
The release of cytochrome c from mitochondria: a primary site for Bcl-2 
regulation of apoptosis, Science 275, 1132-1136. 
183. Wei, M. C., Zong, W. X., Cheng, E. H., Lindsten, T., Panoutsakopoulou, V., 
Ross, A. J., Roth, K. A., MacGregor, G. R., Thompson, C. B., and 
Korsmeyer, S. J. (2001) Proapoptotic BAX and BAK: a requisite gateway to 
mitochondrial dysfunction and death, Science 292, 727-730. 
184. Zha, J., Harada, H., Osipov, K., Jockel, J., Waksman, G., and Korsmeyer, S. 
J. (1997) BH3 domain of BAD is required for heterodimerization with BCL-
XL and pro-apoptotic activity, J Biol Chem 272, 24101-24104. 
185. Nechushtan, A., Smith, C. L., Hsu, Y. T., and Youle, R. J. (1999) 
Conformation of the Bax C-terminus regulates subcellular location and cell 
death, EMBO J 18, 2330-2341. 
186. Suzuki, M., Youle, R. J., and Tjandra, N. (2000) Structure of Bax: 
coregulation of dimer formation and intracellular localization, Cell 103, 
645-654. 
187. Griffiths, G. J., Dubrez, L., Morgan, C. P., Jones, N. A., Whitehouse, J., 
Corfe, B. M., Dive, C., and Hickman, J. A. (1999) Cell damage-induced 
conformational changes of the pro-apoptotic protein Bak in vivo precede the 
onset of apoptosis, J Cell Biol 144, 903-914. 
188. Basanez, G., Sharpe, J. C., Galanis, J., Brandt, T. B., Hardwick, J. M., and 
Zimmerberg, J. (2002) Bax-type apoptotic proteins porate pure lipid bilayers 
through a mechanism sensitive to intrinsic monolayer curvature, J Biol 
Chem 277, 49360-49365. 
189. Kuwana, T., Mackey, M. R., Perkins, G., Ellisman, M. H., Latterich, M., 
Schneiter, R., Green, D. R., and Newmeyer, D. D. (2002) Bid, Bax, and 
lipids cooperate to form supramolecular openings in the outer mitochondrial 
membrane, Cell 111, 331-342. 
190. Shimizu, S., Narita, M., and Tsujimoto, Y. (1999) Bcl-2 family proteins 
regulate the release of apoptogenic cytochrome c by the mitochondrial 
channel VDAC, Nature 399, 483-487. 
191. Li, P., Nijhawan, D., Budihardjo, I., Srinivasula, S. M., Ahmad, M., 
Alnemri, E. S., and Wang, X. (1997) Cytochrome c and dATP-dependent 
  
119 
 
formation of Apaf-1/caspase-9 complex initiates an apoptotic protease 
cascade, Cell 91, 479-489. 
192. Du, C., Fang, M., Li, Y., Li, L., and Wang, X. (2000) Smac, a mitochondrial 
protein that promotes cytochrome c-dependent caspase activation by 
eliminating IAP inhibition, Cell 102, 33-42. 
193. Verhagen, A. M., Ekert, P. G., Pakusch, M., Silke, J., Connolly, L. M., Reid, 
G. E., Moritz, R. L., Simpson, R. J., and Vaux, D. L. (2000) Identification of 
DIABLO, a mammalian protein that promotes apoptosis by binding to and 
antagonizing IAP proteins, Cell 102, 43-53. 
194. Hegde, R., Srinivasula, S. M., Zhang, Z., Wassell, R., Mukattash, R., 
Cilenti, L., DuBois, G., Lazebnik, Y., Zervos, A. S., Fernandes-Alnemri, T., 
and Alnemri, E. S. (2002) Identification of Omi/HtrA2 as a mitochondrial 
apoptotic serine protease that disrupts inhibitor of apoptosis protein-caspase 
interaction, J Biol Chem 277, 432-438. 
195. Suzuki, Y., Imai, Y., Nakayama, H., Takahashi, K., Takio, K., and 
Takahashi, R. (2001) A serine protease, HtrA2, is released from the 
mitochondria and interacts with XIAP, inducing cell death, Mol Cell 8, 613-
621. 
196. Hill, R. A., Chua, H. K., Jones, M. E., Simpson, E. R., and Boon, W. C. 
(2009) Estrogen deficiency results in apoptosis in the frontal cortex of adult 
female aromatase knockout mice, Mol Cell Neurosci 41, 1-7. 
197. Tomkinson, A., Gevers, E. F., Wit, J. M., Reeve, J., and Noble, B. S. (1998) 
The role of estrogen in the control of rat osteocyte apoptosis, J Bone Miner 
Res 13, 1243-1250. 
198. Spyridopoulos, I., Sullivan, A. B., Kearney, M., Isner, J. M., and Losordo, 
D. W. (1997) Estrogen-receptor-mediated inhibition of human endothelial 
cell apoptosis. Estradiol as a survival factor, Circulation 95, 1505-1514. 
199. Pike, C. J. (1999) Estrogen modulates neuronal Bcl-xL expression and beta-
amyloid-induced apoptosis: relevance to Alzheimer's disease, J Neurochem 
72, 1552-1563. 
200. Jia, J., Guan, D., Zhu, W., Alkayed, N. J., Wang, M. M., Hua, Z., and Xu, 
Y. (2009) Estrogen inhibits Fas-mediated apoptosis in experimental stroke, 
Exp Neurol 215, 48-52. 
201. Hughes, D. E., Dai, A., Tiffee, J. C., Li, H. H., Mundy, G. R., and Boyce, B. 
F. (1996) Estrogen promotes apoptosis of murine osteoclasts mediated by 
TGF-beta, Nat Med 2, 1132-1136. 
202. Kameda, T., Mano, H., Yuasa, T., Mori, Y., Miyazawa, K., Shiokawa, M., 
Nakamaru, Y., Hiroi, E., Hiura, K., Kameda, A., Yang, N. N., Hakeda, Y., 
and Kumegawa, M. (1997) Estrogen inhibits bone resorption by directly 
inducing apoptosis of the bone-resorbing osteoclasts, J Exp Med 186, 489-
495. 
  
120 
 
203. Okasha, S. A., Ryu, S., Do, Y., McKallip, R. J., Nagarkatti, M., and 
Nagarkatti, P. S. (2001) Evidence for estradiol-induced apoptosis and 
dysregulated T cell maturation in the thymus, Toxicology 163, 49-62. 
204. Nilsen, J., Mor, G., and Naftolin, F. (2000) Estrogen-regulated 
developmental neuronal apoptosis is determined by estrogen receptor 
subtype and the Fas/Fas ligand system, J Neurobiol 43, 64-78. 
205. Perillo, B., Sasso, A., Abbondanza, C., and Palumbo, G. (2000) 17beta-
estradiol inhibits apoptosis in MCF-7 cells, inducing bcl-2 expression via 
two estrogen-responsive elements present in the coding sequence, Mol Cell 
Biol 20, 2890-2901. 
206. Sharma, K., and Mehra, R. D. (2008) Long-term administration of estrogen 
or tamoxifen to ovariectomized rats affords neuroprotection to hippocampal 
neurons by modulating the expression of Bcl-2 and Bax, Brain Res 1204, 1-
15. 
207. Jablonka, E., and Lamb, M. J. (2002) The changing concept of epigenetics, 
Ann N Y Acad Sci 981, 82-96. 
208. Holliday, R. (1994) Epigenetics: an overview, Dev Genet 15, 453-457. 
209. Feinberg, A. P. (2008) Epigenetics at the epicenter of modern medicine, 
JAMA 299, 1345-1350. 
210. Berger, S. L., Kouzarides, T., Shiekhattar, R., and Shilatifard, A. (2009) An 
operational definition of epigenetics, Genes Dev 23, 781-783. 
211. Holliday, R. (2006) Epigenetics: a historical overview, Epigenetics 1, 76-80. 
212. Doerfler, W. (1983) DNA methylation and gene activity, Annu Rev Biochem 
52, 93-124. 
213. Goll, M. G., and Bestor, T. H. (2005) Eukaryotic cytosine 
methyltransferases, Annu Rev Biochem 74, 481-514. 
214. Richmond, T. J., Finch, J. T., Rushton, B., Rhodes, D., and Klug, A. (1984) 
Structure of the nucleosome core particle at 7 A resolution, Nature 311, 
532-537. 
215. Kornberg, R. D., and Lorch, Y. (1999) Twenty-five years of the 
nucleosome, fundamental particle of the eukaryote chromosome, Cell 98, 
285-294. 
216. Li, G., and Reinberg, D. (2011) Chromatin higher-order structures and gene 
regulation, Curr Opin Genet Dev 21, 175-186. 
217. Bhaumik, S. R., Smith, E., and Shilatifard, A. (2007) Covalent 
modifications of histones during development and disease pathogenesis, Nat 
Struct Mol Biol 14, 1008-1016. 
218. Berger, S. L. (2007) The complex language of chromatin regulation during 
transcription, Nature 447, 407-412. 
219. Mosammaparast, N., and Shi, Y. (2010) Reversal of histone methylation: 
biochemical and molecular mechanisms of histone demethylases, Annu Rev 
Biochem 79, 155-179. 
  
121 
 
220. Shi, Y., Lan, F., Matson, C., Mulligan, P., Whetstine, J. R., Cole, P. A., and 
Casero, R. A. (2004) Histone demethylation mediated by the nuclear amine 
oxidase homolog LSD1, Cell 119, 941-953. 
221. Arney, K. L., and Fisher, A. G. (2004) Epigenetic aspects of differentiation, 
J Cell Sci 117, 4355-4363. 
222. Shukla, V., Vaissiere, T., and Herceg, Z. (2008) Histone acetylation and 
chromatin signature in stem cell identity and cancer, Mutat Res 637, 1-15. 
223. Mattout, A., and Meshorer, E. (2010) Chromatin plasticity and genome 
organization in pluripotent embryonic stem cells, Curr Opin Cell Biol 22, 
334-341. 
224. Bernstein, B. E., Mikkelsen, T. S., Xie, X., Kamal, M., Huebert, D. J., Cuff, 
J., Fry, B., Meissner, A., Wernig, M., Plath, K., Jaenisch, R., Wagschal, A., 
Feil, R., Schreiber, S. L., and Lander, E. S. (2006) A bivalent chromatin 
structure marks key developmental genes in embryonic stem cells, Cell 125, 
315-326. 
225. Rasmussen, T. P. (2008) Developmentally-poised chromatin of embryonic 
stem cells, Front Biosci 13, 1568-1577. 
226. Fisher, C. L., and Fisher, A. G. (2011) Chromatin states in pluripotent, 
differentiated, and reprogrammed cells, Curr Opin Genet Dev 21, 140-146. 
227. Fullgrabe, J., Hajji, N., and Joseph, B. (2010) Cracking the death code: 
apoptosis-related histone modifications, Cell Death Differ 17, 1238-1243. 
228. Shi, L., Sun, L., Li, Q., Liang, J., Yu, W., Yi, X., Yang, X., Li, Y., Han, X., 
Zhang, Y., Xuan, C., Yao, Z., and Shang, Y. (2011) Histone demethylase 
JMJD2B coordinates H3K4/H3K9 methylation and promotes hormonally 
responsive breast carcinogenesis, Proc Natl Acad Sci U S A 108, 7541-7546. 
229. Yao, Y., Li, H., Gu, Y., Davidson, N. E., and Zhou, Q. (2010) Inhibition of 
SIRT1 deacetylase suppresses estrogen receptor signaling, Carcinogenesis 
31, 382-387. 
230. Libby, P. R. (1972) Histone acetylation and hormone action. Early effects of 
oestradiol-17beta on histone acetylation in rat uterus, Biochem J 130, 663-
669. 
231. Sakai, N., Maruyama, T., Sakurai, R., Masuda, H., Yamamoto, Y., Shimizu, 
A., Kishi, I., Asada, H., Yamagoe, S., and Yoshimura, Y. (2003) 
Involvement of histone acetylation in ovarian steroid-induced 
decidualization of human endometrial stromal cells, J Biol Chem 278, 
16675-16682. 
232. Hwang, C., Giri, V. N., Wilkinson, J. C., Wright, C. W., Wilkinson, A. S., 
Cooney, K. A., and Duckett, C. S. (2008) EZH2 regulates the transcription 
of estrogen-responsive genes through association with REA, an estrogen 
receptor corepressor, Breast Cancer Res Treat 107, 235-242. 
233. Bredfeldt, T. G., Greathouse, K. L., Safe, S. H., Hung, M. C., Bedford, M. 
T., and Walker, C. L. (2010) Xenoestrogen-induced regulation of EZH2 and 
  
122 
 
histone methylation via estrogen receptor signaling to PI3K/AKT, Mol 
Endocrinol 24, 993-1006. 
234. Bradford, M. M. (1976) A rapid and sensitive method for the quantitation of 
microgram quantities of protein utilizing the principle of protein-dye 
binding, Anal Biochem 72, 248-254. 
235. Zhou, S., Zilberman, Y., Wassermann, K., Bain, S. D., Sadovsky, Y., and 
Gazit, D. (2001) Estrogen modulates estrogen receptor alpha and beta 
expression, osteogenic activity, and apoptosis in mesenchymal stem cells 
(MSCs) of osteoporotic mice, J Cell Biochem Suppl Suppl 36, 144-155. 
236. Mattsson, C., and Olsson, T. (2007) Estrogens and glucocorticoid hormones 
in adipose tissue metabolism, Curr Med Chem 14, 2918-2924. 
237. Astudillo, P., Rios, S., Pastenes, L., Pino, A. M., and Rodriguez, J. P. (2008) 
Increased adipogenesis of osteoporotic human-mesenchymal stem cells 
(MSCs) characterizes by impaired leptin action, J Cell Biochem 103, 1054-
1065. 
238. Rodriguez, J. P., Astudillo, P., Rios, S., and Pino, A. M. (2008) Involvement 
of adipogenic potential of human bone marrow mesenchymal stem cells 
(MSCs) in osteoporosis, Curr Stem Cell Res Ther 3, 208-218. 
239. Stringer, B., Waddington, R., Houghton, A., Stone, M., Russell, G., and 
Foster, G. (2007) Serum from postmenopausal women directs differentiation 
of human clonal osteoprogenitor cells from an osteoblastic toward an 
adipocytic phenotype, Calcif Tissue Int 80, 233-243. 
 
  
123 
 
APPENDIX 
SOLUTIONS AND BUFFERS 
4% Paraformaldehyde (PFA) 
4g PFA 
Complete volume to 100ml with 1XPBS 
Dissolve by heating and constant stirring 
10% formaldehyde 
2 ml formaldehyde 
18 ml ddH2O 
70% Ethanol 
70 ml 100% Ethanol 
30 ml ddH2O 
10x PBS (pH: 7,2) 
80 g NaCl 
2 g KCl 
8,01g Na2HPO4.2H2O 
2g KH2PO4 
Complete volume to 1Lt with ddH2O   
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10X Agarose Gel Loading Dye 
0,009g bromophenolblue  
0,009g XC 
2,8mL ddH2O 
1,2ml 0,5M EDTA 
Complete volume to 15 mL with glycerol 
50X TAE Buffer 
2M Tris Base (242 g) 
57,1 ml Glacial Acetic Acid 
50mM EDTA 
Complete volume to 1Lt with ddH2O   
1M Tris (pH:8) 
60.55g Tris 
300ml ddH2O 
21ml 37% HCl 
pH adjusted to 8.0 with HCl, total volume brought to 500ml by adding ddH2O. 
Total Protein Lysis Buffer 
2M NaCl 
1M Tris pH:8.2 
0.9% Igepal CA-630 (Sigma, Germany, Germany) 
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10x Protease Inhibitor Cocktail (Roche, Germany) 
778.5μl ddH2O 
Bradford Reagent 
100 mg Coomassie Brilliant Blue G-250 
100 ml 85%phosphoric acid 
50 ml 95%EtOH 
Complete volume to 1Lt with ddH2O 
Filtered through Whatman no:1 
10%SDS 
10g SDS 
Complete volume to 100µ with ddH2O 
30% Acrylamide Mix 
145g Acrylamide 
5g bis-acrylamide 
Complete volume to 500ml with ddH2O 
Filtered, stored in dark at 40C. 
SDS-PAGE Running Buffer (5X stock solution) 
15g Tris 
73,2g Glycine 
5g SDS 
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Complete volume to 1L with ddH2O 
Cracking Buffer (2X Protein Loading Buffer) 
50mM Tris HCl pH: 6,8 
2mM EDTA pH: 6,8 
1% SDS 
20% Glycerol 
0,02% BFB 
Add 10% ß-mercaptoethanol prior to use 
10X TBS (pH:8) 
12.19 g Tris 
87,76 g NaCl 
pH adjusted to 8, Complete volume to 1Lt with ddH2O 
1X TBS-T 0.3% 
50 ml 10X TBS 
450 ml ddH2O 
1,5 ml Tween-20 
1X TBS-T 0.1% (pH: 7.5) 
50 ml 10X TBS 
450 ml ddH2O 
500 µl Tween-20 
pH adjusted to 7.5 
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Blocking Solution for Western Blot (5% BSA) (Histone protein) 
0.5g BSA 
10mL 1X TBS-T 0.1% 
Blocking Solution for Western Blot (4% milk powder) 
2 g milk powder 
50mL 1X TBS-T 0.3% 
Semi-dry Transfer Buffer 
2,5 g glycine 
5,8 g Tris base 
0,37 g SDS 
200 ml methanol 
Complete volume to 1 Lt with ddH2O 
Wet transfer buffer for small proteins 
3 g Tris 
14.25 g Glycine 
200 ml methanol 
Complete volume to 1 Lt with ddH2O 
Coomassie Blue Staining Solution 
0,25 g coomassie brilliant blue 
45 ml Methanol 
10 ml glacial acetic acid 
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Complete volume to 100 ml with ddH2O 
Destaining Solution 
100 ml methanol 
35 ml acetic acid 
365 ml ddH2O 
Blocking Solution for Immunofluorescence (IF) Staining 
1 ml 2% BSA 
1 ml 1X PBS 
5 μl tween-20 
2N HCl solution 
16.38μl ddH2O 
4.3μl HCl 
TEB buffer 
0.5% triton-100 
0.02% NaN3 
In 1XPBS 
Add 1X protease inhibitor prior to use 
Blocking Solution for Immunocytochemistry (histone protein) 
2%FBS 
0.3% TritonX-100 
In 1XPBS 
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Permeabilization solution for histone protein immunocytochemistry 
0.5% saponin 
0.3% tritonX-100 
In 1XPBS 
Lb 
10 g Tryptone 
10 g NaCl 
5 g Yeast extract 
Complete volume to 1 Lt with ddH2O and autoclave 
Agar 
10 g Tryptone 
10 g NaCl 
5 g Yeast extract 
15 g Bacto agar 
Complete volume to 1 Lt with ddH2O and autoclave 
Adipogenic Induction Media (Prepared in DMEM –LG) 
1 µM dexamethasone (Sigma, Germany)  
0.5 mM IBMX (Sigma, Germany)  
10 µg/mL insulin (Sigma, Germany)  
100 µM indomethacine (Sigma, Germany) 
10% FBS 
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1% penicillin/streptomycin antibiotic solution 
Osteogenic Induction Media (Prepared in DMEM –LG) 
0.1 µM dexamethasone  
0.2 mM ascorbic acid ɣ-irradiated (Sigma, Germany)  
10 mM glycerol phosphate disodium salt hydrate (Sigma, Germany)  
10% FBS 
1% penicillin/streptomycin antibiotic solution  
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Abstract Mesenchymal Stem Cells (MSCs) have high
therapeutic value for regenerative medicine and tissue
engineering due to their differentiation potential and non-
immunogenic characteristics. They are also considered as
an effective in vivo delivery agent because of their ability to
migrate to the site of injury. A major roadblock in their use
for cell-based therapies is their rareness in vivo. Therefore,
it is important to obtain increased number of functional
MSCs in vitro in order to have adequate numbers for
therapeutic regiments. We aimed to investigate the role of
estrogen and its mechanism in obtaining more MSCs.
MSCs were isolated from female and ovariectomized rats
and cultured in the presence and absence of 10−7 M
estrogen. In the presence of estrogen, not only their CFU-
F activity increased but also apoptotic rate decreased as
shown by TUNEL staining leading to obtain more MSCs.
Also the number of the cells in the colonies increased upon
estrogen treatment. To reveal the mechanism of this effect,
we focused on Bcl-2 family of proteins. Our immunoblot-
ting experiments combined with knockdown studies sug-
gested a critical role for anti-apoptotic Bcl-xL and Bcl-2.
Estrogen treatment up regulated the expression Bcl-xL and
Bcl-2. When we knocked down the expression of bcl-xL
and bcl-2, MSCs lacking these genes showed an increase in
the apoptotic rate in contrast to normal MSCs following
estrogen treatment. Therefore, estrogen treatment will be of
great advantage for cell-based therapies in order to get more
functional MSCs and may provide opportunities to develop
new strategies for debilitating diseases.
Keywords Mesenchymal stem cells . Estrogen . Apoptosis .
Bcl-2 . Bcl-xL . Rat . Tunel
Introduction
Increased human lifespan has brought the concept of a
better life quality, since the body functions and health
conditions decline with time. Identifying with the pioneer-
ing studies of Friedenstein [1], mesenchymal stem cells
(MSCs) have demonstrated great potential to tackle these
problems. Multipotent MSCs have potential to differentiate
into tissue-specific cell types such as osteocytes, adipo-
cytes, chondrocytes, myoblasts, cardiomyocytes [1–3].
MSCs emerge as an important player of cellular-based
therapies in wide variety of pathologies such as neurode-
generative and cardiovascular diseases, diabetes, and cancer
due to their ability to migrate in vivo to promote
regeneration of damaged tissue, treat inflammation, and
promote angiogenesis without inducing immune reaction
[4–7]. Besides being a future promise for many disease
treatments, there are also some handicaps in their applica-
tions. One major roadblock is their rareness and the fact
that they constitute a very small population of nucleated
cells in the bone marrow [8]. Their number has to be
increased before they can be used for therapeutic purposes.
Similar to stem cells, estrogen hormone can also be
accepted as a key factor in the preservation of life
standards. Estrogen is mainly responsible for female sexual
features but also influences many physiological processes
in mammals including cellular proliferation and apoptosis
[9, 10]. In humans, increased incidence of osteoporosis and
coronary heart diseases after menopause suggests the
involvement of estrogen in these disorders [11, 12]. Since
MSCs differentiate into bone and muscle cells, the effect of
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estrogen on MSCs is also critical. Understanding the
mechanism of their interaction is vital for obtaining the
maximum efficiency from this collaboration. Apoptotic
pathways, which are conserved throughout evolution, are
strong candidates for this cooperation. Estrogen has a dual
role on apoptosis; it can both stimulate and inhibit
apoptosis depending on the type of cell, the duration and
amount of estrogen and the downstream target signaling
pathway. Estrogen promotes apoptosis in osteoclasts,
thymocytes and neurons [13–16]. On the other hand, it
has antiapoptotic effect on osteocyte, umbilical vein
endothelial cells, hippocampal neurons and breast cancer
cell lines [17–20].
Although the mechanism of the apoptotic or antiapop-
totic function of estrogen is not always through the same
pathway, regulation through the bcl-2 family of genes is a
major candidate in this process. The members of the Bcl-2
family of proteins determine the life-or-death of a cell by
controlling the release of mitochondrial apoptogenic fac-
tors, cytochrome c and apoptosis inducing factors (AIF),
which activate the downstream executional phases, includ-
ing the activation of the caspases [21, 22]. Estrogen
increases the expression of anti-apoptotic but decreases
the expression of pro-apoptotic bcl-2 family of genes [19,
23, 24]. The effect of estrogen on the expression of bcl-xL
and bcl-2 is mediated through estrogen response element
(ERE) sites of these genes [19, 23]. In addition, estrogen
can also affect the expression of Bcl-2 family of genes
through the non genomic pathway which involves the
phosphorylation of the proteins [24]. Regardless of the
mechanism, it is evident that estrogen has a crucial role in
apoptotic regulation.
The present study was undertaken to investigate the
molecular mechanisms of estrogen during MSC mainte-
nance. In order to explain the mechanism of the action of
estrogen, we hypothesize that estrogen differentially regu-
lates the expression of bcl-2 family of genes and this
control results in obtaining more MSC by inhibiting
apoptosis.
Material and Methods
Isolation and Culture of MSCs
MSCs were obtained from female and ovariectomized
female 9-week old, 280–300 g Sprague–Dawley rats. The
animals were permitted unlimited access to food and water
at all times and were housed under controlled environmen-
tal conditions (22°C) with a 12-hour light and 12 h dark
cycle in the animal holding facility of the Department of
Molecular Biology and Genetics at the Bilkent University.
This study protocol complied with Bilkent University’s
guidelines on humane care and use of laboratory animals.
Bone marrow heterogeneous cell population was collected
from the femur and tibia by flushing with a 5 mL syringe
containing 10% FBS (Hyclone, Logan, UT, USA) in
DMEM (Invitrogen, Paisley, UK) after the rats were
sacrificed by cervical dislocation. The cells were cultured
in plastic culture dishes with Mesencult Media (StemCell
Technology, Vancouver, Canada) with 20% supplement
(StemCell Technology) and a 1% penicillin/streptomycin
solution (Hyclone) in a 5% CO2 incubator at 37°C. The
next day, the media of the tissue culture plates were
changed and the non-adherent cells were removed. The
media of the cells were changed every 4 days, after washing
with sterile 1x PBS prior to the change. For the estrogen
treatment, MSCs were cultured with 10−7 M estrogen (17 ß-
estradiol, Sigma, MO, USA).
Colony-Forming Assay
After washed in 1x PBS and air dried, MSCs were fixed
with cold methanol for 5 min. The cells were washed again
in a 1x PBS buffer and stained with giemsa (Carlo Erba,
Milano, Italy) for 5 min. The reaction of the giemsa
staining was stopped by the addition of tap water. The
number of colonies was counted under light microscope.
In Situ Analysis of DNA Fragmentation (TUNEL)
DNA fragmentation was detected in situ by TdT- (terminal
deoxynucleotidyl transferase) mediated fluorescein-dUTP
labeling kit (Roche Diagnostics, Mannheim, Germany).
Cells were fixed in 4% paraformaldehyde in PBS for
20 min at room temperature and then washed in PBS for
30 min. After incubating with a permeabilisation solution
(0.1% Triton X-100, 0.1% sodium citrate) for 2 min on ice,
50 μl of TUNEL reaction mixture was put into each sample
and incubated for 1 h at 37°C in the dark in a humidified
chamber. Slides were then directly analyzed by fluores-
cence microscopy. For evaluation by fluorescence micros-
copy, we used an excitation wavelength in the range of
450–500 nm and detection in the range of 515–565 nm. As
negative control, we incubated the samples in the absence
of terminal deoxynucleotidyl transferase. For positive
controls, the samples were first treated with DNase I
(1,000 U/ml in 50 mM Tris–HCl, pH 7.5, 1 mg/ml BSA)
for 10 min at 20°C to induce DNA strand breaks prior to
labeling procedures and then incubated with 50 μl of
TUNEL reaction mixture.
Total RNA Isolation and Reverse Transcription
MSCs were trypsinized and the total cellular RNA was
isolated from the precipitate by using the RNeasy Mini kit
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(Qiagen, Hilden, Germany) according to the manufacturer’s
protocol, with additional DNase treatment. The cDNAs
were synthesized from the total RNA samples with the
DyNAmo cDNA synthesis kit (Finnzymes, Espoo, Finland)
according to the manufacturer’s protocol.
RT-PCR
cDNA amplification for bcl2, bcl-xL, CD90, CD71, CD45,
CD34, CD29, MMP12, GAPDH, and β-Actin were per-
formed by using DyNAzyme II (Finnzymes). The primers
and conditions of amplification indicated in Table 1 and 2
respectively.
Protein Isolation and Quantification
MSCs were scraped from the cell culture plates in 1x PBS
and the precipitate was treated with a lysis buffer containing
0.05 M Tris HCl, 1x protease inhibitor, 0.25 M NaCl and
1% (v/v) IGEPAL for 30 min on ice. Then the lysate was
centrifugated for 20 min at 13,000 rpm and 4°C. Protein
concentrations of supernatants were determined with
Bradford protein assay as described [25].
Western Blotting
The proteins were separated on 10% SDS-PAGE and
transferred to a polyvinylidene fluoride membrane. The
membrane was blocked with blocking solution for 2 h at
room temperature and was incubated in antibody solution at
the concentration of 1:500 (for Bcl-xL, Bak, Bcl-2, Bax);
1:200 (for ERα, ERß) and 1:1000 for Actin for o/n at 4°C.
Then the secondary antibody, anti-Rabbit-HRP were ap-
plied for 1 h in blocking solution at a concentration of
1:1000. Finally, Super Signal West Femto Maximum
Sensitivity Substrate (Thermo Scientific, IL, USA) was
applied to the membrane for 4 min and placed in an X-ray
film cassette and developed. All antibodies, except for anti-
Rabbit-HRP, were purchased from Santa Cruz (Santa Cruz,
CA, USA).
Transfection of bcl-2 and bcl-xL shRNA
shRNA of bcl-2 and bcl-xL were purchased from Open-
biosystems, (AL,USA) and prepared according to the
manufacturer’s protocol. 1 μg Bcl-2 and Bcl-xL shRNA
was added to 100 μL serum free, antibiotic free DMEM-LG
(HyClone). In another tube 4 μL and 3 μL transfection
reagent Dharmafect (Thermo Scientific) was diluted with
196 μL and 197 μL serum free antibiotic free DMEM-LG
for Bcl-2 and Bcl-xL respectively. After 5 min of incuba-
tion, the contents of shRNA and transfection reagent
containing tubes were mixed and incubated at room
temperature for 20 min. 1,200 μL antibiotic free complete
DMEM-LG was added to the mixture. The cells were
washed with 1x PBS and then the transfection mixture was
added. DMEM-LG and transfection reagent only was given
to the cells as two types of control. Next day the medium
Table 1 Primers and the product size of the genes
gapdh forward 5′-CCTCCTCATTGACCTCAACTAC -3′ 210 bp
reverse 5′-CATGGTGGTGAAGACGCCAG-3′
bcl-2 forward 5′-CCTGGCATCTTCTCCTTC-3′ 584 bp
reverse 5′-TGCTGACCTCACTTGTGG-3′
bcl-xL forward 5′-TCAATGGCAACCCTTCCTGG-3′ 346 bp
reverse 5′-ATCCGACTCACCAATACCTG-3′
beta actin forward 5'-CTGGCCTCACTGTCCACCTT- 3' 65 bp
reverse 5'-GGGCCGGACTCATCGTACT- 3'
CD 90 forward 5′- CCAGTCATCAGCATCACTCT- 3′ 374 bp
reverse 5′- AGCTTGTCTCTGATCACATT- 3′
CD 34 forward 5′- TGTCTGCTCCTTGAATCT-3′ 281 bp
reverse 5′- CCTGTGGGACTCCAACT- 3′
CD 71 forward 5′- ATGGTTCGTACAGCAGCAGA- 3′ 182 bp
reverse 5′- CGAGCAGAATACAGCCATTG- 3′
CD 29 forward 5′-ACTTCAGACTTCCGCATTGG -3′ 190 bp
reverse 5′- GCTGCTGACCAACAAGTTCA- 3′
CD 45 forward 5′- ATGTTATTGGGAGGGTGCAA-3′ 175 bp
reverse 5′- AAAATGTAACGCGCTTCAGG-3′
Mmp 12 forward 5′- GGCAACTGGACACCTCAACT -3′ 382 bp
reverse 5′- GTCCAGGTTTCTGCCTCATC -3′
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was changed to their normal media. 4 days after transfec-
tion, RNA isolation and TUNEL assays were performed.
Adipogenic Differentiation
An adipogenic induction medium was prepared freshly by
adding 1 μM dexamethasone (Sigma), 10 μg/ml insulin
(Sigma), 100 μM indomethacin (Sigma) and 0.5 mM
IBMX to LG-DMEM (HyClone), containing 1x penicillin-
streptomycin (HyClone) and 10% FBS (HyClone). The
MSCs were cultured for 21 days, changing the medium
every 2 days with freshly prepared medium. After 21 days
the cells were fixed with 4% paraformaldehyde and stained
with Oil Red O (Sigma).
Osteogenic Differentiation
An osteogenic induction medium was prepared by freshly
adding 0.1 μM dexamethasone (Sigma), 0.2 mM ascorbic
acid 2-phosphate (Sigma) and 10 mM glycerol-2-phosphate
(Sigma) to LG-DMEM (HyClone), containing 1x
penicillin-streptomycin (HyClone) and 10% FBS
(HyClone). The MSCs were cultured for 21 days, changing
the medium every 2 days with freshly prepared medium.
After 21 days the cells were fixed with 10% formaldehyde
and stained with Von Kossa (Sigma).
Statistical Analysis
All data are expressed as means ± SD. Data were analyzed
by performing paired t-test using Minitab Statistical
Software ® (State College, Pennsylvania, USA). A value
of P<0.05 was considered to be statistically significant.
Results
We first examined the characteristics of MSCs isolated from
normal and ovariectomized rats and cultured in the absence
or presence of 10−7 M estrogen (Fig. 1). We repeated our
experiments three times with three animals per group. By
using RT-PCR, we showed that all of the experimental
groups were positive for mesenchymal stem cell markers
(CD29, CD71 and CD90) and negative for hematopoietic
cell markers (CD34, CD45) (Fig. 1a). We also examined the
expression levels of ER α and ER β in our experimental
groups. Our western blot data showed that both ER α and
ER β were expressed in MSCs isolated from normal and
ovariectomized rats (Fig. 1b). We also showed that upon
estrogen addition, the expression of an estrogen responsive
gene, MMP12 increased both in normal and ovariectomized
animals (Fig. 1c).
We then investigated the effect of estrogen treatment on
MSCs’ CFU-F activities and differentiation capabilities
(Fig. 2). The results of our CFU-F assay showed that
estrogen treatment caused an increase in the colony
numbers of MSCs that were isolated from both normal
and ovariectomized rats (Fig. 2a). Moreover, the number of
the cells in the colonies also increased when MSCs were
treated with estrogen (Fig. 2a). When MSCs isolated from
both normal and ovariectomized animals were put into
adipogenic and osteogenic differentiation medium, they
Table 2 PCR conditions for the genes
Genes Initial denaturation Denaturation Annealing Extension Cycles Final extension
gapdh 95°C, 5 min 94°C 45 sec 55°C
40 sec
72°C
40 sec
23 72°C, 5 min
bcl-2 95°C, 5 min 94°C 40 sec 63°C
35 sec
72°C
40 sec
36 72°C, 5 min
bcl-xL 95°C, 5 min 94°C 30 sec 52°C
30 sec
72°C
30 sec
31 72°C, 5 min
beta actin 95°C, 5 min 94°C 40 sec 60°C
35 sec
72°C
40 sec
25 72°C, 5 min
CD 90 95°C, 5 min 94°C 30 sec 55°C
30 sec
72°C
30 sec
30 72°C, 5 min
CD 34 95°C, 5 min 94°C 30 sec 55°C
30 sec
72°C
30 sec
30 72°C, 5 min
CD 71 95°C, 5 min 94°C 40 sec 66°C
60 sec
72°C
40 sec
35 72°C, 5 min
CD 29 95°C, 5 min 94°C 30 sec 60°C
30 sec
72°C
30 sec
29 72°C, 5 min
CD 45 95°C, 5 min 94°C 30 sec 60°C
30 sec
72°C
30 sec
23 72°C, 5 min
Mmp 12 95°C, 10 min 94°C 40 sec 48°C
60 sec
72°C
40 sec
28 72°C, 5 min
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were able to form adipocytes and osteocytes (Fig. 2b). Our
results revealed that the capacity of differentiation into
adipocyte lineage was to a lesser degree when MSCs were
incubated in the presence of estrogen (Fig. 2b (ii vs iv)).
Since the cell number may be directly related to the
involvement of apoptosis, we then examined the effect of
estrogen on the apoptotic rate of MSCs (Fig. 3). Apoptotic
rate was calculated as the ratio of TUNEL (+) cells to the
Fig. 1 Characterization of bone marrow-derived mesenchymal stem
cells. a The expression of the markers of MSCs (CD90, CD29 and
CD71) and hematopoietic cells (CD34, CD45) by RT-PCR. b Protein
expression of ERα and ERβ determined by Western blot. Actin
expression was used as loading control. c mRNA expression estrogen
regulatory gene, MMP12 determined by RT-PCR. Actin expression
was used as loading control. (F: MSCs obtained from female rats; F
+e: MSCs obtained from female rats treated with estrogen; Ovx:
MSCs obtained from ovariectomized rats; Ovx+e: MSCs obtained
from ovariectomized rats treated with estrogen.)
Fig. 2 Effect of estrogen on the bone marrow-derived mesenchymal
stem cells. a CFU activities and the number of the cells in a colony *
indicates p≤0.05; b Differentiation capacities of MSCs in the absence
(i, iii) and presence (ii, iv) of estrogen. MSCs were stained with Oil
Red O to determine adipogenic differentiation (i, ii), with Von Kossa
staining to determine osteogenic differentiation (iii, iv)
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total number of cells. Addition of estrogen decreased the
number of TUNEL (+) MSCs isolated both from normal
(Fig. 3a and b) and ovariectomized rats (Fig. 3c and d). Our
results suggested that estrogen protects MSCs from apo-
ptosis (Fig. 3e).
In order to understand the molecular mechanism of
estrogen action on apoptosis, we focused on Bcl-2 family of
proteins. We examined the expressions of both anti-
apoptotic (Bcl-xL, Bcl-2) and pro-apoptotic (Bak and Bax)
members of this family (Fig. 4). Our western blot experi-
ments revealed that addition of estrogen caused an increase
in the expression of anti-apoptotic members of Bcl-2 family
of proteins (Fig. 4a). On the other hand, we did not observe
any change in the expression of pro-apoptotic members
(Fig. 4b). We knocked down the expression of bcl-2 and
bcl-xL by using shRNA to reveal that the anti-apoptotic
effect of estrogen on MSCs was through these genes
(Fig. 5a) and checked the effect of this silencing on the
apoptotic rates of MSCs determined by TUNEL assay
(Fig. 5b,c). Our results showed that the decreasing effect of
estrogen on apoptosis in non-transfected MSCs reversed
after transfecting the cells with shRNA of either bcl-2or
bcl-xL. The percentage of the apoptotic cells increased
when bcl-xL or bcl-2 shRNA transfected cells cultured even
in the presence of estrogen (Fig. 5b and c respectively).
Discussion
Stem cells are the new hope for the humans since they have
the potential to differentiate to several types of cells and
tissues. They are future candidates for many therapeutic
applications and can be the cure for many diseases such as
neurodegenerative diseases, diabetes, and cancer [26].
Estrogen also influences the quality of life both in men
and women and is a strong candidate in the maintenance of
life standards. Estrogen has important effects on blood
vessels, neurotransmitter release, sexual behaviour, bone
structure, cognitive function and spermatogenesis and
regulates many pathways vital for the homeostasis [27,
28]. Therefore our understanding of its importance should
not be limited only to the reproductive system. In this study,
we aimed to understand the role of estrogen on the MSCs
which emerge as an important player of cellular-based
therapies due to lack of immunogenicity and ethical
problems.
Since we focused on the role of estrogen on MSCs, we
first examined the expression status and functionality of ER
α and ER β on these cells (Fig. 1b and c). Bone marrow is
one of the target tissues of estrogen and osteoblasts,
Fig. 3 In situ analysis of DNA fragmentation (TUNEL) of MSCs.
MSCs were isolated from normal (a, b) and ovariectomized (c, d) rats.
Cells were cultured in the absence (a, c) and presence (b, d) of
estrogen. e Percentage of apoptotic cells. * indicates p≤0.05
Fig. 4 Expression of a anti-apoptotic and b pro-apoptotic members of
Bcl-2 family of proteins in MSCs determined by Western blot. Actin
expression was used as loading control (F: MSCs obtained from
female rats; F+e: MSCs obtained from female rats treated with
estrogen; Ovx: MSCs obtained from ovariectomized rats; Ovx+e:
MSCs obtained from ovariectomized rats treated with estrogen)
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osteocytes, osteoclasts, T cells and B cells in human and
mouse bone marrow express both ERα and ERβ [29]. Our
results showed that rat bone marrow-derived MSCs also
express ERα and ERβ (Fig. 1b). Our data regarding to the
expression of estrogen regulated gene, MMP12 [30],
suggest that these receptors are functional. MSCs isolated
both from normal and ovariectomized rats increased the
expression of MMP12 upon estrogen addition (Fig. 1c).
Estrogen addition to the culture media increased the
number of colonies both in the normal and ovariectomized
group which suggests that estrogen has an increasing effect
on the number of functional MSCs both in normal and
estrogen deprived conditions (Fig. 2). In addition the
number of cells in a colony was more when cells were
treated with estrogen. These results are also in accordance
with a previous study which showed that the number of
MSCs obtained from ovariectomized animals was increased
upon estrogen addition [31].
In addition, we observed that the differentiation potency of
MSCs into adipocyte but not to osteocytes could be affected
with estrogen. Estrogen has been shown to have an important
role on adipocyte metabolism [32] and our results provided
support that this effect might also be at the level of
differentiation. It has been reported that MSCs from
osteoporotic post-menopausal women showed an increase
in PPARγ expression and thus an increase in adipocytes [33].
In addition, serum from post menopausal in comparison to
serum from pre-menopausal women, were able to induce
adipogenic differentiation in a human bone progenitor cell
clone (hOP 7) derived from bone marrow [34]. Therefore, in
the absence of estrogen, MSCs’ adipocyte differentiation
capacity increased suggesting that estrogen influences adipo-
genesis and this may explain why post-menopausal women
gain weight and develop diseases associated with obesity.
Molecular mechanism of this effect in MSCs is not known
and clearly warranted new experiments.
The proliferative effect of estrogen has been shown on
rat bone marrow-derived MSCs before [35]. In contrast to
proliferation, the effect of estrogen on the maintenance of
rat bone marrow-derived MSCs from normal animals have
not been reported. We examined the effect of estrogen in the
apoptotic rates of MSC by in situ cell death assay. When the
ratios of apoptotic cells to total cells in the colonies were
compared, the addition of estrogen decreased the death
ratios in the normal and ovariectomized groups suggesting
that estrogen is effective in the process of MSC colony
formation both by decreasing apoptosis in addition to
increasing proliferation. It is important to note that in our
system, we did not induce apoptosis with any factor
therefore we evaluated the spontaneous physiological
apoptosis of bone marrow-derived MSCs.
In order to understand the molecular mechanism of the
decrease in apoptosis upon estrogen administration, we
focused on the Bcl-2 family of proteins. The Bcl-2 protein
family consists of both pro- and anti-apoptotic members.
The founder of the family, Bcl-2, was first identified in
1985 as the part of the most common translocation in
human B-cell lymphoma [36]. After the identification of
Bcl-2 as a survival factor, many different homologues were
identified and characterized [37]. Recent reports established
the effect of estrogen on the expression of Bcl-2 family of
Fig. 5 Effect of silencing the expression of bcl-xL and bcl-2 on the
apoptotic rates. a Expression of bcl-2 and bcl-xL determined by RT-
PCR in MSCs transfected with and without shRNA of bcl-2 and bcl-
xL. T: control vector transfection. Expression of GAPDH was used as
loading control. b Percentage of apoptotic cells after MSCs were
transfected with bcl-xL shRNA determined by TUNEL assay. *
indicates p≤0.05. c Percentage of apoptotic cells after MSCs were
transfected with bcl-2 shRNA determined by TUNEL assay
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proteins in other systems [19, 23, 24]. Our immunoblotting
and knock down data also suggested that estrogen controls
the apoptosis by regulating the expression of Bcl-2 family
of proteins in rat MSCs (Fig. 4). These results are in
correlation with other studies performed on other stem cells
like skin stem cells, HSCs, and epithelial stem cells where
apoptosis and members of the bcl-2 family of genes were
shown to be important in the differentiation and regulatory
pathways [38–40]. When we cultured MSCs in the presence
of estrogen, the expression of anti-apoptotic Bcl-2 and Bcl-
xL were increased. This effect was more evident when
MSCs were isolated from normal female rats than the
ovariectomized rats. The Bcl-2 protein expression did not
increase in the ovariectomized group, which might be
explained by the loss of estrogen susceptibility due to a
long period in an estrogen deprived environment. On the
other hand, the expression of proapoptotic Bak and Bax
proteins did not change with estrogen treatment. To confirm
the role of anti-apoptotic Bcl-2 family of proteins on
MSCs’ maintenance, we silenced the expression of Bcl-2
and Bcl-xL. Our data showed that upon knocking down the
expression of these genes, we observed the inhibition of
apoptosis (Fig. 5) and CFU-F capacity of (data not shown)
in MSCs isolated from normal and ovariectomized rats,
suggesting a critical role for these genes in the estrogen
regulation of apoptosis.
In conclusion, we have shown that apoptosis is one of
the main regulatory mechanisms in the maintenance of
MSCs. Bcl-2 and Bcl-xL are important proteins in this
regulation and estrogen affects the expression rates of these
proteins, increasing the colonies and decreasing the
apoptotic rate. Modulation of with estrogen may help to
obtain more MSCs which might be important for clinical
applications.
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